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Abstract 
Medication safety at various stages of the patient journey continues to be a significant 
problem. The increasingly ageing population worldwide, together with the growing use 
of multiple medications, leads to an increased risk of medication‐related problems. In 
Australia, the proportion of all hospital admissions that are medication-related is between 
2% and 3%. Adverse drug reactions (ADRs) are the most common medication-related 
problems causing significant morbidity and mortality. Based on data collected from 
general practitioners’ encounters in 2003 and 2004 in Australia, ADRs represented the 
most common adverse drug event in the community (72%). Older patients are particularly 
susceptible to ADRs due to multiple comorbidities, cognitive and functional impairment, 
a high prevalence of polypharmacy, and age-related changes in pharmacokinetics and 
pharmacodynamics. Of particular concern are ADR-related hospital admissions which 
are one of the main reasons for hospitalisation in older patients living in the community. 
More than half of these ADR-related admissions are considered preventable. Even though 
several methods of ADR identification exist, prospective and intensive monitoring 
methods using patient interviews usually have the highest ADR detection rate and allow 
more accurate recording of both drug history and symptoms for assessing the causality of 
ADRs. A prospective cross-sectional survey in Australia (1998) estimated that 13.3% of 
elderly admissions to medical wards were ADR-related. A recent meta-analysis found 
that one in ten hospital admissions in older patients were due to ADRs. Despite the 
current efforts to identify and prevent ADRs, the burden of ADRs is continuing. A 
secondary data analysis of case series in Australia (1981-2002) found that hospital 
admissions due to ADRs in elderly patients had increased despite programs to promote 
rational and safer use of medicines. In addition to this burden, ADRs that result in 
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hospitalisation in patients with a history of ADR-related hospitalisation, or ‘repeat ADRs’ 
are also increasingly common and an important contributor to the burden of ADRs. A 
population-based longitudinal study (1980-2003) in Australia found that repeat ADR-
related hospitalisations had increased faster than first-time ADRs in the elderly since 1980 
and were responsible for 30.3% of all ADR-related admissions in 2003.  
Hence, strategies to reduce the risk of ADR-related admissions, as well as repeat 
admissions due to ADRs, are required to reduce the global burden of ADR-related 
admissions, especially in the elderly. While various strategies including medication 
review, avoiding use of potentially inappropriate medications, computer-based 
prescribing systems, and comprehensive geriatric assessment have been suggested, health 
professionals are not able to easily identify elderly community-dwelling outpatients who 
are at high risk of being hospitalised due to an ADR. To our knowledge, there are no 
empirical data that allow stratification of community-dwelling older people according to 
the likelihood of ADRs leading to hospital admission. A tool that focusses on ADRs as a 
cause of hospitalisation could potentially be used in primary care and at the point of 
hospital discharge to prioritise primary care-based medication management services to 
prevent ADR-related morbidity and mortality in patients at the highest risk of such events. 
Furthermore, given the scarcity of ADR-related hospital admissions data in the elderly 
identified using prospective intensive monitoring, and the lack of recent data from 
Australia, more recent estimates of the burden of ADRs are needed. 
The overall objective of the body of work contained in this thesis was to fill these 
gaps in the literature by developing a practical, efficient and simple method of identifying 
people 65 years and older who are at high risk of experiencing an ADR leading to 
hospitalisation. The specific aims were: 
xvii 
 
1. To investigate the proportion, clinical characteristics, causality, severity, 
preventability, and outcome of ADR-related admissions in older patients admitted 
to medical wards of two Tasmanian hospitals. 
2. To develop and validate a prediction model for ADR-related hospitalisation in 
patients aged ≥65 years. 
3.  To investigate the occurrence of repeat ADR-related admissions in elderly 
patients within 12 months of a hospital admission to a medical ward due to an 
ADR.  
4.  To investigate the utility of a validated ADR score in identifying patients at 
higher risk of a repeat ADR-related hospitalisation. 
5. To compare the rates of ADR-related hospitalisations using different methods of 
detection. 
In order to achieve these aims, we conducted a prospective cross-sectional study in the 
medical wards of two hospitals in Tasmania, Australia: the Royal Hobart Hospital (RHH) 
and the Launceston General Hospital (LGH). ADR-related hospital admission was 
determined by clinical pharmacists through expert consensus from comprehensive 
reviews of medical records and patient interviews. The causality, preventability, and 
severity of each ADR-related admission were assessed. We pooled the data from both 
hospitals, which allowed us to investigate the extent of the problem by determining the 
proportion of ADR-related admissions in older patients admitted to Tasmanian hospitals, 
identifying commonly implicated drugs, and describing the clinical manifestations and 
outcomes of ADRs. Of 1008 admissions from the pooled analysis of the RHH and LGH 
data, 18.9% of admissions were potentially related to ADRs categorised as ‘definite, 
probable or possible’; 88.5% of these admissions were preventable. Cardiovascular 
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complaints (29.3%) represented the most common ADRs, followed by neuropsychiatric 
(20%) and renal and genitourinary disorders (15.2%). The most frequently implicated 
drug classes were diuretics (23.9%), renin–angiotensin system inhibitors (16.4%), β-
blocking agents (7.1%), antidepressants (6.9%), and antithrombotic agents (6.9%). ADR 
severity was rated moderate and severe in 97.9% and 2.1% of admissions, respectively.  
A predictive score named the ‘PADR-EC score’ was developed using the data 
from the RHH (derivation cohort), and the score was validated using the data from the 
LGH (validation cohort). In the derivation sample at the RHH, 115 (15%) patients were 
admitted due to a ‘definite or probable’ ADR; 92.2% of these admissions were deemed 
preventable. In the validation sample at the LGH, 30 (12.5%) patients’ admissions were 
related to definite or probable ADRs; 80% of these admissions were deemed preventable. 
The predictive ability of the score in the derivation sample at the RHH was 0.70 (95% 
confidence interval (CI), 0.65–0.75) and 0.67 (95% CI 0.56–0.78) in the validation 
sample at the LGH. The PADR-EC score assigns points to five significant predictors of 
ADR-related hospitalisation: (i) antihypertensive use (three or five points if 1-2 or ≥3 
antihypertensives, respectively), (ii) renal failure (two points), (iii) dementia (two points), 
(iv) inappropriate anticholinergic use (two points) and (v) drug changes in the preceding 
three months (two points). These points are summed to produce the final score, with the 
risk of ADR-related hospitalisation more than three times higher in those with a score ≥6.  
After the development and validation of the ADR score, the occurrence of repeat 
ADR-related admissions was estimated using the data from the RHH participants who 
had an ADR-related admission and experienced a subsequent admission due to an ADR 
within 12 months of discharge from their initial index admission. Of the 112 definite or 
probable ADR-related admissions among the RHH cohort (three patients died during their 
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index admission), repeat ADR-related admissions occurred in 13.4% (n=15). Patients 
with a repeat ADR-related admission had significantly higher PADR-EC scores at the 
discharge of their index admission (median PADR-EC score 7, interquartile range (IQR) 
2-11) than patients who did not have a repeat admission due to ADRs (median PADR-
EC score 7, IQR 5-7, P=0.034).  
Finally, to compare the rates of ADR-related hospitalisations using different 
methods of detection, we linked the records of patients from the RHH cohort, where 
clinical pharmacists prospectively identified ADRs, to their hospital administrative data. 
We then identified patients in the prospective study whose admissions were coded as 
ADRs using the International Classification of Diseases 10th Revision Australian 
Modification (ICD-10 AM) codes. We found that only 2.7% of patients were identified 
as having been admitted due to ADRs using the ICD-10 AM codes compared to the 15% 
identified by the prospective review.  
This body of work has resulted in the development and external validation of a 
simple and robust approach to identifying community-dwelling elderly patients at risk of 
hospitalisation due to preventable ADRs. To our knowledge, this approach has never been 
adopted before in the field of assessing ADR-related admissions in the elderly. 
Furthermore, our research has identified the extent of the current problem of ADR-related 
admissions as well as ADR-related repeat admissions in the elderly Tasmanian 
population. Our study found that almost one in five unplanned overnight hospital 
admissions to medical wards in elderly Australian patients were related to ADRs. 
Additionally, our study showed that one in eight elderly patients hospitalised due to an 
ADR had a repeat admission for ADR within 12 months of discharge. These findings 
update the existing information on the rate of ADR-related admissions and repeat 
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admissions in the elderly. More detailed prospective review of admissions gave a clearer 
understanding of the true number of ADRs for directing appropriate medication 
management services towards addressing the problem. We suggest that the PADR-EC 
score has the potential to assist healthcare practitioners at the point of discharge and in 
primary care to identify those elderly patients for whom intervention may reduce the risk 
of ADRs and subsequent hospitalisation. Future studies are required to investigate the 
utility of the PADR-EC score in these settings and thereafter the effectiveness of 
interventions, such as deprescribing, in reducing the risk of ADR-related admissions in 
elderly populations.  
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THESIS OVERVIEW 
 
1.1. Problem statement  
Adverse drug reactions (ADRs) represent a major public health problem causing 
significant morbidity, mortality, and healthcare costs [1, 2]. ADRs pose a significant risk 
especially in the elderly because ageing is associated with pharmacokinetic and 
pharmacodynamic changes, co-administration of multiple medications or polypharmacy, 
comorbidities, cognitive impairment and functional disability [3, 4]. Of particular concern 
is the high prevalence of ADRs leading to hospitalisation in the elderly. A large body of 
research exists regarding the consequences of ADRs causing admissions or repeat 
admissions to hospital in older adults, and various preventive strategies have been 
suggested. Despite strategies promoting rational and safer use of medicines such as 
medication review, avoiding the use of potentially inappropriate medications, using 
computer-based prescribing systems and comprehensive geriatric assessment [3], the 
problem of ADRs has persisted [5]. ADR-related admissions and repeat admissions due 
to ADRs continue to be a leading cause of preventable morbidity and mortality in the 
older population worldwide [6-8]. One possible solution to this issue is to improve the 
targeting of medication management services to those at highest risk and to better inform 
the design of these services through enhancing our understanding of ADRs that lead to 
hospitalisation. Previous studies suggest that identification of the population at risk of 
ADRs using a prediction tool may be a useful first step to allow health professionals to 
target medication management services towards this group, and to put in place strategies 
to prevent ADRs [9, 10]. However, currently available ADR tools in the elderly are 
developed for identifying the risk of ADRs occurring during hospitalisation. A tool that 
2 
 
focusses on ADRs as a cause of hospitalisation could potentially be used in primary care 
and at the point of hospital discharge, to prioritise primary care-based medication 
management services to prevent ADR-related morbidity and mortality in patients at the 
highest risk of such events. Furthermore, the scarcity of prospectively identified data, 
together with a lack of recent Australian data on ADR-related admissions in the elderly, 
necessitates the estimation of the current burden of ADR-related admissions as well as 
repeat admissions due to ADRs in the older population. We also need to better understand 
the risk factors associated with ADR-related hospitalisations, as most of the Australian 
data has focussed on risk factors derived from administrative databases. Prospective data 
provides us with a greater range of events, and potentially a better understanding of the 
risk factors involved.  
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1.2. Aim and objectives 
The overall aim of this thesis was to develop and validate a practical, efficient and simple 
method of identifying people aged 65 years and older who are at high risk of experiencing 
an ADR leading to hospitalisation. This aim was addressed through a narrative literature 
review, and a prospective study involving two Tasmanian hospitals. Data from the 
prospective study is presented in four separate analyses to address the specific objectives 
of the work. These objectives were as follows: 
  
1. To investigate the proportion, clinical characteristics, causality, severity, 
preventability, and outcome of ADR-related admissions in older patients admitted 
to medical wards of two Tasmanian hospitals. 
2. To develop and validate a prediction model for ADR-related hospitalisation in 
patients aged ≥65 years.  
3. To investigate the occurrence of repeat ADR-related admissions in elderly 
patients within 12 months of a hospital admission to a medical ward due to an 
ADR,  
4. To investigate the utility of a validated ADR score in identifying patients at higher 
risk of a repeat ADR-related hospitalisation. 
5. To compare the rates of ADR-related hospitalisations using different methods of 
detection. 
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1.3. Thesis outline 
This thesis is composed of seven chapters, including five manuscripts. At the time of 
submission of this thesis, three of the five manuscripts have been published in peer-
reviewed journals, and the last two are under review. A brief description of each chapter 
is provided below. 
  
Chapter 1 outlines a general introduction and background information to the research 
project. 
 
Chapter 2 is a narrative literature review outlining the importance of the topic and the 
rationale for the study approach. This review outlines the need for the current research 
and was published in the journal Clinical Interventions in Aging in 2016. 
 
Chapter 3 presents the descriptive findings of a prospective cross-sectional study 
conducted in two Tasmanian hospitals, namely the Royal Hobart Hospital (RHH) and the 
Launceston General Hospital (LGH). The study evaluated the proportion, clinical 
characteristics, causality, severity, preventability and outcomes of ADR-related 
admissions in older patients admitted to these hospitals. The study’s findings provide a 
clear picture of the current extent of the problem of ADR-related admissions in the 
elderly. The results were published in the journal Drug Safety in 2017. 
 
Chapter 4 describes the development and validation of an ADR tool, named the “PADR-
EC (Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community-
Dwelling Patients) score” to identify patients aged ≥65 years at risk of ADR-related 
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hospitalisation. The ADR tool was developed and validated using the prospective data 
from the RHH (the derivation cohort) and the LGH (the validation cohort) respectively. 
The results were published in the journal PLoS ONE in 2016. 
 
Chapter 5 describes the findings of a retrospective study, which investigated the 
occurrence of repeat ADR-related hospital admissions in elderly patients within 12 
months of an ADR-related admission to a medical ward. This study also investigated 
whether the PADR-EC score could be useful in identifying patients at higher risk of a 
repeat ADR-related hospitalisation. This study followed elderly participants who were 
hospitalised with an ADR from the PADR-EC study to identify repeat ADR-related 
hospital admissions within 12 months of discharge. The manuscript is under review in the 
journal Drugs & Aging. 
   
Chapter 6 describes the findings of a retrospective study, which compared the rates of 
ADR-related hospitalisations using different methods of detection. This study linked the 
records of prospectively enrolled RHH patients from the PADR-EC study, where clinical 
pharmacists prospectively identified ADRs, to their hospital administrative data. The 
manuscript is under review in the journal Pharmacoepidemiology and Drug Safety. 
   
Chapter 7 presents an overall discussion of the study findings, implications for practice 
and policy and recommendations for future research. This chapter ends with an overall 
conclusion. 
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CHAPTER ONE 
 
1. Introduction 
 
“The person who takes medicine must recover twice, once from the disease and once from 
the medicine.” 
-William Osler, M.D. (1849-1919). 
 
1.1. Preface 
Patient safety is defined as “the prevention of harm to patients” [11], and medications can 
be an important source of patient harm. The purpose of this chapter is to provide a general 
introduction to the research project. This chapter focusses on the ageing population, drug-
related problems (DRPs), adverse drug reactions (ADRs), ADRs as a cause of hospital 
admissions, ADRs in the elderly, ADRs as a cause of hospital admissions in the elderly, 
repeat ADRs and different methods of ADR detection and various strategies used to 
prevent the risk of ADR-related admissions in elderly patients. 
  
1.2. The ageing population 
According to the World Health Organisation (WHO) report on ageing and health, the 
number of people aged 60 years or older will rise from 900 million to 2 billion between 
2015 and 2050 (moving from 12% to 22% of the total global population) [12]. In 
Australia, the estimated population in 2016 was 24.4 million, of whom 3.7 million 
(15.2%) were aged 65 or older [13]. The number of elderly Australians is projected to 
increase more rapidly over the next decade as further cohorts of those born between the 
years 1946 and 1964 turn 65 [14]. These projections were estimated to be from 3.2 million 
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in 2012 to between 5.7 million and 5.8 million in 2031, and to between 9.0 million and 
11.1 million in 2061 [15]. In 2009, about half (49%) of Australian people living in the 
community aged 65-74 had five or more long-term conditions or chronic diseases; this 
rate increased to 70% of those aged 85 or over [16]. In other international findings, the 
prevalence of multiple chronic conditions or multimorbidity [17] in older patients ranges 
from 55% to 98% [18]. The ageing population, together with a concomitant rise in the 
number of people living with multimorbidity, has major implications for both healthcare 
needs and higher healthcare costs associated with disability and functional decline or poor 
quality of life [18, 19]. In a cross sectional analysis conducted on a nationally random 
sample of older patients, the odds of experiencing a preventable inpatient admission were 
almost 99 (odds ratio [OR] 98.52 (95% CI 86.11-112.72) times higher among older 
people with four or more chronic conditions in comparison to their counterparts without 
a chronic condition [20]. The use of multiple medications and/or the administration of 
more medications than are clinically indicated [21], termed polypharmacy [22], is often 
associated with multimorbidity because patients receive and accumulate medications over 
time to treat each disease [23]. Polypharmacy is common among elderly Australians 
admitted to medical units of Australian hospitals [24]. Similar findings of polypharmacy 
were observed in a descriptive study in the United States (US), which found at least five 
or more prescription medications were used by 36% of community-dwelling older adults 
aged 62-85 years old [25]. 
  
1.3. Drug-related problems 
The combination of an increasingly ageing population [15, 26], together with the growing 
use of multiple medications, leads to an increased risk for problems associated with 
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pharmacotherapy, collectively referred to as DRPs [27]. A DRP is an event or 
circumstance involving drug therapy that actually or potentially interferes with desired 
health outcome [28]. These DRPs, also termed ‘medication incidents’ [29], may adversely 
affect successful pharmacotherapy in a given patient. A medication incident can occur at 
any point in the medication use process (ordering, transcribing, dispensing, administering 
and monitoring) [30]. Medication incidents may include medication errors (MEs), 
adverse drug events (ADEs) and ADRs [31]. A ME error is defined as: 
Any preventable event that may cause or lead to inappropriate medication use or patient harm 
while the medication is in the control of the healthcare professional, patient, or consumer. Such 
events may be related to professional practice, healthcare products, procedures, and systems 
including prescribing, order communication, product labelling, packaging, and nomenclature, 
compounding, dispensing, distribution, administration, education, monitoring and use [32].  
MEs are common, although relatively few result in ADEs [33], which are defined as 
injuries resulting from the use of a drug [34]. ADEs may also result from the manner in 
which the medicine is used (such as an error or system failure) [29]. MEs with potential 
for injury but in which no injury occurred have been classified as potential ADEs [33].    
Some ADEs are termed ADRs, which result from the pharmacological actions of the 
medicine itself [29]. The WHO defines an ADR as “a response to a drug that is noxious 
and unintended and occurs at doses normally used in humans for the prophylaxis, 
diagnosis or therapy of disease, or for modification of physiological function” [36, 37]. 
Various authors have described the relationship between MEs, ADEs and ADRs. 
According to Bates et al. only a small proportion of MEs represent an ADE or a potential 
ADE [33]. Among these ADEs, only some ADEs are associated with a ME while others 
are not, which indicates that some ADEs would have been considered as ADRs according 
to the WHO definition [38]. However, all potential ADEs are MEs since they are 
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unintentional medication discrepancies which do not actually cause any injury, either 
because of specific circumstances, chance, or because the error is intercepted and 
corrected [30, 35]. Ackroyd-Stolarz et al. classified DRPs into those that result in injury 
and those that do not. The DRPs that result in injury include MEs, ADEs and ADRs 
whereas the non-injury DRPs include MEs and potential ADEs [39]. Nebeker et al. 
explained the relationship between key terms in DRPs, which is depicted in Figure 1 [40]. 
The grey areas represent injuries caused by drug use (ADEs). The dark grey area 
represents harm caused by a drug (ADRs). MEs are more common than ADEs, and less 
than 1% of MEs result in harm [33]. 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission from Nebeker JR, Barach P, Samore MH. Clarifying adverse drug 
events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004; 
140:795-801[40].  
 
Figure 1. Relationship of key terms in drug-related problems 
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1.4. Adverse drug reactions 
ADRs are the most common DRPs [41-43]. ADRs are harms caused by drugs 
administered at usual therapeutic doses and are the primary focus of regulatory agencies 
and post-marketing surveillance [40]. The WHO defines an ADR as “a response to a drug 
that is noxious and unintended and occurs at doses normally used in humans for the 
prophylaxis, diagnosis or therapy of disease, or for modification of physiological 
function” [2, 37]. This definition excludes therapeutic failures, under-treatment, 
intentional and accidental poisoning (i.e., overdose) and drug abuse. The thalidomide 
tragedy in the 1960s has intensified the interest in ADRs worldwide [44]. ADRs were 
ranked the fourth to sixth leading cause of death in the US [36], and ADRs cause almost 
197,000 deaths annually throughout the European Union [45]. Fatal ADRs account for 
approximately 3% of all deaths in the general population based on a Swedish study [46]. 
Another study estimated that over 350,000 ADRs occur each year in US nursing homes 
[34]. The Institute of Medicine reported that an estimated 7,000 deaths occur annually 
due to ADRs out of the total 44,000 to 98,000 deaths occur annually from medical errors 
[47] in the US. ADR prevalence is often reported in the literature as a proportion of 
hospital admissions, hospitalisations or ADRs occurring in outpatient settings. A 
retrospective observational study in Australia in 2004 concluded that 3.3% of 
hospitalisations were associated with an ADR that occurred as a cause of, or during 
admission [48]. Another study in general practice patients in Australia revealed a high 
frequency (10.4%) of ADEs in patients attending general practice, and for 95.3% of these 
patients, one reason for the most recent event was an ADR [49]. 
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1.4.1. Adverse drug reactions as a cause of hospital admissions 
ADRs can cause serious harm to patients and can lead to hospital admissions. ADRs as a 
reason for hospitalisation were first reported in Belfast hospitals in 1965-1966 [50, 51]. 
In Europe, the median percentage of hospital admissions due to an ADR was 3.5%, based 
on a recent systematic review of observational studies [52]. In another systematic review 
of prospective observational studies, the median prevalence of hospital admissions 
associated with ADRs was 6.3% [53]. In 2013-14, about 1% of all hospital separations 
(single patient encounters resulting in discharge [48]) in Australia were reported to have 
a drug-related principal diagnosis [54]. The most recent Australian data (2008-2013) 
shows that the proportion of all hospital admissions that are medication-related is between 
2% and 3% [55], and approximately 50% of these are potentially preventable [29], 
causing an estimated annual cost of AUD $1.2 billion [55]. A 2012 meta-analysis also 
reported that more than 50% of ADRs causing emergency visits or hospital admissions 
are potentially preventable [56]. A 10-week study on drug-related admissions to an 
Australian hospital estimated that almost 10% of medical admissions to the hospital were 
drug-related and most of these admissions were attributable to an ADR (30.9%) or 
intentional overdose (38.2%) [57]. In other international studies, the prevalence of ADR-
related admissions has ranged from 1.7% to 8.4% [58-61]. 
   
1.4.2. Adverse drug reactions in the elderly 
ADRs occur commonly in the elderly. Premarketing drug clinical trials often exclude 
elderly patients, even though they are the major users of medications [62]. Hence, there 
is a lack of sufficient clinical data in the elderly on the risk-benefit ratio of medications. 
There is often a need for dosage adjustments from initially approved doses in elderly 
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patients, which illustrates the lack of adequate clinical data in this patient group [62]. 
Older patients are particularly susceptible to ADRs since ageing is associated with 
pharmacokinetic and pharmacodynamics changes that might affect drug concentration 
and effects [63]. There is a natural decrease in creatinine clearance with true renal ageing 
in addition to other specific diseases or medications, which might change glomerular 
filtration rate in the elderly [64]. Additionally, a decline in the ability of the liver to 
inactivate toxins may contribute to a pro-inflammatory state, which in turn downregulates 
drug metabolism and results in reduced systemic clearance of prescribed medications 
leading to ADRs in the elderly [65]. The adverse effects of some drug combinations may 
be synergistic and be greater than the sum of the risks of adverse effects of either drug 
used alone [66]. Thus, the risk for ADRs increases with advancing age though the clinical 
reality is far more complex [67]. In one study, the risk of ADR-related deaths was greatest 
in older adults aged 75 years or older (OR 6.96, 95% CI 6.30–7.69) [68].  
 
1.4.3. Adverse drug reactions as a cause of hospitalisation in the elderly 
ADRs are frequently a cause of hospitalisation or may happen during hospital admission 
[51]. Of concern are ADR-related hospital admissions, particularly in the elderly who are 
the most likely to develop ADRs as they receive most medications [6]. ADRs have been 
found to be the most common type of drug-related admission in the elderly [69]. A survey 
of drug-related admissions in older medical patients in Canada estimated 19% of the 
admissions were drug-related, and a frequent contributing cause was ADRs (48%) [43]. 
A recent meta-analysis found one in ten hospital admissions in older patients were due to 
ADRs [6]. A retrospective cohort study (2004-2008) amongst elderly Australian veterans 
estimated that the overall proportion of potentially preventable medication-related 
hospitalisations was 20.3% [70]. When these results are extrapolated to the overall 
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Australian population aged ≥65 years, as many as 90,000 admissions annually are 
potentially preventable medication-related admissions. In Australia, the age-standardised 
rate of ADR-related hospital stays increased from 2.5 per 1000 person-years in 1981 to 
12.9 per 1000 person-years in 2002 [5]. A detailed discussion of ADRs as a reason of 
hospitalisation in the elderly, including the risk factors, is provided in Chapter 2. 
   
1.4.4. Repeat adverse drug reactions-related hospitalisation in the elderly  
ADRs that result in hospitalisation in patients with a history of ADR-related 
hospitalisation, or ‘repeat ADRs,’ are increasingly common and are of equally significant 
concern as ADRs though few studies have examined repeat ADRs in the elderly. In a 
Hong Kong-based study, ADRs were found to be one of the significant risk factors (OR 
4.19, 95% CI 1.56–11.2) for early emergency readmission in elderly medical patients 
[71]. In a US study on the association between post-discharge ADRs and 30-day hospital 
readmissions in patients aged 80 and older, 23.4% of all readmitted patients had an ADR 
that contributed to readmission [72]. A population-based longitudinal study in Australia 
estimated that repeat ADR-related hospitalisations consistently increased faster than first-
time ADRs in the elderly in Western Australia from 1980 and had reached 30.3% of all 
ADRs by 2003 [73]. In another study in Australia, comorbidity, but not advancing age, 
predicted repeat admission for ADRs in the elderly, especially those with comorbidities 
often managed in the community [8].  
 
1.4.5. Detection of adverse drug reactions 
Several methods exist for the detection of ADRs. These are spontaneous reporting of 
ADRs, utilising administrative databases, computerised surveillance of ADRs, manual 
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chart reviews and prospective and intensive monitoring. These methods are discussed 
below. 
  
1.4.5.1. Spontaneous reporting 
In spontaneous reporting, healthcare professionals report ADRs whenever there is 
suspicion of ADRs. Using this system, case reports of ADRs are voluntarily submitted by 
health professionals and pharmaceutical manufacturers to the national regulatory 
authority [74]. The main drawback of this method is underreporting of ADRs [75], and 
this method identifies the lowest number of ADRs compared to other methods of ADR 
detection [76]. It also tends to result in more reports related to newer ‘drugs of interest’ 
rather than established therapies [77]. 
  
1.4.5.2. Administrative databases 
Administrative databases, electronic health records, and disease registries contain a large 
amount of health data that can be used to identify health outcomes in clinical practice 
[78]. Administrative databases increasingly use the International Classification of 
Diseases (ICD) 10th Revision system for identifying drug-related hospital admissions, 
readmissions or ADRs by assigning codes to inpatient discharges [79-81]. In Australia, 
the Australian Modification of ICD-10 (ICD-10-AM) is used, which allows ADR codes 
to be applied to any diagnosis and thereby retrospective ADR reporting is possible [48]. 
 
1.4.5.3. Computerised surveillance 
In some studies, the use of computer-assisted screening of laboratory values that are 
potentially associated with ADRs were utilised to identify ADRs [82, 83]. Computer-
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assisted surveillance identifies many ADRs not identified by spontaneous reporting but 
detects less ADRs compared to chart review [76]. However, few hospitals are equipped 
with these types of systems. For example, LDS Hospital, Salt Lake City, Utah (USA) has 
an integrated computerised surveillance system that prospectively screens electronic 
patient data for indicators of ADRs [84].  
 
1.4.5.4. Manual chart or medical record review 
In some studies, ADRs are detected either prospectively or retrospectively by reviewing 
patient charts, generally by specialists in ADR identification [85]. ADR identification 
using chart reviews identifies more ADRs than spontaneous reporting, but it is expensive 
and time-consuming [76]. 
 
1.4.5.5. Prospective and intensive monitoring 
Prospective and intensive monitoring refers to studies performed prospectively in 
hospitalised patients by skilled staff (doctors, nurses or pharmacists), often involving 
interviews with patients or health team members [85]. In this method, a population of 
patients receiving an individual drug, alone or in combination with other drugs, is kept 
under close surveillance; this method, though very expensive, results in an increased rate 
of ADR reporting compared to other methods of ADR detection [37]. 
  
1.5. Prevalence of ADR-related admissions in the elderly based on methods of 
detection 
The different methods of ADR detection result in different rates of reported ADRs [51]. 
In a systematic review of prospective observational studies, the estimated median 
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prevalence of hospital admissions associated with ADRs in the elderly was 10.7% 
(interquartile range, 9.6%–13.3%) [53]. In this review, studies that utilised multiple ADR 
identification methods such as medical record review and patient interview reported 
higher ADR admission rates (9.6%–15.7%) compared with studies that used medical 
record review alone (7.2%–10.6%). In another recent systematic review of hospital-based 
observational studies (prospective and retrospective), the median prevalence of ADRs 
leading to hospitalisation in the elderly in the acute care setting was 10.0% (95% CI, 
7.2%–12.8%) [86]. The prevalence of ADR-related admissions based on the different 
method of detection in the elderly population admitted to the medical wards is shown in 
Table 1. 
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Table 1. Prevalence of ADR-related admissions based on different methods of detection in 
the elderly admitted to medical wards 
Abbreviations: ADR, adverse drug reaction; UK, United Kingdom. 
 
There are also studies that compared the prevalence of ADR-related admissions using 
different methods of detection in the same cohort, though there is a scarcity of such 
studies in the elderly. In a study conducted in Slovenia, the frequency of ADRs-related 
admissions identified using retrospective medical review was much higher (5.8% of 
admissions) than that identified by the ICD-10 coding system (0.2%) [98]. In this study, 
no ADRs were identified using the spontaneous reporting method. In another study in the 
Netherlands, 1.8% of all acute hospital admissions were ADR-related identified by ICD-
10 coding, and only 1% of these coded ADRs was identified using the spontaneous ADR 
Method of ADR detection ADR 
prevalence 
Location Author/year 
Prospective and intensive 
monitoring 
 
14.6% 
13.3% 
10.79% 
11.29% 
19.48% 
Greece 
Australia 
UK 
Brazil  
Brazil 
Alexopoulou et al., 2008 [87] 
Chan et al., 2001 [88] 
Kongkaew et al., 2013 [89] 
Passarelli et al., 2005 [90] 
Varallo et al., 2011 [91] 
Spontaneous reporting 3.6% Belgium Somers et al., 2007 [92] 
Medical record review 
(prospective) 
 
2.9% 
4.6% 
10.66% 
UK 
Italy  
Canada 
Rogers et al., 2009 [93] 
Caamano et al., 2005 [94] 
Courtman et al., 1995[95] 
Medical record review 
(retrospective) 
7.8% Slovakia Wawruch et al., 2009 [96] 
Clinical coding 2.9% Netherlands van der Hooft et al., 2006 [97] 
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reporting system [97]. In a United Kingdom (UK) based study, only 31.5% of the ADR-
related admissions identified using a prospective observational method in a paediatric 
centre were also detected using ICD-10 codes [99], while in a study conducted in two 
Canadian hospital emergency departments (EDs), only 28.1% of prospectively identified 
ADEs (62 of 221 events) were identified using ICD-10 codes [100]. 
  
1.6. Strategies for preventing adverse drug reaction-related hospitalisations in the 
elderly 
Prevention of unnecessary hospitalisations by ADRs is an important goal in health policy 
decision-making [101]. Several strategies have been described in the literature and are 
discussed below. 
 
1.6.1. Medication review 
‘Medication review is a structured evaluation of patient’s medicines with the aim of 
optimising medicines use and improving health outcomes. This entails detecting DRPs 
and recommending interventions’ [102]. In 2008, the National Prescribing Centre, 
Department of Health, UK defined three types of medication review depending on the 
purpose of the review [103, 104]. The classification includes: 
i) Prescription review (Type 1): This addresses technical issues relating to a 
prescription, and takes place in the absence of the patient.  
ii) Concordance and compliance review (Type 2): This addresses issues relating 
to the patient’s medicine-taking behaviour, and takes place usually in the 
presence of the patient. 
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iii) Clinical medication review (Type 3): This addresses issues relating to the 
patient’s use of medicines in the context of their clinical condition, and takes 
place in the presence of the patient. 
 
There is a range of potential approaches to medication review used in different countries.  
In the UK, US, and Australia, clinical medication review is increasingly used [27]. In the 
UK, community pharmacists in England and Wales provide Medicines Use Reviews 
(MURs) which are now targeted towards particular patient groups, including those taking 
high-risk medicines [105]. Dispensing practices in England provide Dispensing Review 
of Use of Medicines (DRUM), and its main aim is to help patients understand their 
treatment and to identify potential DRPs [104]. In Scotland, the Chronic Medication 
Service (CMS) is another similar service in community pharmacies, aimed at patients 
with long-term conditions [106]. In the US, Medication Therapy Management (MTM) 
services are provided by community pharmacists and other service providers, with the 
aim of improving adherence or detecting ADEs and medication misuse [107]. 
Furthermore, in the US, patients are asked to bring all their medications including over-
the-counter and alternative medicines to a community pharmacist for a detailed 
medication review (‘brown bag reviews’) [108]. In Australia, accredited pharmacists 
conduct medication reviews for patients to identify and resolve DRPs [109]. The two 
established pharmacist-led medication review programs are Home Medicines Review 
(HMR) and Residential Medication Management Review (RMMR) [110].  HMR or  
Domiciliary Medication Management Review (DMMR) is a collaborative medication 
review for people in the community, and RMMR is for residents of aged care facilities 
[111]. In both programs, the main goal is to maximise an individual patient’s benefit from 
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their medication regimen and prevent or address medication-related problems through a 
team approach involving the general practitioner (GP) and a pharmacist. The Australian 
Department of Health also commenced two new programs in the last five years, 
Medicines Use Review and the Diabetes Medication Management Services, now known 
as the MedsCheck and Diabetes MedsCheck programs, respectively [112]. The 
MedsCheck/Diabetes MedsCheck Program involves in-pharmacy reviews with patients 
who are taking multiple medications and/or have newly diagnosed or poorly controlled 
type 2 diabetes. These reviews are aimed at enhancing the quality use of medicines and 
reducing the number of ADEs experienced by patients. 
  
Studies on the effectiveness of medication reviews  
Several studies have investigated the effectiveness of medication reviews. While most 
have demonstrated that medication reviews are effective in terms of DRP identification 
and rationalisation of medication regimens, the results relating to health outcomes have 
been more variable. In South East London, a study of brown bag reviews by pharmacists 
resulted in pharmacist intervention in 87% of medication reviews and identified 12% of 
reviews with medication-related problems such as ADRs that could potentially result in 
a hospital admission [113]. In a further 34% of cases, the potential for an improved 
outcome for the patient if drug therapy was changed was also identified. The 
implementation of clinical medical reviews in Dutch community pharmacies identified 
an average of 2.9 DRPs per review [114]. In the Netherlands, pharmacist-based 
medication reviews in the elderly significantly reduced the mean number of DRPs per 
patient (mean difference -16.3%, 95% CI 24.3–8.3) [115]. In a randomised controlled 
trial in elderly primary care patients, a pharmacist-led structured medication review 
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contributed to reductions in numbers of drugs and maintenance of self-rated health in 
elderly patients with polypharmacy [116]. However, in a cluster randomised controlled 
trial, clinical medication reviews did not influence the quality of life and geriatric 
problems in the elderly, and the higher percentage of resolved DRPs in the intervention 
group did not result in effects on the patients’ health [117]. In another randomised 
controlled trial in the UK, home-based medication review was associated with a 
significantly higher rate of hospital admissions in the elderly and did not significantly 
improve the quality of life or reduce deaths [118]. A randomised controlled study, which 
evaluated pharmacist-conducted follow-up at home of high-risk elderly patients 
discharged from an Australian hospital, found that 45% of the control group patients had 
unplanned readmissions to the hospital during the 90 days following discharge, compared 
to 28% of the intervention group patients (P = 0.05) [119]. In another randomised 
controlled trial in older adults undergoing first-time transfer from three Australian 
hospitals to a long-term care facility, the addition of a pharmacist transition coordinator 
improved aspects of the inappropriate use of medicines across health sectors, but not 
ADEs [120]. A pilot study in Australia concluded that an HMRs conducted post-
discharge could identify clinically significant medication-related issues [121]. In a 
prospective, non-randomised controlled cohort study in Australia, the patients who 
received a post-discharge service that involved point-of-care international normalised 
ratio monitoring, warfarin education and an HMR demonstrated statistically significantly 
decreased rates of combined major and minor haemorrhagic events [122]. In this study, 
combined haemorrhagic and thrombotic events were also decreased, while persistence 
with warfarin therapy improved. In a retrospective study of DRPs in Australian aged care 
homes, medication reviews by clinical pharmacists identified potential DRPs with a risk 
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of ADR in 96% of the residents [123]. In another retrospective cohort study in Australian 
war veterans, GP-pharmacist collaborative medication reviews delayed the time to next 
hospitalisation for bleeding in those treated with warfarin during the period 2 to 6 months 
after the review, but this was not sustained over time [124]. 
 
Systematic reviews on the effectiveness of medication review 
Many systematic reviews have been published addressing the effectiveness of medication 
review though few have focussed on community settings. A recent overview of 
systematic reviews of pharmacist-led medication reviews in community settings supports 
the value of medication reviews by pharmacists for a range of clinical outcomes such as 
diabetes control (78% of studies reporting the outcome), blood pressure control (74%), 
cholesterol (63%), medication adherence (56%) and medication management (47%) 
[125]. Medication review as an isolated short-term intervention, irrespective of the patient 
population and the outcome measures used, influenced most drug-related outcomes, with 
minimal effect on clinical outcomes and no effect on quality of life [126]. 
Currently, there is less evidence on the effectiveness of medication reviews on 
outcomes related to adverse events in the elderly population. In a review addressing the 
outcomes reported in trials of medication review in older patients, only 21% of the studies 
evaluated the impact of medication reviews on adverse events (AEs) such as ADRs or 
drug-related hospital admissions and consequently, only four published studies (9%) had 
a primary outcome in the AE domain [127]. Most of the outcomes were related to 
medication use (the number of drugs, the number of potentially inappropriate medicines 
[PIMs], or overuse) (n = 114, 35%) and healthcare use (hospitalisations or GP visits) 
(n = 74, 23%). Another systematic review addressing the processes and outcomes of 
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clinical medication review in community settings in Australia concluded that clinical 
medication reviews are beneficial in improving the quality use of medications. However, 
the impact on clinical outcomes is inconclusive [128]. 
In conclusion, clinical medication review appears to be a useful strategy for 
preventing ADRs among the different types of medication reviews. However, there is not 
sufficient evidence to determine which level of medication review is most effective in 
preventing ADR-related hospitalisations in the older population.   
 
1.6.2. Medication reconciliation  
Medication reconciliation is a formal process of obtaining and verifying a complete and 
accurate list of each patient’s current medicines, matching the medicines the 
patient should be prescribed to those they are actually prescribed [129]. It identifies and 
resolves unintentional discrepancies between patients’ medication lists across transitions 
in care [130]. In systematic reviews, pharmacy-led medication reconciliation 
interventions were found to be an effective strategy in reducing medication discrepancies 
[131]. A prospective, randomised, non-blinded study, assessing the effectiveness and 
feasibility of pharmacist-led admission medication reconciliation for geriatric patients, 
identified a significant number of discrepancies, including predominantly omissions and 
wrong doses, dosage forms, or frequencies [132]. Most unintentional discrepancies 
identified had no clinical significance and did not reduce post-discharge hospital 
utilisation, or the impact of medication reconciliation on clinical outcomes such as 
reductions in hospital readmissions was less clear [130, 133]. In a systematic review, 
hospital-based medication reconciliation interventions did not have any effect on clinical 
outcomes, though the medication reconciliation was focussed on patients at high risk of 
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adverse events [134]. In a prospective, randomised, single-period longitudinal study, 
pharmacist involvement in hospital discharge transitions of care of high-risk patients 
through medication reconciliation, medication education, and post-discharge call-backs 
had a positive impact on decreasing composite inpatient readmissions and ED visits 
[135]. In this study, there was no significant difference in ADEs observed between the 
intervention group and the control group. A recent systematic review showed that 
pharmacist-led medication reconciliation at hospital transitions in adult patients 
substantially reduced ADE-related hospital revisits (relative risk reduction of 67%), ED 
visits (28%) and hospital readmissions (19%) [136]. 
Medication reconciliation, in addition with other services, prevented ADR-related 
hospital admissions in two studies. In a prospective controlled study, medication 
reconciliation upon admission and discharge, and medication review and monitoring 
significantly reduced unscheduled drug-related hospital revisits (p = 0.0469) among 
elderly patients [137]. In a randomised trial, a pharmacist intervention focused on 
medication reconciliation, medication review, patient counseling, and telephone follow-
up was associated with a lower rate of preventable ADEs 30 days after hospital discharge 
[138]. In this study, discharge medication regimens were compared with pre-admission 
regimens, all discrepancies were reconciled, and patients were screened for previous 
DRPs. Additionally, in order to explore any discrepancies, the pharmacist compared the 
patient's self-reported medication list with the discharge list during the follow-up 
telephone call.  
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1.6.3. Avoiding inappropriate medications 
Inappropriate prescribing in the elderly has become an important public health issue 
worldwide since the prescription of PIMs is associated with an increase in AEs, 
prescribing cascades, morbidity, mortality and health-care costs [139, 140]. Prescribing 
appropriateness can be evaluated by process or outcome measures that are explicit 
(criterion-based) or implicit (judgement-based) [141]. Explicit criteria tend to focus on 
specific medications or disease states and are usually developed from published reviews, 
expert opinions, and consensus techniques [140, 142]. Implicit criteria are not drug or 
disease specific and rely on clinical judgement or expert professional judgement but are 
more patient-focused [141, 142].  
Various explicit criteria have been developed by experts in the US [143] and 
Canada [144] to identify PIM use in elderly patients, to help minimise DRPs. The most 
widely used criteria is the one developed by Beers and colleagues for PIM use in older 
adults, which was published in 1991 [143]. The original Beers criteria have been revised 
and updated in 1997, 2003, 2012 and 2015 [145-148]. In 2015 update by the American 
Geriatrics Society, 50 medications or medication classes are divided into three categories, 
namely PIMs that should be (i) avoided in older adults, (ii) avoided in older adults with 
certain diseases and syndromes and (iii) used with caution [148]. The new additions in 
the updated version are selected drugs for which dose adjustment is required based on 
renal impairment, and the addition of selected drug-drug interactions. In 2008, the 
Screening Tool of Older Person's Prescriptions (STOPP) criteria was developed for 
identifying inappropriate prescribing in the elderly [149]. The START (Screening Tool 
to Alert doctors to the Right Treatment) criteria, another screening tool was developed 
and validated in 2007 to detect prescribing omissions in elderly patients [150]. 
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STOPP/START is a comprehensive screening tool that enables the prescribing physician 
to appraise older patients’ prescription drugs in the context of their current diagnoses 
[151, 152]. In a prospective study in the elderly, STOPP criteria PIMs were significantly 
associated with avoidable ADEs in older people that cause or contribute to urgent 
hospitalisation [153]. 
The most cited implicit criteria is the Medication Appropriateness Index, which 
was developed by Hanlon et al. in 1992 [141, 154]. This tool assesses prescribing 
appropriateness using ten criteria: indication for the drug, effectiveness for the condition, 
correct dose, correct direction, practical directions, clinically significant drug-drug 
interactions, clinically significant drug-disease interactions, unnecessary duplication, 
acceptable duration of therapy and cost effectiveness [154]. The Assessment of 
Underutilisation of Medication is another tool, which assessed omitted but necessary drug 
therapies for chronic conditions [155, 156]. The Inappropriate Medication Use and 
Prescribing Indicators Tool is an instrument developed by Australian researchers in 2008, 
and is based on 45 explicit and three implicit prescribing indicators [157]. 
  
1.6.4. Computer-assisted decision support systems 
Computerised physician order entry (CPOE) and clinical decision support systems 
(CDSSs) have the potential to improve drug safety [158]. CDSSs and CPOE provide 
support in the ordering stage of the medication use process by identifying PIMs, drug 
interactions, ADRs, appropriate drug dosage and contraindicated treatments [3, 159]. 
They also use different algorithms and tools to identify drug-related illness. In one study, 
the implementation of CPOE reduced the potential ADE rate by 84% [160]. However, in 
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a systematic review, CDSSs inconsistently improved process of care measures and did 
not improve patient outcomes [161]. 
  
1.6.5. Comprehensive geriatric assessment 
Comprehensive geriatric assessment allows a complete and global assessment [3] and is 
used to determine the medical, psychosocial, functional capabilities of a frail older adult 
to develop a coordinated and integrated plan for treatment and long-term follow-up [162]. 
A comprehensive assessment and management of healthcare problems in the elderly help 
in recognising and preventing potential DRPs and thereby reduces the risk of ADRs [163]. 
In a randomised controlled trial, outpatient geriatric evaluation and management reduced 
serious ADRs and reduced suboptimal prescribing in frail elderly patients compared with 
usual care [164]. 
  
1.7. Adverse drug reaction risk prediction tools 
ADR risk prediction tools for use in the elderly have been developed in recent years [9, 
10]. ADR risk stratification in the elderly could assist in case prioritisation and allow 
more cost-effective allocation of additional health resources towards this group to reduce 
their risk of developing ADRs. However, the available ADR prediction tools developed 
for use in the elderly are used to identify ADRs occurring in hospital, and no tools have 
been developed to date to predict ADR-related admissions in older patients living in the 
community. The development of a validated tool to identify elderly patients at risk of 
ADR-related admissions requires urgent action since this approach has never been 
adopted before in the field of ADRs. The need for the development of such a tool is 
discussed in detail in Chapter 2.  
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CHAPTER TWO 
 
2. Hospitalisation in Older Patients due to Adverse Drug 
Reactions – the Need for a Prediction Tool 
 
2.1. Preface  
The previous chapter provided an overview of the evidence relating to adverse drug 
reactions (ADRs) and highlighted various strategies to prevent ADR-related 
hospitalisation in the elderly. The review identified several gaps in the literature, 
including the lack of a narrative review investigating the need for a prediction tool for 
ADR-related hospitalisation in older patients. Hence, this chapter presents a narrative 
evaluation of studies that evaluated the predictors of ADR-related hospitalisation in the 
elderly and recommends the need for a prediction tool. 
  
Publication: 
Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, 
Bereznicki LR. Hospitalization in older patients due to adverse drug reactions – the need 
for a prediction tool. Clinical Interventions in Aging 2016; 11: 497-505. 
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2.2. Abstract 
Adverse drug reactions (ADRs) represent a major burden on society, resulting in 
significant morbidity, mortality and healthcare costs. Older patients living in the 
community are particularly susceptible to ADRs and are at an increased risk of ADR-
related hospitalisation. This review summarises the available evidence on ADR-related 
hospital admission in older patients living in the community, with a particular focus on 
risk factors for ADRs leading to hospital admission and the need for a prediction tool for 
risk of ADR-related hospitalisation in these individuals. The reported proportion of 
hospital admissions due to ADRs has ranged from 6% to 12% of all admissions in older 
patients. The main risk factors or predictors for ADR-related admissions were advanced 
age, polypharmacy, comorbidity and potentially inappropriate medications. There is a 
clear need to design intervention strategies to prevent ADR-related hospitalisation in 
older patients. To ensure the cost-effectiveness of such strategies, it would be necessary 
to target them to those older individuals who are at highest risk of ADR-related 
hospitalisation. Currently, there are no validated tools to assess the risk of ADRs in 
primary care. There is a clear need to investigate the utility of tools to identify high-risk 
patients to target appropriate interventions toward prevention of ADR-related hospital 
admissions. 
  
Keywords: adverse drug reactions, hospital admission, prediction, older patients, primary 
care, risk factors 
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2.3. Introduction 
Medication-related adverse events (AEs) in general practice represent an important cause 
of morbidity and are thought to cause between 10% and 30% of all hospital admissions 
in older patients [165, 166]. These AEs are defined as “any untoward medical occurrences 
that may present during treatment with a pharmaceutical product but which does not 
necessarily have a causal relationship with this treatment” [40]. Among these AEs, 
adverse drug reactions (ADRs) represent a major burden, causing significant morbidity, 
mortality, and health care costs [3, 4]. The World Health Organisation (WHO) defines an 
ADR as any noxious, unintended, and undesired effect of a drug, excluding therapeutic 
failures, intentional and accidental poisoning, and drug abuse [37, 167]. ADRs can be 
assessed as severe, moderate, or mild reactions [88]. A severe ADR is life-threatening, 
causing permanent damage or requiring intensive care. Moderate ADRs require hospital 
admission, a change in therapy, or specific treatment. In a meta-analysis of prospective 
studies, 100,000 deaths per year could be attributed to ADRs in the USA, which highlights 
the seriousness and extent of the problem [36]. Furthermore, a Swedish study estimated 
that 3.1% of deaths in the general population (including subjects who died in and outside 
hospitals) were attributed to ADRs [46].  
Older patients are particularly susceptible to ADRs due to multiple comorbidities, 
cognitive and functional impairment, a high prevalence of multiple medications 
(polypharmacy), [168] and age-related changes in pharmacokinetics and 
pharmacodynamics [4]. A significant consequence of ADRs in older adults living in the 
community is hospitalisation and its related costs [169]. These patients then become 
susceptible to hospitalisation-related complications, such as cardiovascular and 
neurological disorders, nosocomial infections, and deconditioning [170]. It may be 
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challenging for primary care physicians (or general practitioners [GPs]) to easily identify 
patients who are at risk of hospitalisation due to ADRs, partly due to significant time 
pressures in office-based practice [171]. This narrative review explores our current 
understanding of ADR-related hospitalisation in older patients, with a particular focus on 
risk factors and the need for a prediction tool for ADR-related hospitalisation for 
utilisation in community settings. 
  
2.4. ADR-related hospitalisation in older patients – how significant is the problem? 
Based on a retrospective cohort study in a veteran population (median age 81 years), the 
overall proportion of potentially preventable medication-related hospitalisations was 
20.3% over a 5-year period [70]. ADRs were the most common cause, accounting for 
one-third of hospitalisations based on a study by Chan et al. [88]. Data collected from GP 
encounters in 2003–2004 in Australia indicated that ADRs represented the most common 
adverse drug event (ADE) in the community (72%), of which the majority were moderate 
or severe and required hospitalisation [49]. The proportion of all hospital admissions due 
to ADRs has ranged from 6% to 12% among older patients [96, 169, 172-174]. Also, one 
study conducted in Canada found that emergency department visits and hospital 
admissions due to ADRs in older patients cost an estimated US$35.7 million annually 
[175]. 
  
2.5. Severity, causality, and avoidability of ADR-related hospitalisation in older 
patients 
ADR-related hospitalisation can lead to fatal outcomes and increased length of stay in 
older patients [58, 176]. The severity of ADR-related admissions was assessed in a 
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prospective study, in which 18.6% of cases were identified as severe ADRs [87]. The 
most severe ADRs were related to haemorrhage and other haematological disorders, and 
acute renal failure. Most of the ADRs causing hospital admission in older patients were 
type A reactions, which are predictable from the known pharmacology of the drug, [58, 
176] whereas type B reactions (bizarre or non-dose-related reactions) accounted for only 
8.1% based on a cross-sectional study [176].  
Since ADRs are a major cause of morbidity and mortality, it is important to 
demonstrate a causal relationship between the drug and the adverse clinical event. 
Furthermore, it is often difficult to decide if an adverse clinical event is an ADR or due 
to deterioration in the patient’s disease state. Therefore, causality assessment is used to 
determine the likelihood that a drug caused a suspected ADR [177]. The most widely 
used and generally accepted causality assessment scales in clinical practice are the 
probability scales developed by the WHO Collaborating Centre for International Drug 
Monitoring (Uppsala Monitoring Centre, Sweden) and the Naranjo ADR Probability 
Scale [178, 179]. These scales use inter-rater agreement scores, which are superior to 
subjective clinical judgment. However, they can be difficult to interpret in the context of 
older patients with multiple comorbidities and medications [180]. Based on different 
studies, the majority of ADRs in older adults leading to hospital admissions were either 
probable or possible based on causality assessments [58, 87, 181]. Definite or certain 
ADRs accounted for only 4% and 6.8%, respectively, in some studies [173, 181].  
While some ADR-related hospitalisations are unavoidable, even with the most 
extraordinary precautions (e.g., immunological reactions), more than half of hospital 
admissions for ADRs are preventable [88]. Potentially avoidable ADRs leading to 
hospital admission in older adults could be due to improper dosage, missed 
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contraindications and drug interactions, or re-exposure of patients who had known drug 
allergies. ADRs can be classified into definitely avoidable, possibly avoidable, 
unavoidable, and unclassifiable based on the Halls criteria [182]. Among the ADRs 
causing hospital admission in older patients, most were either definitely or possibly 
avoidable, with only 18.6%–28% of cases considered unavoidable [58, 173]. 
  
2.6. Most common ADRs causing hospitalisation in older patients 
Advancing age can contribute to a significant increase in sensitivity to particular drugs 
and a corresponding increase in the incidence of ADRs [183]. Older patients demonstrate 
an exaggerated response to central nervous system-active drugs (e.g., benzodiazepines, 
anaesthetics, opioids) and a decreased response to some cardiovascular agents (e.g.,  beta-
adrenergic agents) [184]. Also, the most important pharmacokinetic changes in older 
people include a decrease in the excretory capacity of the kidney, rather than a decline in 
the rate of hepatic drug metabolism [185]. The most frequent ADRs causing hospital 
admission in older patients are typically gastrointestinal disorders [4, 58, 87, 173, 176] 
and cardiovascular and metabolic/endocrine complications [4, 58, 87, 96, 169, 173]. A 
summary of the most common ADRs causing hospitalisation in older patients is shown 
in Table 2. 
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Table 2. Most common ADRs causing hospitalisation in the elderly  
Most common ADRs Examples 
Gastrointestinal complications [4, 58, 87, 
173, 176]   
Gastrointestinal bleeding, peptic ulcer, 
erosive gastritis, nausea, vomiting 
Cardiovascular disorders [58, 96, 169, 173] Hypotension, bradycardia, falls, arrhythmias 
Metabolic/endocrine complications [4, 87, 
169] 
Hypoglycaemia 
Renal and urinary disorders [58, 87, 176]  Renal impairment, acute renal failure 
Electrolyte disorders [58, 174] Hypokalaemia, hyperkalaemia, hyponatremia 
Nervous system disorders [169, 176]  
 
Depressed level of consciousness, mental 
status changes 
Abbreviation: ADRs, adverse drug reactions. 
 
2.7. Drugs most frequently causing ADR-related hospitalisation in older patients 
Older patients, due to the presence of multiple disease states, frequently use medications 
including prescription, over-the-counter, and herbal preparations. According to a survey 
conducted in 3,005 community-dwelling older adults aged 57–85 years in the USA, at 
least one prescription medication was used by 81% of the overall survey population, and 
five or more prescription medications were used by 36% of people aged 75–85 years 
[186]. The drugs most frequently causing ADR-related hospital admissions in older 
patients have varied between studies; these findings are summarised in Table 3. 
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Table 3. Most common drugs causing ADR-related hospital admission in the elderly 
Abbreviation: ADR, adverse drug reaction. 
 
 
2.8. Predictors of and risk factors for ADR-related hospitalisation in older patients  
Despite concerns that ADRs represent an important medical problem in older patients, 
the predictive factors are still poorly understood, particularly in the community-dwelling 
elderly. The characteristics and major findings of studies that have investigated the risk 
factors for ADR-related hospital admission in older patients are shown in Table 4.
Most common drugs Reference 
Antibacterials  
Anticonvulsants  
Antineoplastic agents  
Antipsychotics  
Antithrombotics (anticoagulants and 
antiplatelets)  
Cardiovascular drugs  
Diuretics  
Cardiac glycosides  
Angiotensin converting enzyme inhibitors  
β-Blockers 
Antiarrhythmics 
Calcium channel blockers  
Corticosteroids  
Hypoglycaemics  
Nonsteroidal anti-inflammatory drugs  
[4, 173, 174] 
[187] 
[4, 188] 
[4, 188] 
[87, 173, 174, 176, 187, 188] 
 
 
[4, 58, 87, 174, 176, 188] 
[4, 173, 187] 
[87, 173, 176, 181, 187] 
[181, 187] 
[87, 173] 
[4] 
[4] 
[187, 188] 
[4, 58, 87, 173, 176, 187] 
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Table 4. Studies investigating risk factors for ADR-related hospital admission in older patients 
Study Country and 
year 
conducted 
Design Duration Settings Mean/ 
median 
age 
(Years) 
Main outcome 
measures 
Predictors/risk factors 
Onder  
et al. [4] 
 
 
 
Italy  
1988–1997 
Multicentre 
pharmacoepidemiology 
survey 
10 years Academic 
hospitals 
70 ADR severity, 
potentially 
responsible 
drugs, 
predictors 
Female sex (OR 1.30, 95% CI 1.10–1.54)  
Alcohol use (OR 1.39, 95% CI 1.20–1.60)  
Number of drugs (OR 1.24, 95% CI 1.20–1.27 for 
each drug increase)  
Severe ADRs  
Age (OR 1.50, 95% CI 1.01–2.23 for age 65–79 
years and OR 1.53, 95% CI 1.00–2.33 for age ≥80 
years)  
Comorbidity (OR 1.12, 95% CI 1.05–1.20 for each 
point in the CCI)  
Number of drugs (OR 1.18, 95% CI 1.11–1.25 for 
each drug increase) 
Marcum  
et al. [169] 
 
US  
2004–2006 
Retrospective cohort 3 years All 
admissions 
(veterans) 
76.4 ADR causality, 
preventability, 
predictors 
Polypharmacy ( ≥9 and 5–8 medications) 
 (AOR 3.90, 95% CI 1.43–10.61 and AOR 2.85, 95% 
CI 1.0–7.85, respectively) 
Mannesse 
et al. [172] 
 
Netherlands 
1994 
Observational  
cross-sectional 
3 months University 
hospital 
78  Risk indicators 
for severe 
ADRs 
Fall before admission (OR 51.3, P=0.006)  
Gastrointestinal bleeding or haematuria (OR 19.8, 
P<0.001) Use of three or more drugs (OR 9.8, 
P=0.04) 
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Study Country and 
year 
conducted 
Design Duration Settings Mean/ 
median 
age 
(Years) 
Main outcome 
measures 
Predictors/risk factors 
Franceschi 
et al. [173] 
Italy  
2004–2005 
Prospective  
cross-sectional 
1 year Geriatric 76.5 ADR 
prevalence, 
avoidability 
Drug–drug interactions (32.3%)  
Inappropriate prescription (21.8%) 
Wawruch  
et al. [96] 
 
Slovakia  
2003–2005 
Retrospective 
cross-sectional 
1.4 years Internal 
medicine  
76.6 ADR predictors Ischaemic heart disease (OR 4.50, 95% CI 1.36–
14.88) Depression (OR 2.49, 95% CI 1.08–5.77)  
Heart failure (OR 2.08, 95% CI 1.13–3.81) 
Wu  
et al. [175] 
 
Canada  
2003–2008 
Retrospective cohort 5 years Emergency 
department 
77 Incidence, cost, 
risk factors  
Sex (for females, AOR 0.81, 95% CI 0.72–0.92)  
Age (AOR 1.03, 95% CI 1.02–1.04)  
CCI score >3 (AOR 1.86, 95% CI 1.48–2.33)  
Number of drugs (AOR 1.48, 95% CI 1.13–1.93 for 
6–10 drugs and AOR 1.93, 95% CI 1.49–2.51 for >11 
drugs) Multiple pharmacies (AOR 1.13, 95% CI 1.00–
1.27)  
Newly prescribed drugs (AOR 1.17, 95% CI 0.93–
1.47) Recent hospital admission (AOR 1.47, 95% CI 
1.23–1.76) Long-term care residence (AOR 2.08, 
95% CI 1.62–2.67) 
Pedros  
et al. [176] 
 
Spain  
2009–2010 
Cross-sectional 120 days Teaching 
hospital 
75 ADR predictors Age ≥65 years (OR 1.59, 95% CI 1.10–2.29)  
Number of drugs taken 3–5 (OR 5.07, 95% CI 2.71–
9.50), 
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Study Country and 
year 
conducted 
Design Duration Settings Mean/ 
median 
age 
(Years) 
Main outcome 
measures 
Predictors/risk factors 
6–9 (OR 5.90, 95% CI 3.16–11.01), and ≥10 (OR 
8.94, 95% CI 4.73–16.89) 
Alexopoulou  
et al. [87] 
 
Greece  
2005 
Prospective  
cross-sectional 
6 months University 
hospital 
65 Frequency of 
ADRs, 
causality, 
severity, 
preventability, 
predictors 
Number of drugs (OR 1.064, 95% CI 1.019–1.109) 
 
Olivier  
et al. [188] 
 
France  
2002–2003 
Prospective  
cross-sectional 
4 weeks Emergency 
department 
80.2 ADR incidence, 
risk factors 
Number of drugs (OR 1.18, 95% CI 1.08–1.29)  
Self-medication (OR 2.34, 95% CI 1.18–4.66)  
Use of antithrombotics (OR 2.26, 95% CI 1.33–3.88)  
Use of antibacterial drugs (OR 4.04, 95% CI 1.50–
10.83) 
Malhotra  
et al. [189] 
 
India 
2000 
Prospective  
cross-sectional 
7 months  Emergency 
department 
72.5 Risk factors Number of drugs ≥3 (OR 4.3) 
Consulting >3 physicians (OR 5.7)  
Living alone (OR 4.3) 
Chen  
et al. [190] 
 
Taiwan  
2009–2010 
Prospective  
case–control 
1 year Emergency 
department 
65 Risk factors Number of drugs (AOR 4.1, 95% CI 2.4–6.9 for 3–7 
drugs; AOR 6.4, 95% CI 3.7–11.0 for eight or more 
drugs) and increased concentration of serum 
creatinine (AOR 1.5, 95% CI 1.1–2.2) 
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Study Country and 
year 
conducted 
Design Duration Settings Mean/ 
median 
age 
(Years) 
Main outcome 
measures 
Predictors/risk factors 
Zhang  
et al. [8] 
Australia  
2005 
 
Retrospective cohort Records 
of ADR 
admission 
from 1980 
to 2000 
and 
followed 
for three 
years 
All public 
and private 
hospitals 
Mean age 
not 
reported, 
study in 
patients 
aged ≥60 
years 
ADR predictors Sex (HR 1.08, 95% CI 1.02–1.15, for men)  
First admission in 1995–1999 (HR 2.34, 95% CI 
2.00–2.73) Length of hospital stay (HR 1.11, 95% CI 
1.05–1.18, for stays ≥14 days)  
CCI (HR 1.71, 95% CI 1.46–1.99, for score ≥7)  
Comorbid congestive cardiac failure (HR 1.56, 95% 
CI 1.43–1.71), peripheral vascular disease (HR 1.27, 
95% CI 1.09–1.48), chronic pulmonary disease (HR 
1.61, 95% CI 1.45–1.79), rheumatological disease 
(HR 1.65, 95% CI 1.41–1.92),  
mild liver disease (HR 1.48, 95% CI 1.05–2.07), 
moderate to severe liver disease (HR 1.85, 95% CI 
1.18–2.92), moderate diabetes (HR 1.18, 95% CI 
1.07–1.30), diabetes with chronic complications (HR 
1.91, 95% CI 1.65–2.22), renal disease (HR 1.93, 
95% CI 1.71–2.17), any malignancy including 
lymphoma and leukaemia (HR 1.87, 95% CI 1.68–
2.09), and metastatic solid tumors (HR 2.25, 95% CI 
1.92–2.64) 
Abbreviations: ADR, adverse drug reaction; OR, odds ratio; CI, confidence interval; CCI, Charlson Comorbidity Index; AOR, adjusted odds ratio; HR, 
hazard ratio. 
40 
 
Age as a significant contributing factor to ADR-related hospitalisation had been observed 
in community-dwelling older patients in some studies [4, 175, 176]. The odds of 
experiencing severe ADRs increased by 3% per 1-year increase in age above 66 years 
[175].  
The number of drugs being taken has also been highlighted in many studies as an 
independent risk factor for ADR-related hospital admissions [4, 87, 169, 172, 175, 176, 
188-191]. It has been estimated that the chance of an older patient having an ADR 
increases from 10%, when one medication is used, to 75% if more than five medications 
are used concurrently [192]. The risk increase of an older patient (mean age 70 years) 
having an ADR-related hospitalisation is 24% for each drug increase [4]. 
The prevalence of multimorbidity (the coexistence of multiple chronic diseases)  
in older patients ranges from 55% to 98% based on the systematic reviews [18]. The 
presence of comorbidity also predicted ADR-related hospitalisation in community-
dwelling older patients [4, 8, 96, 175, 191]. Relevant comorbidities included ischaemic 
heart disease; heart failure; depression; diabetes; peripheral vascular disease; and 
pulmonary, rheumatological, hepatic, renal, and malignant diseases. In a population-
based retrospective study, comorbidity predicted repeat admission for ADRs in older 
patients, especially those with comorbidities often managed in the community [8]. 
Potentially inappropriate drug prescribing is highly prevalent among community-
dwelling older patients, and potentially inappropriate medications (PIMs) in these 
patients are significantly associated with ADRs and subsequent hospital admission [193, 
194]. According to Price et al., exposure to a PIM from the Beers list of medications was 
associated with a significant increase in unplanned hospitalisations (odds ratio [OR] 1.18, 
95% confidence interval [CI] 1.15–1.21) [195]. There was also an increase in inpatient 
41 
 
visits (OR 1.99, 95% CI 1.76–2.26) in older patients who were prescribed PIMs based on 
a retrospective cohort study [196].  
A range of other factors has also been associated with ADR-related 
hospitalisation, but these associations have been less consistently described. The presence 
of drug interactions was identified as a risk factor for ADRs in one study [173]. Female 
sex was also associated with ADR-related hospitalisation in older patients based on a 
study by Onder et al. [4]. However, sex was not found to be an independent risk factor 
based on a cross-sectional study [176]. An overview of the predictors of ADR-related 
hospitalisation in older patients is provided in Table 5.  
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Table 5. An overview of predictors of ADR-related hospital admission in the elderly 
Frequently reported predictors Other predictors 
Number of medications  
[4, 87, 169, 172, 175, 176, 188-191] 
Comorbid conditions [4, 96, 175, 191, 197] 
Age [4, 175, 176] 
Potentially inappropriate medications  
[195, 196] 
 
Drug interactions [173] 
Female sex [4] 
Self-medication [188] 
Use of antithrombotics [188] 
Use of antibacterial drugs [188] 
Alcohol use [4] 
Falls before admission [172] 
Patients living alone [189] 
Increased serum creatinine [190] 
Multiple pharmacy visits [175] 
More than three consulting physicians [189] 
Newly prescribed drugs [175] 
Recent hospital admission [175] 
Long-term care residence [175] 
Patients with diabetes or neoplasms [189] 
Gastrointestinal bleeding or haematuria [172] 
Ischaemic heart disease [96] 
Depression [96] 
Heart failure [96] 
Abbreviation: ADR, adverse drug reaction. 
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2.9. The need for an ADR prediction tool in older patients in primary care 
Prediction tools use multiple predictors to estimate the absolute risk that a certain outcome 
is present and enable the stratification of individuals or group of individuals by these risks 
[198]. They are usually developed to guide health care professionals in their decision 
making regarding further management and to inform individuals about their risk of 
experiencing a certain outcome [199]. Risk prediction models for ADRs have begun to 
emerge in recent years, which aim to assist health care professionals to make clinical and 
therapeutic decisions to minimise the risk of drug-related harm, especially in the older 
population having the highest risk of ADRs [9, 10, 167]. This will help the physician and 
the pharmacist to pay extra attention to a patient’s medications when they are identified 
as being at risk [9].  
It is often difficult to predict the occurrence of ADRs in older patients for several 
reasons. The presentation of an ADR is often atypical and nonspecific in nature, which 
can be misinterpreted as a new medical problem or a complication relating to a preexisting 
diagnosis [200]. This may lead to the addition of another drug to treat the symptoms 
(referred to as a “prescribing cascade” [201]), which will again increase the risk of drug–
drug interactions and another ADR [202]. Sometimes, due to inappropriate 
polypharmacy, there is a chance that two or more drugs taken by the patient may lead to 
the same ADR [203]. The prediction of ADRs is especially challenging in patients with 
dementia, and cognitive impairment since problems with the patient’s communication 
and reporting of adverse effects might reduce the clinician’s ability to detect ADRs [204]. 
Hence, identification of the various risk factors for ADRs and predicting high-risk elderly 
patients is essential for better therapy outcomes and targeting additional resources toward 
this group [9]. To our knowledge, there are no empirical data that allow stratification of 
44 
 
community-dwelling older people according to the likelihood of ADRs leading to hospital 
admission. A fundamental problem is that there is only a limited understanding of the risk 
factors associated with ADR-related hospitalisation in the older population living in the 
community. Also, considerably more research has been focused on ADRs occurring in 
the hospital than in the community setting [205].  
The contemporary validated ADR risk prediction tools used in hospital settings, 
detailed in Table 6, could be used as guides to develop similar models in community 
settings. The GerontoNet ADR risk score is one such validated model proposed by Onder 
et al. to identify hospitalised patients who are at an increased risk of an ADR [9]. This 
risk score identified several risk factors for the development of ADRs and developed a 
score that allows stratification of patients according to the likelihood of an ADR. The 
strongest predictors of ADRs in this study were the number of medications and a history 
of an ADR, followed by the presence of heart failure, liver disease, four or more medical 
conditions, and renal failure. The GerontoNet ADR risk score was reported to have 
satisfactory predictive value for ADRs with an area under the curve (AUC) of 0.71 (95% 
CI 0.68–0.73) [9, 167]. But, one of the important limitations of this study was that data 
on the preventability of ADRs were not collected, so the authors could not assess the risk 
factors for preventable ADRs. Also, these study findings cannot be extrapolated to older 
patients living in the community setting since the data were collected based on 
hospitalised patients 65 years or above. Another important limitation is that the 
GerontoNet ADR risk score did not account for the use of PIMs as a risk factor, which 
could be a stronger predictor of ADRs. 
 
 
45 
 
Table 6. Features of validated ADR prediction tools for elderly hospitalised patients 
Features Onder et al. [9] 
(GerontoNet ADR risk score) 
Tangiisuran et al. [10] 
(BADRI) model 
Study design                                     
Developmental stage 
Validation stage 
 
Retrospective cohort 
Prospective cohort 
 
Prospective cohort 
Prospective cohort 
Main outcome measure ADR (6.5%) ADR (12.5%) 
Age of study participants (years) Mean (SD)  
78 (7.2) 
Median (IQR)  
85 (81–89) 
Most common ADRs  Cardiovascular and arrhythmic 
complications 
– 
Predictors of ADRs ≥4 Comorbid conditions  
Heart failure  
Liver disease  
Number of drugs  
History of ADR  
Renal failure 
≥8 drugs  
Hyperlipidaemia  
Raised white cell count  
Use of antidiabetic 
agents  
Length of stay ≥12 days 
Predictive ability of risk score 
(AUROC) 
Developmental stage         
Validation stage     
 
 
0.71 (95% CI 0.68–0.73) 
0.70 (95% CI 0.63–0.78) 
 
 
0.74 (95% CI 0.68–0.79) 
0.73 (95% CI 0.66–0.80) 
Cut-off score Between 3 and 4 >1 
Sensitivity  68% 80% 
Specificity  65% 55% 
Abbreviations: ADR, adverse drug reaction; AUROC, area under the receiver operating 
characteristic curve; CI, confidence interval; SD, standard deviation; IQR, interquartile range. 
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O’Connor et al. investigated the clinical applicability and the ability to predict ADRs 
using the GerontoNet ADR risk score in hospitalised older patients [167]. The variables 
that increased ADR risk in their alternative model included renal failure, increasing 
number of medications, inappropriate medications, and age ≥75 years. The study results 
showed that 37.7% of ADRs were not predicted by the GerontoNet ADR risk score. The 
authors’ model included additional predictors like PIMs which would influence the 
presence of ADRs, but had a lower predictive value for ADRs (AUC of 0.62 [95% CI 
0.57–0.68]) compared to the GerontoNet ADR risk score.  
Tangiisuran et al. recently developed and validated an ADR risk model in a 
population of patients with a median age of 85 years [10]. This model was based on five 
clinical variables, some of which have not been previously reported. Compared with the 
GerontoNet ADR risk score and the model developed by O’Connor et al., this model had 
a higher predictive value for ADRs. Again, this model did not account for the use of PIMs 
as a risk factor. Also, this model did not use a uniform criterion for causality assessment 
of ADRs, which might have affected the outcome of the study.  
The utility of an ADE trigger tool had been explored in a few studies conducted 
among older patients living in the community. One such tool used a 39-item trigger tool 
in patients aged 65 years or above in ambulatory primary care practices [206]. The most 
common triggers and their positive predictive values (PPVs) for ADE were “Medication 
stop” (26.3%), “Hospitalisation” (21.8%), and “Emergency Room visit” (14.9%). Most 
of the triggers had very low PPVs, and only nine of the triggers had PPVs >5% which 
could detect 94.4% of the ADEs. Similarly, the utility of an ADE trigger tool in Veterans 
Affairs nursing homes has also been studied and found an overall PPV of 40.1% [207]. 
The most common ADEs detected by this tool were acute kidney injury, hypokalaemia, 
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hypoglycaemia, and hyperkalaemia. Even though these tools could be used to identify 
ADEs in community-dwelling older patients, there is a clear need to predict the future 
occurrence of these events, especially ADRs. 
 
2.10. Development of an ADR prediction tool for older patients in primary care 
A study has suggested that the majority of older patients had their own family physicians 
(95%) at the time of presenting to the ED due to ADRs [175]. Primary care physicians 
are best able to understand the complete medical, functional, and social issues that are in 
play when optimising medications in older people living in the community. Since the 
older population is likely to have multiple risk factors for ADRs, ideally, the GPs should 
be able to predict those older adults who have a severe risk of ADRs that may lead to 
emergency hospital admissions. The development of an ADR prediction tool in 
community settings would facilitate this. The design of such a tool would require 
identification of a comprehensive list of possible predictive factors contributing to ADR-
related hospitalisation based on the literature, available validated ADR prediction tools 
and clinical experience. These predictive factors could then be quantified in large 
populations of elderly subjects admitted and not admitted to hospital with an ADR 
preferably using a prospective study design. Univariate and multivariate analyses could 
be undertaken, and the significant predictors of ADR-related hospitalisation assigned a 
score based on their respective ORs. Finally, an ADR risk score could be computed based 
on the sum of the scores of individual variables as described by Onder et al., with a 
subsequent validation stage [9]. A risk score may also be used to improve prescribing 
practice. The ADR risk score could potentially be integrated into prescribing software to 
alert GPs regarding their patients’ risk of ADRs and prompt appropriate preventive 
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measures, which might include medication review in high-risk patients, avoiding 
inappropriate medications, comprehensive geriatric assessment, [3] and cessation of high-
risk medications which are least likely to be beneficial. Similarly, policy makers could 
use the score to target limited health care resources to patients in real need of intervention 
to address the issue of quality use of medicines. 
 
2.11. Conclusion 
It is clear that older patients are at significant risk of hospital admissions due to ADRs 
and many ADRs occurring in this population are considered preventable. There is a need 
for greater understanding of the predictors of ADRs in these patients, and how these 
predictors are interrelated. This will provide the basis for improved risk assessment 
practices. Even though various risk models in older populations have been suggested for 
use in hospital settings, there is a clear need for a simple, practical, and efficient tool to 
identify the high-risk group of older patients most likely to be admitted to hospital due to 
ADRs. These patients can be targeted in order to reduce their risk of ADRs and their 
associated morbidity and costs. 
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CHAPTER THREE 
 
3. Adverse Drug Reaction-Related Hospitalisation in Elderly 
Australians: A Prospective Cross-Sectional Study in Two 
Tasmanian Hospitals 
 
3.1. Preface  
Chapter 2 highlighted the need for a validated adverse drug reaction (ADR) tool to 
identify high-risk elderly patients most likely to be admitted to hospital due to ADRs. To 
better inform the design of such a tool, we needed to enhance our understanding of ADRs 
that lead to hospitalisation. Hence, this chapter describes the results of a descriptive 
analysis, which pooled the available data from two prospective studies that were 
conducted to develop and validate an ADR prediction tool. This descriptive analysis 
enabled us to understand the current extent of the problem of ADR-related admissions in 
elderly Australians before the development of a validated ADR tool. 
  
Publication: 
Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Curtain C, 
Connolly M,  Bereznicki LR. Adverse Drug Reaction-related Hospitalizations in Elderly 
Australians: A Prospective Cross-Sectional Study in two Tasmanian Hospitals. Drug 
Safety 2017; 40(7):597-606.  
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 3.2. Abstract 
Introduction: Adverse drug reactions (ADRs) have been commonly cited as a major 
cause of hospital admissions in older individuals. However, despite the apparent 
magnitude of this problem, there are limited prospective data on ADRs as a cause of 
hospitalisation in elderly medical patients. 
  
Objectives: The objective of this study was to evaluate the proportion, clinical 
characteristics, causality, severity, preventability, and outcome of ADR-related 
admissions in older patients admitted to two Tasmanian hospitals. 
  
Methods: We conducted a prospective cross-sectional study at the Royal Hobart and 
Launceston General Hospitals in Tasmania, Australia. A convenience sample of patients, 
aged 65 years and older, undergoing unplanned overnight medical admissions was 
screened. ADR-related admissions were determined through expert consensus from 
detailed review of medical records and patient interviews. The causality, preventability, 
and severity of each ADR-related admission were assessed. 
 
Results: Of 1,008 admissions, the proportion of potential ADR-related medical 
admissions was 18.9%. Most (88.5%) ADR-related admissions were considered 
preventable. Cardiovascular complaints (29.3%) represented the most common ADRs, 
followed by neuropsychiatric (20.0%) and renal and genitourinary disorders (15.2%). The 
most frequently implicated drug classes were diuretics (23.9%), agents acting on the renin 
angiotensin system (16.4%), β-blocking agents (7.1%), antidepressants (6.9%) and 
antithrombotic agents (6.9%). Application of the Naranjo algorithm found 5.8% definite, 
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70.1% probable and 24.1% possible ADRs. ADR severity was rated moderate and severe 
in 97.9% and 2.1% of admissions, respectively. For most (93.2%) ADR-related 
admissions the ADR resolved, and the patient recovered. 
 
Conclusion: Hospitalisation due to an ADR is a common occurrence in this older 
population.  There is need for future studies to implement and evaluate interventions to 
reduce the risk of ADR-related admissions in elderly populations. 
 
Key Points 
• Almost one in five unplanned overnight hospital admissions to medical wards in 
elderly Australian patients were related to ADRs. 
• Most ADRs were preventable, and cardiovascular medications were commonly 
implicated. 
• In the majority of patients, ADR-related admissions were caused as a result of a 
combination of two or more drugs sharing a similar ADR profile (e.g., 
hypotension).  
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3.3. Introduction 
Adverse drug reaction (ADR) rates in the USA increased between 1999 and 2006, with 
higher ADR death rates observed among elderly individuals [68]. It has also been 
estimated that ADRs cause 100,800–197,000 deaths annually in the European Union [45], 
while a considerable proportion (5.6%) of all unplanned admissions were medication-
related based on a multicentre prospective study in The Netherlands [208]. An Australian 
study found that hospital admissions due to ADRs in elderly patients had increased 
despite programs to promote rational and safer use of medicines [5]. Elderly people are 
particularly vulnerable to ADRs due to an increased chronic disease burden, 
polypharmacy (concomitant prescription of five or more drugs [209]), and age-related 
physiological changes affecting the pharmacokinetics and pharmacodynamics of drugs 
[9, 86, 210]. Although one of the more serious outcomes of ADRs in elderly people living 
in the community is hospitalisation, data on the occurrence of these events are often not 
well-documented and difficult to obtain [169, 175].  
Prospective studies allow more accurate recording of both drug history and 
symptoms to assess the causality of ADRs [58]. Pirmohamed et al. [58] conducted a large 
prospective analysis of ADR-related hospital admissions in two large general hospitals in 
the UK (2001–2002) and found that patients admitted with ADRs (median age 76 years) 
were significantly older than hospitalised patients without ADRs (median age 66 years) 
[58]. The majority of other prospective studies [86] on ADR-related admissions in the 
elderly were conducted in specialist settings (geriatric/emergency departments), rather 
than general medical settings.  Furthermore, few studies have utilised patient interviews 
to complement ‘intensive monitoring’ [37] in identification of ADRs and assessment of 
ADR preventability. Franceschi et al. [173] and Conforti et al. [174] conducted 
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prospective studies in Italy (2004–2005 and 2009, respectively) and found 6–11% of 
admissions to a geriatric unit were due to ADRs. De Paepe et al. [211], Olivier et al. [188], 
and Ma et al. [212] conducted prospective studies in Belgium (2007), France (2002–2003) 
and China (2008–2011), respectively, and found 7–30% of admissions to an emergency 
department were due to ADRs. From an Australian perspective, Chan et al. [88] 
conducted a prospective cross-sectional survey in 1998 at the Royal Hobart Hospital 
(RHH) and found that 13.3% of admissions to medical wards were ADR-related, although 
this study was small relative to other studies.  
Given the scarcity of ADR-related hospital admissions data in the elderly 
identified using intensive monitoring, and the lack of recent data from Australia, 
additional prospective studies on elderly ADR-related admissions are needed. Hence, our 
aim was to ascertain the proportion of ADR-related medical admissions in older patients 
admitted to Tasmanian hospitals, identify the commonly implicated drugs, describe the 
clinical manifestations and outcomes of these ADRs, and determine their causality, 
preventability, and severity. 
 
3.4. Methods 
This prospective cross-sectional study was carried out at two tertiary care hospitals in 
Tasmania, Australia: the Royal Hobart Hospital (RHH) and Launceston General Hospital 
(LGH). The RHH is Tasmania’s largest public acute care hospital for Southern 
Tasmanians (500-bed capacity in a population of approximately 250,000). The LGH 
provides acute care for the northern region of Tasmania (300-bed capacity in a population 
of approximately 87,000). Both hospitals are within the Tasmanian Health Service and 
provide a comprehensive range of general and specialty medical and surgical services. 
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The majority of patients in both hospitals are seen by clinical pharmacists on the wards, 
who undertake an admission medication history and reconciliation as per national 
standards [213]. The best possible medication history is collected from the patients and 
their relatives and/or caregivers, their general practitioner (GP), and/or community 
pharmacy. This information is entered into a state-wide hospital medication management 
system available for all staff to access across the state. The patients’ previous 
admission/discharge details are also stored as an electronic patient file or digital medical 
record, which could also be accessed during the study for any missing information.  
The study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (Appendix 1), and study participants provided written informed 
consent (Appendix 2). The data presented here were collected as part of the PADR-EC 
(Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community-
Dwelling Patients) study, which has been published elsewhere [214]. The previous paper 
reported on the derivation of the prediction score from the RHH cohort and the validation 
of the dataset in the LGH cohort. In the present analysis, we pooled the available data to 
create a larger dataset to allow us to report on the proportion of ADR-related hospital 
admissions in older patients admitted to Tasmanian hospitals, identify commonly 
implicated drugs, and describe the clinical manifestations and outcomes of ADRs. 
A convenience sample of community-dwelling patients aged ≥65 years with acute, 
unplanned admissions to the medical wards of the RHH and LGH was included in the 
study. Data were collected from March 2014 to March 2015 at the RHH and from 
September 2015 to December 2015 at the LGH. Exclusion criteria included an inability 
to be interviewed due to their medical condition (e.g., patients with infections in isolation, 
55 
 
a terminal illness, or a hearing impairment or low vision), refusal to participate, or 
unavailability of medical records.  
We assessed each patient to determine whether the admission was potentially due to 
an ADR. An ADR was defined as “a response to a drug that is noxious and unintended 
and occurs at doses normally used in humans for the prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function” [36, 37]. This definition excludes 
therapeutic failures, under-treatment, intentional and accidental poisoning (i.e., 
overdose), and drug abuse. ADRs that were observed during the hospital stay were 
excluded. All elderly admissions to the medical wards between Monday and Friday (9 
am-5 pm) were identified by the primary clinical pharmacist researcher (NPN) using 
computerised admission entry details. Patients were followed until discharge to collect 
sufficient information for the final assessment of the ADR. All data were collected 
manually using a data collection form (Appendix 3) and later transferred into a Microsoft 
Access® database (Microsoft Corporation, Redmond, WA, USA). Each ADR 
contributing to the patient admission was assessed if the symptoms of admission were 
consistent with the known adverse effect profile of the drug/drugs (according to the 
Australian Medicines Handbook, or UpToDate database [215, 216]) and, after 
investigation, other causes were excluded [58]. The assessment of whether a certain 
drug/drugs may have caused or contributed to an acute admission was determined through 
expert consensus from comprehensive review of medical records and patient interviews. 
The patient interviews were conducted in the presence of their family members using a 
pre-tested structured questionnaire (Appendix 4). During the recruitment process, we 
initially tested the questionnaire in a small sample of patients and structured it to suit the 
patients’ understanding of specific questions. Questions that patients found difficult to 
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answer (e.g., recent drug changes, previous history of ADRs) were confirmed with family 
members. These data were verified using the detailed medication reconciliation notes 
from clinical pharmacists, GPs’ medical records if available, and other patient history 
notes by nurses and doctors. Patients who could not be interviewed due to their illness at 
the time of their admission were interviewed at a later stage of their hospital stay. All 
patients initially categorised as having an ADR-related admission by the clinical 
pharmacist researcher (NPN) and a random selection of 10% of cases without a suspected 
ADR-related admission were independently and blindly assessed by a senior clinical 
pharmacist (MC). The clinical pharmacists met to reach a consensus decision regarding 
the presence of an ADR-related admission, causality, and preventability and subsequently 
excluded the doubtful cases. This method of ADR assessment had been reported in 
previous studies [169, 208, 217]. During expert consensus, the average time spent for 
assessment of ADR cases was 15–30 min per case. The causality of the relation between 
drug use and ADRs were determined using the Naranjo algorithm (Appendix 8) [179]. 
ADRs were classified as definite (score from 9 to 12), probable (score from 5 to 8), 
possible (score from 1 to 4) or doubtful (score from 0 to -2) and only definite, probable, 
and possible ADRs were considered for this study. We assessed the causality of each 
suspected ADR [4, 218] and of the ADR-related admission [58, 173]. When a patient had 
multiple ADRs, we used the ADR with the highest score using the Naranjo algorithm for 
further analysis [172].  
The Anatomical Therapeutic and Chemical (ATC) classification was used to code the 
medications taken before hospital admission [219]. We determined the preventability of 
the ADRs using the modified Schumock and Thornton criteria [220, 221], as follows: 
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• The drugs were not appropriate for the patient’s condition; 
• The dose, frequency, and route of administration were inappropriate for the 
patient’s age, weight, or disease state; 
• Therapeutic drug monitoring or other necessary laboratory tests were not 
performed; 
• The patient had a history of allergy or previous reaction to the administered drug; 
• A documented drug interaction was involved in the ADR; 
• A serum concentration above the therapeutic range was documented; 
• Non-compliance was involved in the ADR; or  
• A medication error was the cause of the reaction. 
 
We assessed the preventability of each suspected ADR [218] and the preventability of the 
ADR-related admission [58]. When a combination of drugs was involved, but the 
preventability varied for each drug, the preventability of the ADR was assessed as that 
for the drug scoring the highest grade of preventability [88].  
The severity of ADRs was determined using the Hartwig et al. scale (Appendix 
9) [222]. Severe reactions were defined as those that were life-threatening, caused 
permanent damage, or required intensive care. Moderate reactions were those requiring 
hospital admission, change in therapy, or specific treatment. Although this classification 
also includes a definition for mild ADRs, all ADRs in this study at least resulted in 
hospital admission and were therefore only classified as either moderate or severe.  
We grouped ADRs as Type A and Type B reactions based on the Rawlins and 
Thompson [223] classification and whether it was due to any drug–drug interactions 
(DDIs), including with any ‘over-the-counter’ (OTC) medications, as evaluated 
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according to the UpToDate database (Lexi-InteractTM Online) [216]. Type A reactions 
were defined as dose-dependent reactions as an exaggeration of a drug’s normal 
pharmacological actions, and Type B reactions were dose-independent and unpredictable. 
A drug interaction was defined as the modification of one drug by the prior administration 
of another, producing loss of therapeutic effect or toxicity [88]. The UpToDate database 
assigns each DDI a risk rating of A (no known interaction), B (no action required), C 
(monitor therapy), D (consider therapy modification), or X (avoid combination). The 
outcome of the ADR-related admission was categorised as recovery (i.e., patients were 
clinically stable at discharge), death or unknown.  
 Data were analysed descriptively and presented as median (interquartile range 
[IQR]) or number (%) based on type and distribution of data. Analyses were performed 
using SPSS® version 20.0 (SPSS Inc., Chicago, IL, US). 
 
3.5. Results 
A total of 1789 elderly patients were screened and 781 (43.7%) were excluded either due 
to their unwillingness to consent (253 patients) or inability to be interviewed due to the 
severity of their medical condition (528 patients). The remaining 1008 patients were 
enrolled in the study (RHH, 768 patients; LGH, 240 patients). The characteristics of the 
study population are summarised in Table 7 and Appendix 5. The median age of the 
participants was 81 years (IQR 74–86) and the median number of medications (including 
OTC medications) taken at the time of admission was ten (IQR 7–14). Most (89.0%) were 
taking five or more medications. Males and females were almost equally distributed. The 
patients’ characteristics were comparable in both hospitals [214]. 
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Table 7. Principal characteristics of the study population (n=1008) 
Characteristic  Value 
Age in years [median (IQR)] 81 (74–86) 
Length of stay in days [median (IQR)] 5 (3–10)  
Female (%) 53.4 
Use of alcohol * (%) 37.4 
Smoker (%) 10.7 
Number of drugs taken at the time of admission [median (IQR)] 10 (7–14) 
Number of co-morbid conditions [median (IQR)] 5 (4–7) 
Drug changes in the preceding three months (%) 49.4 
Use of OTC medications (%) 44.0 
Use of herbal medicines (%)  23.2 
Living status (%)  
     Alone 40.6 
     With family or friends 56.3 
     Nursing home 3.1 
Medical history (%)  
     Cardiovascular disease 89.1 
     Renal failure 52.7 
     Anaemia 43.9 
     Vascular disease 39.6 
     Hyperlipidaemia 31.2 
     Diabetes 30.3 
     Chronic obstructive pulmonary disease 29.5 
     Cancer 24.4 
     Cerebrovascular disease 17.7 
     Depression 12.8 
     Falls 5.1 
     Dementia 6.8 
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Characteristic  Value 
Other variables (%)  
     Regular GP visits 93.0 
     Assistance required with ≥1 activity of daily living 65.4 
     Previous ADR 58.3 
     Presence of ADR within past three months 16.7 
     HMR in preceding three months 6.3 
Abbreviations: ADR, adverse drug reaction; GP, general practitioner; HMR, Home Medicines 
Review; IQR, interquartile range; OTC, over-the-counter.  
* More than two standard drinks daily [224].  
 
 
Of the 1008 patients examined, ADRs potentially caused or contributed to 191 (18.9%) 
acute medical admissions. Participants with an ADR had a median age of 82 years (IQR 
73–86) and 54.5% were females. The median number of medications taken at the time of 
admission was 11 (IQR 8–15), and the median length of hospital stay was six days (IQR 
3–12). Among the 191 patients with ADRs, 83 (43.5%) were using OTC medications and 
43 (22.5%) were using herbal medications; no ADRs to these medications were identified. 
Of the 191 patients, 108 (56.5%) had a history of previous ADRs, and in 102 (94.4%) of 
these patients, the medications were altered after the last ADR was experienced. Only 
two (1.1%) patients were admitted with the same ADR (rash induced by furosemide and 
dizziness induced by pregabalin) as previously reported. 
Of the 191 patients with potential ADRs, 100 (52.4%) had a single ADR; 62 
(32.5%) had two ADRs; 18 (9.4%) had three ADRs; six (3.1%) had four ADRs; four 
(2.1%) had five ADRs, and one (0.5%) had six ADRs. In 58 (30.4%) cases the ADRs 
were caused by a single drug, and in 133 (69.6%) cases the ADRs were caused by a 
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combination of drugs. Also, in the majority (123 [64.4%]) of cases, a combination of two 
or more drugs sharing a similar ADR profile (e.g., hypotension) caused the ADR-related 
admissions. Thus, a total of 328 ADRs caused by 452 drugs contributed to all ADR-
related admissions. Applying the Naranjo algorithm to the 328 ADRs, there were 27 
(8.2%) definite ADRs, 208 (63.4%) probable ADRs, and 93 (28.4%) possible ADRs. 
When only the one highest scoring ADR per patient was considered, 11 (5.8%) patients 
had definite ADRs, 134 (70.1%) had a probable ADR, and 46 (24.1%) had a possible 
ADR.  
The most frequently involved drug classes were cardiovascular drugs (269 
[59.5%]), followed by drugs acting on the nervous system (100 [22.1%]) and 
antithrombotic agents (31 [6.9%]). Among the cardiovascular drugs, diuretics (108 
[23.9%]), agents acting on the renin–angiotensin system (74 [16.4%]), and β-blockers (β-
adrenoceptor antagonists) (32 [7.1%]) were frequently implicated in causing ADRs 
(Appendix 6). Antidepressants (31 [6.9%]) and opioids (22 [4.9%]) were the most 
frequently implicated centrally acting drugs. Considering individual drugs, furosemide 
was the most common drug responsible for ADRs (61 [13.5%]), followed by perindopril 
(19 [4.2%]), metoprolol (15 [3.3%]), candesartan (15 [3.3%]), and amitriptyline (14 
[3.1%]).  
The type of ADRs observed in the study cohort, and the most frequently 
implicated drugs are presented in Table 8. The most common manifestations of ADRs 
were cardiovascular (96 [29.3%]), neuropsychiatric (72 [20.0%]), renal and genitourinary 
(50 [15.2%]), and haematological (35 [10.7%]) in nature (Appendix 7)
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Table 8. Adverse drug reactions contributing for hospital admission and the drugs most potentially implicated 
Type of ADR 
 (n=328)* 
n (%) Most common clinical  
presentation of ADR* 
n (%)  Most common drugs implicated* 
Cardiovascular  96 (29.3) Hypotension/orthostatic  
hypotension/syncope  
64 (33.5) Diuretics, RAS inhibitors, β-blockers (β-adrenoceptor antagonists), 
calcium channel blockers (antagonists) 
  Bradycardia 12 (6.3) β-Blockers 
Neuropsychiatric 72 (20.0) Dizziness 44 (23.0) Diuretics, β-blockers, calcium channel blockers, RAS inhibitors, 
antidepressants  
  Confusion 14 (7.3) Benzodiazepines, opioids, anticonvulsants, antidepressants 
Renal and genitourinary 50 (15.2) Acute kidney injury  49 (25.7) Diuretics, RAS inhibitors 
Haematological 35 (10.7) Haemorrhage  22 (11.5) Antiplatelets, anticoagulants  
Endocrine and metabolic 30 (9.1) Hyperkalaemia 11 (5.8) RAS inhibitors 
  Hyponatremia 11 (5.8) Diuretics 
Gastrointestinal  24 (7.3) Nausea and vomiting  8 (4.2) Cardiac glycosides 
Neuromuscular and skeletal 12 (3.7) Myalgia  4 (2.1) HMG-CoA reductase inhibitors (statins) 
Others 9 (2.7) Infections 5 (2.6) Immunosuppressants  
The fourth column represents the number and percentage of patients (total number of ADR-related admissions = 191) who experienced the most 
common clinical presentation of ADR. 
Abbreviations: ADR, adverse drug reaction; RAS, renin–angiotensin system. 
* Multiple drugs were suspected to be involved in some ADRs, or one drug might have contributed to multiple ADRs.  
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Of the 328 ADRs, 286 (87.2%) were assessed as preventable. When the preventability of 
ADR-related admissions was assessed based on the highest grade of preventability, 169 
(88.5%) ADR-related admissions were considered preventable. Overall, 187 (97.9%) of 
ADR-related admissions were classified as moderately severe, while only 4 (2.1%) were 
severe. Of the 191 ADR-related admissions, the ADR resolved in 178 (93.2%) and the 
patient recovered, while in four cases (2.1%) the outcome was fatal and in nine cases 
(4.7%) the outcome was unknown due to the patient’s transfer to another hospital.  The 
severe ADRs that contributed to the four deaths were ‘probable’ ADRs and these included 
digoxin toxicity, pancytopenia related to antiplatelets (aspirin) in combination with other 
drugs (methotrexate, hydroxychloroquine), hypotension caused by a combination of 
diuretic (furosemide), ACE inhibitor (ACEI) (perindopril) and a β-blocker (carvedilol), 
and acute kidney injury  related to the combination of an ACEI (fosinopril) and a diuretic 
(indapamide) (glomerular filtration rate on admission was 7 mL/min). The patients who 
were admitted with digoxin toxicity and pancytopenia died due to hospital-acquired 
pneumonia and multiple organ failure, respectively. The patient admitted due to severe 
hypotension eventually died because of arrhythmia. Multiple organ failure was the reason 
of death in the patient admitted with acute kidney injury. 
 A total of 181 DDIs were potentially involved in 82 (42.9%) of the ADR-related 
admissions. Of 181 DDIs observed, 131 (72.4%) were assigned a risk rating of C, 48 
(26.5%) a risk rating of D, and two (1.1%) a risk rating of B.  Examples of DDIs included 
confusion caused by multiple nervous system depressants, hypotension caused by 
multiple blood pressure-lowering agents, bleeding caused by clopidogrel and aspirin, and 
acute kidney injury associated with concomitant use of diuretics and ACEIs. All ADRs 
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were classified as Type A reactions except one ADR (rash induced by furosemide), which 
was considered a Type B reaction. 
  
3.6. Discussion 
We have conducted a prospective analysis of ADR-related hospital admissions in an 
elderly Tasmanian population. Our study found that approximately one in five unplanned 
admissions to medical wards were potentially due to ADRs in patients aged ≥65 years. A 
similarly high rate (17%) of ADR-related hospitalisations in the elderly was also found 
in a meta-analysis of 17 observational studies [101]. Determining the number of ADR-
related admissions depends primarily on the methods used in their detection [98]. 
Prospective and intensive monitoring usually have the highest detection rate and can 
provide data not otherwise available [37, 85]. In other studies, the proportion of all 
hospital admissions due to ADRs has ranged from 3% to 20% [92, 96, 169, 172, 217, 
225]. Differences in definitions of ADR, method of data collection, and target populations 
may account for the difference in these proportions [173]. In our study, the inclusion of 
all definite, probable and possible ADRs, together with a thorough review of ADR cases 
by the two expert clinical pharmacists, might have contributed to the identification of 
more ADRs. We interviewed all patients included in the study, in addition to reviewing 
medical records, to identify ADR-related admissions. Patient interviews by pharmacists 
identified more ADRs than spontaneous reporting by physicians and nurses in a previous 
prospective study [92]. There is also strong evidence that pharmacists report higher rate 
of adverse drug events than non-pharmacists [226].  
 Almost 90% of ADR-related hospitalisations were preventable, which is 
consistent with a subgroup meta-analysis demonstrating that 88% of ADR-related 
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hospitalisations in the elderly were preventable [101]. In other studies, the preventability 
varied from 37 to 77% [87, 169, 173]. Even though the preventability estimates vary 
across studies, it is evident that more than 50% of ADRs are preventable [56]. We found 
a predominance of ADRs due to Type A reactions resulting from known pharmacological 
actions, consistent with other studies [4, 58, 88, 96]. This study found 2.1% of patients 
had fatal outcomes due to ADRs. Fatal outcomes and increased length of stay in older 
patients due to ADRs have been observed in some studies [58, 173], and the proportion 
of severe ADRs was found to be as high as 18.6% in a prospective study [87]. A recent 
study found the crude in-hospital mortality rate was 10.2% in elderly patients with an 
ADR-related admission [225]. 
 Our data showed that cardiovascular complaints, such as hypotension/orthostatic 
hypotension/syncope, were the most common ADRs resulting in hospital admission, and 
these results are consistent with other studies [88, 96, 212, 227]. This proportion may 
have been even higher if cases of dizziness associated with antihypertensives were also 
included. Some studies have reported gastrointestinal complaints as frequent ADRs 
causing admission [4, 173, 225], while haematological complaints were reported in other 
studies [188, 228]. Patients with cardiovascular disease are particularly vulnerable to 
ADRs due to their advanced age, polypharmacy, and the influence of heart disease on 
drug pharmacokinetics, such as a reduction in the volume of distribution and impairment 
of clearance, as seen in patients with congestive heart failure [229, 230]. Antihypertensive 
agents were the most frequent class of drugs responsible for ADR-related admissions, as 
found in other studies [4, 88, 96, 169, 174, 212, 217, 227]. Additionally, acute kidney 
injury (25.7% of admissions) was impacted by antihypertensive medications such as 
diuretics and agents acting on the renin angiotensin system. In other studies, the most 
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frequent therapeutic classes implicated in ADR-related admissions in the elderly were 
NSAIDs [4, 5, 173], antithrombotic agents [5, 173, 174, 188], or antidiabetic agents [188, 
228]. The prevalence of orthostatic hypotension was very high (35–65%) in one 
international study in the elderly and significantly related to the number of concurrent 
causative medications  [231]; elderly patients are also more prone to diuretic-induced 
dehydration and resulting orthostatic hypotension [232]. Our findings highlight the 
importance of cautious prescribing of antihypertensive agents, especially combinations 
of diuretics and agents acting on the renin–angiotensin system, in the elderly to prevent 
hypotension/orthostatic hypotension/syncope and acute kidney injury.  
 More than 50% of the ADRs identified in the present study were caused by a 
combination of drugs and most of our study participants were exposed to polypharmacy 
(five or more medications). Polypharmacy has been identified as an important potential 
risk factor for ADRs [4, 169, 172]. We also evaluated one important factor that has not 
been explicitly investigated in previous prospective studies, i.e., almost 65% of ADR-
related admissions were caused by two or more drugs that share the same ADRs. Since 
some ADRs (e.g., hypotension) were particularly associated with simultaneous use of 
multiple medications with synergistic therapeutic and adverse effects, such as 
antihypertensives, prescribers need to be sure that the benefit of prescribing multiple 
similar medications is justified, to outweigh the risk of additive adverse effects of these 
agents. DDIs might have played a role in over 40% of ADR-related admissions, which is 
consistent with another prospective study in the elderly (32.3%) [173] and a cross-
sectional study in which DDIs were suspected in 49% of cases [225]. These findings 
highlight the importance of obtaining an accurate medication history at each stage of a 
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patient’s medication journey so that potential DDIs are not overlooked by their healthcare 
team.   
 Decreasing the medication burden in community-dwelling elderly patients will 
lead to reduced adverse events and improvement in health [233]. There is an increasing 
body of research demonstrating that deprescribing inappropriate or unnecessary 
medications is feasible, safe and can improve older patient’s quality of life and decrease 
mortality [234, 235]. From our results, an obvious focus of deprescribing would be to 
reduce the number of different drugs with similar modes of action and/or adverse effects. 
Communication between health professionals such as a physician (geriatrician), nurse, 
and pharmacist enables optimal pharmacotherapy in elderly patients [210]. Clinical 
pharmacists can play a vital role, particularly at the point of discharge of elderly patients, 
to prevent ADR-related readmissions. In a randomised trial, pharmacist medication 
review, patient counselling, and telephone follow-up were associated with a lower rate of 
preventable adverse drug events after hospital discharge [138]. We also suggest 
implementing a comprehensive medication reconciliation at every transition point 
(admission, discharge, transfer) for the elderly, as suggested by the US Joint Commission 
on Accreditation of Healthcare Organisations [236].  
 The major strength of the study is that patients were prospectively included on 
admission and were followed up until discharge. We have also interviewed all the patients 
included in the study in addition to reviewing their medical records, which is different 
from a recent Spanish study [225] in which ADRs were identified either from the medical 
record or by direct patient interview. We also used a large sample from two major 
Tasmanian public hospitals, which allowed us to characterise the ADRs in a detailed 
manner, including their preventability. To our knowledge, many prospective studies on 
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ADRs have focused on patients admitted in a single hospital, and many studies did not 
assess the preventability of ADRs.  
 Our study has some limitations. The main limitation included the difficulty in 
determining the contribution of a certain drug/drugs to an acute admission due to ADRs. 
Some of the parameters for assessing the causality of ADRs, such as the inclusion of a 
re-challenge and use of placebo, could not be performed since they were not routine 
clinical practice. In addition, measurement of drug concentrations was not performed in 
most suspected ADRs. Another limitation was the collection of the data using 
convenience sampling. With limited resources, the study team relied on recruiting elderly 
patients whose availability coinciding with that of the primary clinical pharmacist 
researcher. The degree of generalisability of the study is restrained by this study design. 
In addition, we could not recruit some patients due to the severity of their medical 
conditions and these patients were perhaps at higher risk of admissions due to ADRs. A 
retrospective study could have included all patients, although such a study would lose the 
ability to obtain information through interview. While we believe that the study results 
might be generalisable to the Tasmanian elderly population, as well as in other states of 
Australia that have similar standards of health care delivery to the elderly, there are 
inherent limitations of convenience sampling. We suggest that further studies explore the 
burden of ADRs in elderly residing in other states of Australia. We could only review by 
consensus 10% of patients who were not admitted due to an ADR (controls), which may 
be another limitation of the study. This might have caused an underestimation of the 
ADR-related admissions even though the primary clinical pharmacist researcher assessed 
the cases and controls comprehensively and thoroughly. Participation of a physician 
might have provided a more comprehensive perspective to the assessment of ADRs [217], 
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although clinical pharmacists can play a major role in recognising drug-related problems 
in the elderly [21]. Finally, with limited resources, we could not assess whether patients 
had any sustained disability because of an ADR, despite being clinically stable at 
discharge.  
 Given the fact that the majority of the ADRs that resulted in hospitalisation were 
preventable in the present study, prevention of ADRs represents an important aim for 
physicians treating older patients [237]. Some strategies have been mentioned here, and 
these include medication review, avoiding use of inappropriate medications, and 
comprehensive geriatric assessment and management [3]. In order to ensure the cost 
effectiveness of such strategies, it would be necessary to target them to elderly patients 
who are at highest risk of ADR-related admission [238]. The recently developed PADR-
EC score could facilitate identification of community-dwelling elderly people at risk of 
ADRs and subsequent ADR-related admission [214]. The PADR-EC score could 
potentially be integrated into a prescribing software at the point of patient discharge as 
well as in primary care to alert health care providers (primary care physicians, 
pharmacists, and nurses) to their patients’ risk of ADRs and execute preventive strategies 
such as deprescribing. 
  
3.7. Conclusion  
Our research supports the findings from previous studies and further strengthens the 
evidence of ADRs as a cause of admissions in the elderly, along with updating the 
available information with respect to their proportion, preventability, outcome and 
clinical characteristics. Cardiovascular medications prescribed to elderly patients need 
thorough and regular scrutiny as these medications were frequently implicated in ADRs. 
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Improved medication management services in primary care are required to address the 
high rate of unnecessary hospitalisation due to preventable ADRs. Further research is 
needed to address the effectiveness of some interventions, such as deprescribing, in 
reducing the risk of ADR-related admissions in elderly populations.  
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CHAPTER FOUR 
 
4. Prediction of Hospitalisation due to Adverse Drug Reactions 
in Elderly Community-Dwelling Patients (The PADR-EC 
Score) 
 
 
4.1. Preface  
 
The findings from Chapter 3 strengthened and updated the evidence relating to hospital 
admissions due to ADRs in elderly patients. The results also emphasised that this problem 
is persisting despite available prevention strategies. It is clear that additional strategies of 
ADR prevention are needed, and Chapter 2 discussed the need to investigate the utility of 
an ADR tool to identify high-risk elderly patients who are prone to ADR-related hospital 
admissions. Thus, we have developed and validated such a tool. The development and 
validation results of the ADR tool are presented in this chapter.  
 
Publication: 
Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain 
C, Castelino RL, Bereznicki LR. Prediction of Hospitalization due to Adverse Drug 
Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score). PLoS One 
2016; 11(10):e0165757.  
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4.2. Abstract 
Background: Adverse drug reactions (ADRs) are the major cause of medication-related 
hospital admissions in older patients living in the community. This study aimed to 
develop and validate a score to predict ADR-related hospitalisation in people aged ≥65 
years. 
  
Methods: ADR-related hospitalisation and its risk factors were determined using a 
prospective, cross-sectional study in patients aged ≥65 years admitted to two hospitals. A 
predictive model was developed in the derivation cohort (n = 768), and the model was 
applied in the validation cohort (n = 240). ADR-related hospital admission was 
determined through expert consensus from comprehensive reviews of medical records 
and patient interviews. The causality and preventability of the ADR were assessed based 
on the Naranjo algorithm and modified Schumock and Thornton criteria, respectively. 
 
Results: In the derivation sample (mean [±SD] age, 80.1±7.7 years), 115 (15%) patients 
were admitted due to a definite or probable ADR; 92.2% of these admissions were 
deemed preventable. The number of antihypertensives was the strongest predictor of an 
ADR followed by presence of dementia, renal failure, drug changes in the preceding three 
months and use of anticholinergic medications; these variables were used to derive the 
ADR prediction score. The predictive ability of the score, assessed from calculation of 
the area under the receiver operator characteristic (ROC) curve, was 0.70 (95% 
confidence interval (CI) 0.65–0.75). In the validation sample (mean [±SD] age, 79.6±7.6 
years), 30 (12.5%) patients’ admissions were related to definite or probable ADRs; 80% 
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of these admissions were deemed preventable. The area under the ROC curve in this 
sample was 0.67 (95% CI 0.56–0.78). 
 
Conclusions: This study proposes a practical and simple tool to identify elderly patients 
who are at an increased risk of preventable ADR-related hospital admission. Further 
refinement and testing of this tool is necessary to implement the score in clinical practice. 
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4.3. Introduction 
Advancing age contributes to increased drug usage in older patients, which in turn is 
associated with an increased risk of adverse drug reactions (ADRs), causing significant 
morbidity and mortality [173]. The prevalence of ADRs in older outpatient clinic 
attendees ranges from 5–35% [205, 239]. ADRs are also one of the main reasons for 
hospitalisation in older patients living in the community [169]. The proportion of all 
hospital admissions due to ADRs has ranged from 6–12% among older patients [96, 169, 
172-174]. While individual risk factors for ADRs have been identified [4, 96], health 
professionals are not able to easily identify elderly community-dwelling outpatients who 
are at high risk of being hospitalised due to an ADR. More than half of ADR-related 
hospitalisations are considered preventable [88].  
 In recent years, risk prediction models for ADRs in elderly patients have begun to 
emerge, offering practitioners a potential tool to assist clinical and therapeutic decision 
making and facilitate targeting of additional resources toward this high-risk group [9, 10]. 
These tools were developed for use in secondary care hospital settings to help identify the 
risk of ADRs occurring during hospitalisation. To our knowledge, there is no prediction 
score available that has been developed for use in elderly patients with hospitalisation due 
to ADR (as opposed to ADRs that arise during hospitalisation) as the endpoint [238]. A 
tool developed that focussed on ADRs as a cause of hospitalisation could potentially be 
used in primary care and at the point of hospital discharge to prioritise primary care-based 
medication management services to prevent ADR-related morbidity and mortality in 
patients at the highest risk of such events. We aimed to develop and validate a prediction 
model for ADR-related hospitalisation in patients aged ≥65 years.  
75 
 
4.4. Methods 
4.4.1. Derivation of a score to predict ADR-related hospitalisation 
To develop the score [PADR-EC (Prediction of Hospitalisation due to Adverse Drug 
Reactions in Elderly Community-Dwelling Patients) score], a prospective cross-sectional 
study was conducted at the Royal Hobart Hospital (RHH), which is the major public acute 
care hospital in Southern Tasmania. The study was approved by the Tasmanian Health 
and Medical Human Research Ethics Committee (Appendix 1), and study participants 
provided their written informed consent to participate in the study (Appendix 2). A 
convenience sample of all acute, unplanned, emergency admissions of patients aged ≥65 
years admitted to medical wards over a period of 12 months (March 2014 to March 2015) 
were enrolled in the study. Patients were excluded if they were unwilling to participate, 
unable to be interviewed due to health or other reasons, or if their medical notes were not 
available for further investigation. The medical records of all consenting patients were 
reviewed within 48 hours of admission, and patients were interviewed as soon as practical 
after admission. Data collected included demographics, comorbidities, indicators of 
physical function and cognitive status, clinical diagnoses at admission, medications and 
medication changes prior to admission, previously documented ADRs, function in 
activities of daily living, social supports and living status. Patients and/or their relatives 
who were interviewed provided information about alcohol consumption, smoking status, 
recent hospital admissions, recent drug changes, drug allergies, use of over-the-counter 
(OTC) and herbal medicines, use of dosage administration aids, ADR occurrence within 
the last 3 months, regular pharmacy visits, and receipt of a Home Medicines Review 
(HMR), where a pharmacist conducts an interview with the patient regarding their 
medications and provides a report back to the general practitioner. 
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4.4.2. Predictive variables for ADR-related hospitalisation 
Medications taken prior to admission were coded according to the Anatomical 
Therapeutic and Chemical codes [219]. Calculation of the number of medications was 
based on the number of active ingredients [96], where the active ingredients in 
combination products were also available as single-ingredient products. Clinical 
diagnoses and comorbidities were coded according to the International Classification of 
Primary Care, 2nd edition [240]. Comorbidity was measured using the Charlson 
comorbidity index (CCI) [241]. Renal failure was defined as an estimated glomerular 
filtration rate (eGFR) of less than 60 mL/min/1.73m2 or as documented in the medical 
records [242, 243]. Liver disease was defined as synthetic liver dysfunction or liver injury 
with raised transaminases greater than twice the normal range or documented liver disease 
[167]. Anaemia was defined as a haemoglobin concentration below 120 g/L in women 
and below 130 g/L in men [244]. All comorbidities were defined as present if documented 
in the medical records. Functional independence was measured using the Barthel index 
[245]. Potentially inappropriate medications (PIMs) were identified using the updated 
Beers criteria [147]. Each class of PIMs within the Beers criteria was individually 
assessed. Recent drug changes prior to hospital admission were determined. Recent drug 
change was defined as addition of a new drug or deletion of an existing drug (excluding 
‘when required’ medications) or a change in drug doses in the three months preceding the 
patient’s admission [246]. 
 
4.4.3. Identifying and assessing the presence of ADR-related hospitalisation 
An ADR was defined as “a response which is noxious and unintended, and which occurs 
at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or 
for the modification of physiological function” [37]. We assessed every consenting 
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patient during the study period to determine if the admission had been caused by an ADR. 
The reasons for hospitalisation are multifactorial in many cases [217], and therefore the 
determination of whether a certain drug/ drugs may have caused or contributed to an acute 
admission was based on comprehensive review of medical records and interview with the 
patient/relatives about their medication usage, including recent changes to drug therapy. 
The patients were interviewed in presence of their family members, and the response to 
specific questions (Appendix 4) were again verified using electronic patient file or digital 
medical records which contains all patient previous admission/discharge details. 
Comprehensive review of medical records included detailed review of medical and 
nursing records, medical record notes from primary care when available, medication 
reconciliation notes from clinical pharmacists, and an assessment of laboratory and other 
relevant clinical investigations. Patients were categorised as having an ADR if the cause 
of admission was consistent with the known adverse effect profile of the drug (according 
to Australian Medicines Handbook, or UpToDate database) [215, 216], if there was a 
temporal relation with the start of drug therapy and if, after appropriate investigations, 
other causes were excluded [247]. The clinical description of each ADR and the potential 
drug cause was collected, and the causality, preventability and eventual outcome of the 
suspected ADR-related hospitalisation were assessed. We also classified ADRs as Type 
A and Type B reactions, based on Rawlins and Thompson [223]. Type A reactions were 
defined as dose-dependent and predictable from the known pharmacologic action of the 
drug and Type B reactions if otherwise.  
The Naranjo algorithm (Appendix 8) was used to assess the causality of the 
relation between drug use and hospitalisation [179]. ADRs were classified as definite (9–
12 points), probable (5–8 points), possible (1–4 points), or doubtful (0 points). Only 
78 
 
definite and probable ADRs that provoked hospitalisation were considered for this study. 
ADRs observed during the hospital stay were excluded. The preventability of the ADR-
related hospitalisation was assessed using the modified Schumock and Thornton criteria 
[220, 221]. These criteria included (1) the drugs were not appropriate for the patient’s 
condition, (2) the dose, frequency and route of administration were inappropriate for the 
patient’s age, weight or disease state, (3) therapeutic drug monitoring or other necessary 
laboratory test was not performed, (4) the patient had a history of allergy or previous 
reaction to the administered drug, (5) a documented drug interaction was involved in the 
ADR, (6) a serum concentration above the therapeutic range was documented, (7) 
noncompliance was involved in the ADR or (8) a medication error was the cause of 
adverse reaction. The ADR-related hospitalisation was considered to be preventable when 
it met any of these criteria.  
All patients initially categorised as having an ADR-related admission, and a 
random selection of 10% of cases without a suspected ADR-related admission, were 
independently and blindly assessed by a senior clinical pharmacist for the presence and 
classification of an ADR-related admission. The primary researcher and the senior 
clinical pharmacist met to reach a consensus decision on the presence of an ADR-related 
admission and excluded doubtful cases. The cases thought to involve an ADR-related 
admission were also assessed blindly by the clinical pharmacist reviewer for causality, 
severity, and preventability. This review process had been used previously in similar 
studies [34, 217, 247]. The screening process and identification of ADR-related hospital 
admissions is outlined in Figure 2. 
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Figure 2. Diagram outlining the screening process of ADR-related hospital admission. 
 
4.4.4. Statistical analysis  
The PADR-EC score was developed in a similar manner to that described by Onder et al. 
[9]. Clinically relevant variables that are easily applied and practical for use in a primary 
care setting were considered. The chi-square test or Fisher’s exact test were used to 
compare characteristics of those who experienced an ADR and those who did not. 
Variables identified as being associated with an ADR in the univariate analyses were 
entered into a binary logistic regression model. The variables with P values of <0.20 in 
the univariate analyses were candidates for inclusion in the binary logistic regression 
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model since more stringent significance levels can lead to the exclusion of potentially 
useful predictor variables [10, 248-250]. Multicollinearity between independent 
categorical variables was assessed using the phi coefficient [251]. When two variables 
had a phi coefficient ≥0.30, the model was trialled with each variable independently, and 
the variable with higher predictive ability was entered into the final model. Variables 
retained in the final model were used to compute the PADR-EC score. A score of 1 was 
assigned to variables with an odds ratio (OR) between 1.00 and 1.49; a score of 2 to those 
with an OR between 1.5 and 2.49; a score of 3 to those with an OR between 2.5 and 3.49; 
a score of 4 to those with an OR between 3.5 and 4.49 and a score of 5 to those with an 
OR between 4.5 and 5.49. The PADR-EC score was computed based on the sum of scores 
of individual variables. Receiver operator characteristic (ROC) curves were constructed, 
and area under the curve (AUC) calculated to determine the predictive ability of the 
PADR-EC score. Analyses were performed using SPSS version 20.0 (SPSS Inc, Chicago, 
Illinois). 
  
4.4.5. Validation study 
In order to validate the PADR-EC score developed in the RHH sample (derivation stage), 
it was applied in a separate cohort of adults admitted to medical wards of the Launceston 
General Hospital (LGH). The LGH is the largest acute care facility and teaching hospital 
in the northern region of Tasmania. The study was approved by the Tasmanian Health 
and Medical Human Research Ethics Committee (Appendix 1), and the study participants 
provided their written informed consent to participate in the study (Appendix 2). Patients 
admitted to the LGH during the study period (September to December 2015) were 
enrolled according to the criteria discussed above. As before, data for all variables were 
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recorded for each patient, along with details of any suspected ADR-related admission. To 
evaluate the predictive ability of the PADR-EC score, ROC curves were constructed, and 
AUC calculated. 
 
4.5. Results  
4.5.1. Derivation of the PADR-EC score 
Over the 12-month study period, there were 5027 acute unplanned medical admissions in 
patients aged ≥65 years at the RHH. Of the 1271 (25%) patients screened during the study 
period, 503 (39.6%) were excluded either due to their unwillingness to consent (130 
patients), or an inability to participate due to the severity of their medical condition, 
hearing impairment or low vision (373 patients). In total, 768 patients were included in 
the RHH cohort for final analysis. The characteristics of the study populations at the RHH 
and LGH are summarised in Table 9. 
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Table 9. Characteristics of the study populations in derivation and validation cohort 
Characteristics Derivation stage  
(n = 768) 
Validation stage  
(n = 240) 
Age in years (mean ± SD) 80.1 ± 7.7 79.6 ± 7.6 
Gender (n, %), Female 401 (52.2) 137 (57.1) 
Number of medications before hospital 
admission (mean ± SD) 
10.8 ± 5.2 9.9 ± 4.8 
Number of comorbidities (mean ± SD) 5.5 ± 2.4 6.0 ± 2.5 
Living status (n, %)   
Alone 308 (40.1) 101 (42.1) 
With family or friends 433 (56.4) 135 (56.3) 
Nursing home 27 (3.5) 4 (1.7) 
Comorbidities (n, %)   
Dementia 54 (6.4) 15 (6.3) 
Heart failure 136 (16.2) 52 (21.7) 
Renal failure 406 (48.4) 125 (52.1) 
Cerebrovascular disease 141 (16.8) 37 (15.4) 
Diabetes 236 (28.1) 69 (28.8) 
Chronic obstructive pulmonary disease 208 (24.8) 89 (37.1) 
Cancer 179 (21.3) 67 (27.9) 
Anaemia 327 (39) 116 (48.3) 
Liver disease 22 (2.6) 11 (4.6) 
Depression 94 (11.2) 35 (14.6) 
Hyperlipidaemia 240 (28.6) 74 (30.8) 
Ischaemic heart disease 160 (19.1) 55 (22.9) 
Vascular disease 309 (36.8) 90 (37.5) 
Abbreviation: SD, standard deviation. 
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There was a consensus between the two expert reviewers in the majority of cases and, 
overall, 115 patients (15.0%) were judged as being admitted due to ADRs. There were 17 
doubtful cases that were not classified as ADR-related admissions and were added to the 
control group (n = 653). There were nine (5.8%) definite and 106 (69.3%) probable ADRs 
based on the Naranjo algorithm. Most of the ADR-related hospitalisations were 
considered preventable (106, 92.2%) and all ADRs were classified as Type A reactions 
except one which was considered as a Type B reaction. As seen in Table 10, univariate 
analysis identified that PIMs (anticholinergics, antiarrhythmics, benzodiazepines), PIMs 
use in dementia or cognitive impairment, hospital admission in the preceding month, 
hospital admission in the preceding three months, drug changes in the preceding three 
months, nine or more regular medications, seven or more comorbidities, renal failure, 
dementia, heart failure, anaemia, vascular disease, Charlson comorbidity score ≥6, use of 
alcohol and age ≥85 years were associated with an increased risk of ADR-related hospital 
admission (P ≤ 0.20). Specific drug classes contributing to the risk of ADR-related 
admission included antihypertensives (1–2, ≥3), angiotensin converting enzyme 
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), β-blockers, drugs of narrow 
therapeutic index (digoxin, amiodarone, theophylline, phenytoin, carbamazepine and 
sodium valproate), psycholeptics, benzodiazepines, tricyclic antidepressants, diuretics 
and tricyclic antidepressants or psycholeptics. The antihypertensives included α2-
adrenergic agonists, α1-adrenoreceptor antagonists, β-blockers, calcium channel 
blockers, diuretics, agents acting on the renin-angiotensin system and vasodilators. Fixed-
dose antihypertensive combination therapy, including triple therapy, was used in 12% (n 
= 95) of patients. The PIMs (anticholinergics) included antihistamines (chlorpheniramine 
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and promethazine), antispasmodics (hyoscyamine products and atropine products) and 
tertiary tricyclic antidepressants (amitriptyline, imipramine, and doxepin >6 mg/day).  
 
Table 10. Characteristics of patients experiencing adverse drug reaction-related and non-
adverse drug reaction-related hospital admissions at the Royal Hobart Hospital (n=768) 
Variable Number (%) Number (%) P Value 
 No ADR (n = 653) ADR (n = 115)  
Age (years)    
65–84 454 (69.5) 70 (60.9) 0.07* 
≥85 199 (30.5) 45 (39.1)  
Gender    
Male 316 (48.4) 51 (44.3) 0.42 
Female 337 (51.6) 64 (55.7)  
Drug-related variables    
Use of OTC medications 275 (42.1) 45 (39.1) 0.55 
Use of herbal medications 156 (23.9) 24 (20.9) 0.48 
Drug changes in the preceding 3 months 304 (46.6) 70 (60.9) 0.01* 
Number of medications    
0–8 245 (37.5) 32 (27.8) 0.05* 
≥9 408 (62.5) 83 (72.2)  
Inappropriate medications  
(Therapeutic category/drug) 
   
Anticholinergics 57 (8.7) 21 (18.3) 0.002* 
Benzodiazepines 128 (19.6) 29 (25.2) 0.17* 
Antiarrhythmics 18 (2.8) 8 (7) 0.04* 
Digoxin 10 (1.5) 2 (1.7) 0.70 
Metoclopramide 14 (2.1) 4 (3.5) 0.33 
Inappropriate medications (Disease)    
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Variable Number (%) Number (%) P Value 
Heart failure 10 (1.5) 1 (0.9) 1.00 
Dementia or cognitive impairment 14 (2.1) 8 (7) 0.01* 
Disease-related variables    
Charlson Comorbidity Index    
0–5 344 (52.7) 52 (45.2) 0.14* 
≥ 6 309 (47.3) 63 (54.8)  
Cerebrovascular diseases 117 (17.9) 24 (20.9) 0.45 
≥7 Comorbidities 206 (31.5) 51 (44.3) 0.01* 
Diabetes 200 (30.6) 36 (31.3) 0.89 
Anaemia 270 (41.3) 57 (49.6) 0.10* 
Depression 81 (12.4) 13 (11.3) 0.74 
Acute cognitive impairment 41 (6.3) 5 (4.3) 0.42 
Dementia 42 (6.4) 12 (10.4) 0.12* 
Renal failure** 323 (49.7) 83 (72.8) <0.001* 
Liver disease 18 (2.8) 4 (3.5) 0.56 
Heart failure 108 (16.5) 28 (24.3) 0.04* 
COPD 176 (27) 32 (27.8) 0.85 
Cancer 156 (23.9) 23 (20) 0.36 
Hyperlipidaemia 204 (31.2) 36 (31.3) 0.99 
Ischaemic heart disease 133 (20.4) 27 (23.5) 0.45 
Vascular disease 254 (38.9) 55 (47.8) 0.07* 
Variables related to drug classes    
Drugs of narrow therapeutic index 158 (24.2) 38 (33) 0.05* 
Antithrombotics 444 (68) 85 (73.9) 0.21 
Antihypertensives    
0 131 (20.1) 6 (5.2)  
1–2 328 (50.2) 51 (44.3) <0.001* 
≥3 194 (29.7) 58 (50.4)  
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Variable Number (%) Number (%) P Value 
ACEIs or ARBs 357 (54.7) 77 (67) 0.01* 
Calcium channel blockers 172 (26.3) 34 (29.6) 0.47 
Cardiac glycosides 69 (10.6) 15 (13) 0.43 
β-Blockers 223 (34.2) 52 (45.2) 0.02* 
Drugs used in diabetes 156 (23.9) 29 (25.2) 0.76 
NSAIDs 27 (4.1) 6 (5.2) 0.60 
Opioids 199 (30.5) 41 (35.7) 0.27 
Psycholeptics 158 (24.2) 36 (31.3) 0.11* 
Antipsychotics 37 (5.7) 9 (7.8) 0.37 
Benzodiazepines 137 (21) 32 (27.8) 0.10* 
Tricyclic antidepressants 57 (8.7) 15 (13) 0.14* 
Tricyclic antidepressants or psycholeptics 197 (30.2) 46 (40) 0.04* 
Antiplatelets 320 (49) 61 (53) 0.42 
Diuretics 309 (47.3) 80 (69.6) <0.001* 
Antibacterials 94 (14.4) 14 (12.2) 0.53 
Anticoagulants 140 (21.4) 30 (26.1) 0.27 
Other variables    
Admission in preceding month 159 (24.3) 38 (33) 0.05* 
Admission in preceding 3 months 269 (41.2) 55 (47.8) 0.18* 
Use of dosage administration aid 259 (39.7) 45 (39.1) 0.91 
Use of generics*** 345 (60.5) 62 (62.6) 0.69 
Use of alcohol 241 (36.9) 35 (30.4) 0.18* 
Smokers 72 (11) 9 (7.8) 0.30 
Presence of ADR within 3 months**** 106 (16.5) 22 (20.2) 0.35 
Previous ADR** 389 (59.8) 65 (57) 0.57 
Regular pharmacy visits 582 (89.1) 105 (91.3) 0.48 
HMR in the preceding 3 months 41 (6.3) 5 (4.3) 0.42 
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Variable Number (%) Number (%) P Value 
Assistance required with ≥1 activity of daily 
living 
433 (66.3) 83 (72.2) 0.22 
Albumin <3.5 g/dL 293 (44.9) 54 (47) 0.68 
Falls 38 (5.8) 6 (5.2) 0.80 
Abbreviations: ADR, adverse drug reaction; ACEIs, angiotensin converting enzyme inhibitors; 
ARBs, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; HMR, 
Home Medicines Review; NSAIDs, nonsteroidal anti-inflammatory drugs; OTC, over-the-counter. 
* P value ≤0.20.  
** 4 participants had missing values. 
*** 99 participants had missing values.  
**** 17 participants had missing values. 
 
When variables were excluded due to multicollinearity, the variables retained in the 
model were hospital admission in the preceding month, drug changes in the preceding 
three months, seven or more comorbidities, renal failure, dementia, drugs of narrow 
therapeutic index, antihypertensives (1–2, ≥3), anaemia, PIMs (anticholinergics), 
psycholeptics, age ≥85 years and use of alcohol. Binary logistic regression retained drug 
changes in the preceding three months, renal failure, dementia, antihypertensives (1–2, 
≥3), and PIMs (anticholinergics) as significant predictors of ADR-related hospital 
admission (Table 11). These variables were assigned scores based on their respective ORs 
(Table 12). 
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Table 11. Binary logistic regression of factors associated with adverse drug reaction-
related hospital admission in the derivation study at the Royal Hobart Hospital (n=768) 
Variable Adjusted OR (95% CI) P value 
Age ≥85 years 1.33 (0.86–2.06) 0.20 
Drug changes in the preceding three months 1.54 (1.00–2.37) 0.05 
Anaemia 1.08 (0.70–1.65) 0.74 
Renal failure 1.97 (1.22–3.17) 0.01 
Drugs of narrow therapeutic index 1.15 (0.73–1.81) 0.55 
Dementia 2.44 (1.17–5.10) 0.02 
Admission in preceding month 1.31 (0.82–2.07) 0.26 
Number of comorbidities ≥7 1.07 (0.69–1.66) 0.76 
Number of antihypertensives   
1–2 3.00 (1.22–7.38) 0.02 
≥3 4.75 (1.89–11.93) 0.001 
Anticholinergics 2.09 (1.16–3.75) 0.01 
Psycholeptics 1.24 (0.78–1.98) 0.36 
Use of alcohol 0.80 (0.51–1.25) 0.32 
Abbreviations: CI, confidence interval; OR, odds ratio. 
 
 
  
89 
 
Table 12. Variables included in the risk score 
Variable OR (95% CI) Points 
Drug changes in the preceding three months 1.54 (1.00–2.37) 2 
Renal failure 1.97 (1.22–3.17) 2 
Dementia 2.44 (1.17–5.10) 2 
Number of antihypertensives   
1–2 3.00 (1.22–7.38) 3 
≥3 4.75 (1.89–11.93) 5 
Anticholinergics 2.09 (1.16–3.75) 2 
Abbreviations: CI, confidence interval; OR, odds ratio. 
 
Drug changes in the preceding three months, renal failure, dementia and PIMs 
(anticholinergics) were scored at two points, and antihypertensives received a score of 
three points (1–2 antihypertensive agents) or five points (≥3 antihypertensives). The range 
of scores was from zero to 11, with a median of five (IQR 5). The area under the ROC 
curve, which assesses the ability of the risk score to predict ADR-related hospitalisation 
in the whole population, was 0.70 (95% CI 0.65–0.75) (Appendix 10). A score cut off at 
six provided a good balance between sensitivity (72.2%) and specificity (58.0%). The 
risk of patients having an ADR-related hospitalisation was more than three times higher 
in those who scored ≥6 compared to those who scored <6 (OR 3.59 [95% CI 2.32–5.55]). 
 
4.5.2. Validation study 
Over the study period of 4 months, 518 patients were screened at the LGH. Of these, 123 
patients were excluded due to their unwillingness to consent and 155 patients could not 
be recruited due to the severity of their medical condition. In total, 240 patients were 
included in the LGH cohort for the validation of the PADR-EC score. Definite (2, 5.2%) 
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and probable (28, 73.7%) ADR-related hospital admissions were observed in 30 patients 
(12.5%) in this sample. The patients’ characteristics are summarised in Table 9.  
The majority of the ADR-related hospitalisations were considered preventable 
(24, 80%). When the PADR-EC score was applied to the LGH data set, the AUC was 
0.67 (95% CI 0.56–0.78) (Appendix 10). A score cut off at six provided a good balance 
between sensitivity (63%) and specificity (63%). In the LGH data set, patients who scored 
≥6 had almost three times the risk of ADR-related hospitalisation compared to those 
scoring <6 (OR 2.92 [95% CI 1.32–6.46]). The percentage increase of ADR-related 
hospitalisation with respect to the cut-off score ≥6 in both the RHH and LGH data set is 
outlined in Figure 3. 
 
Figure 3. Adverse drug reaction rate according to risk score 
 (A) The adverse drug reaction rate at cut off score at 6 in the derivation dataset at the Royal 
Hobart Hospital. (B) The adverse drug reaction rate at cut off score at 6 in the validation dataset 
at the Launceston General Hospital. 
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4.6. Discussion 
We developed and validated a simple and robust approach to identifying community-
dwelling elderly patients at risk of hospitalisation due to ADRs. To our knowledge, this 
is the first study to develop such a score. This score has the potential to assist healthcare 
practitioners to identify those elderly patients for whom intervention may reduce the risk 
of ADRs and subsequent hospitalisation. In addition, patients could be stratified at 
hospital discharge according to their risk of subsequent admission of an ADR, and 
appropriate medication management services provided accordingly post-discharge. 
 The variables we identified as independent predictors of ADRs in the elderly have 
been described in previous studies [175, 252-254]. Drug changes in the preceding three 
months were found to predict ADR-related admission in the present study. Changes in 
medications such as using a different dose, discontinuing therapies, and taking new drugs 
were observed in the majority of elderly patients after hospital discharge in a follow-up 
study [246] and clinically significant changes to medicines or treatment plans within the 
last 3 months were found to be a risk factor for medication-related problems [252, 255]. 
ADRs attributed to medication changes occurred in 20% of patients during transfer from 
hospital and nursing home in a study conducted in United States of America [256]. Renal 
failure was found to be another significant predictor of ADR-related admission in the 
present study. The relation between renal insufficiency and ADRs is well documented in 
the literature [257, 258]. Impaired renal function (OR 2.6, 95% CI 1.6–4.2) was found to 
be a major determinant of preventable medication-related hospital admission in a 
prospective multicentre study [208]. Renal failure was also found to be a predictor of 
ADRs in the GerontoNet ADR score study (OR 1.2, 95% CI 0.9–1.5) as well as in a 
prospective study of elderly individuals who presented to an emergency department (OR 
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1.5, 95% CI 1.1–2.2) [9, 190]. In the present study, we found elderly patients with renal 
failure were twice as likely to be hospitalised due to ADRs. The presence of dementia 
was identified as another independent predictor of ADR-related hospitalisation. The 
prevalence of ADRs in elderly patients with dementia was 5.0% in another study; half of 
the ADRs were due to use of psychotropic and anti-dementia drugs [259].  Drug-related 
problems appeared to be responsible for the majority of hospitalisations among old people 
with dementia, and the most common drug-related problem was an ADR (18.7%) in a 
recent study [217].  
PIMs are significantly associated with ADRs and subsequent hospital admission 
[238]. Inappropriate medications were associated with a two-fold increased risk of an 
ADR in the elderly in a prospective study [167]. Among the PIMs, use of anticholinergics 
was found to be the predictor of ADR-related hospital admission in the present study. The 
prevalence of exposure to anticholinergic medicines in the elderly has ranged from 22.8% 
to 55.9% [260]. The use of drugs with anticholinergic adverse effects is often 
inappropriate in older patients aged ≥65 years [261]. Many age-related and disease-
related conditions may predispose older patients to ADRs related to anticholinergic drugs 
[262]. These drugs have many effects in the elderly, ranging from dry mouth and 
constipation to confusion, delirium and severe cognitive impairment [263]. Another 
important predictor of ADR-related admission in the present study was the use of multiple 
antihypertensives. Approximately 70% of patients with hypertension require two or more 
drugs to achieve their target blood pressure [264]. The use of multiple antihypertensives 
in elderly patients is a frequent cause of hospital admission [265]. Antihypertensives were 
found to be one of the most frequently implicated drugs in causing ADRs, and the risk is 
higher with combination therapy and in patients receiving multiple antihypertensive drugs 
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[266-268]. In a community-based randomised open label trial [269] there was a 
significant increase in dizziness reported with combination antihypertensive therapy. The 
prevalence of orthostatic hypotension has been reported to be between 35% and 65% for 
the elderly and is mainly associated with the use of antihypertensive medications [231, 
270, 271]. 
 This study found that almost 15% of admissions in the elderly were due to ADRs. 
Meta-analysis of observational studies in the elderly reported a similarly high rate 
(16.6%) of ADR-related hospitalisation [101]. The PADR-EC score has a predictive 
ability of 70% to discriminate patients who are at high risk of ADR-related hospitalisation 
and those who are not. The subsequent validation study found a predictive ability of 67%. 
The sensitivity of the score was 72% in the derivation cohort, which indicates the ability 
of the score to correctly classify a patient as a victim of preventable ADR-related 
admission. Importantly, the expert reviewers also identified that the majority of ADR-
related admissions were preventable. The predictive ability of the risk score could, 
therefore, be utilised to identify ADRs which may be prevented by monitoring of patients’ 
drug therapy, addressing inappropriate dosing, aiding patient compliance with therapy 
and managing drug interactions to avoid subsequent admission. To our knowledge, there 
is no previously developed ADR prediction tool for use in primary care to which to 
compare the present study findings; however, the score performed comparably to 
validated ADR prediction tools used to predict ADR risk in hospitalised patients, such as 
those developed by Onder et al. (predictive ability of 71%) [9] and Tangiisuran et 
al. (74%) [10]. While there are tools available to predict the risk of emergency admission 
to hospital [272-274], our tool was developed to focus specifically on the risk 
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hospitalisation due to an ADR to enable primary health care professionals to better direct 
medication management services to prevent ADRs. 
 The PADR-EC score consists of five clinical variables that are easy to apply and 
practical to assess in elderly patients. The development of this tool may assist general 
practitioners or primary care physicians in identifying older patients who have a high risk 
of ADRs and subsequent emergency hospital admissions  [238]. This is particularly 
important considering that it may be challenging for healthcare practitioners to easily 
identify patients who are at risk of hospitalisation due to ADRs, partly due to significant 
time pressures in office-based practice  [171]. The PADR-EC score could potentially be 
integrated into prescribing software to alert primary care physicians to their patients’ risk 
of ADRs and prompt appropriate preventive measures. Such preventive measures may 
include medication review, avoiding use of PIMs, computer-based prescribing systems 
and comprehensive geriatric assessment [3], as well as deprescribing (withdrawal of an 
inappropriate medication) [275] and avoiding unnecessary polypharmacy when drugs are 
no longer efficacious or beneficial, or when safer alternatives exist [276]. The PADR-EC 
score could also be applied at hospital discharge to identify older patients who are at 
higher risk of admission for ADRs to facilitate post-discharge medication management 
review services and/or closer monitoring by relevant health professionals to prevent 
subsequent hospitalisation. Thus, application of PADR-EC score could potentially play a 
role in reducing the risk of ADR-related hospitalisations in the elderly.  
 Limitations include the score’s specificity of 58%, resulting in a chance of 
incorrectly labelling patients as ‘having an ADR risk’ who may not be at risk (false 
positives). The validation sample had almost equal or slightly less discriminatory power 
compared to the derivation sample, suggesting that further refinement and testing of the 
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PADR-EC score is required before implementing the score in clinical practice. The time 
restraints did not allow us to validate the tool further in a community setting to follow the 
patients in primary care to observe an ADR related hospital admission outcome versus 
other disease related outcomes. However, the variables used to derive the score only used 
patient information before hospital admission and all the patients recruited in the study 
were primary care patients. There were inherent limitations in assessing the predictor 
‘drug changes in the preceding three months’, as this could have potentially been 
influenced by incomplete records. We minimised this issue by interviewing the 
patient/relatives about their medication usage, including recent changes to drug therapy, 
and comprehensively reviewing medical records and, importantly, medication 
reconciliation reports from clinical pharmacists. Some of the variables arose from patient 
interviews and thus could be a subject to recall bias; this was limited by conducting 
interviews in the presence of family members. We could not recruit some patients due to 
difficulty in getting the consent mainly due to their severity of disease. Thus, obtaining 
consent was the limiting step, and a retrospective study could have included these 
additional patients, although such a study would lose the ability to obtain information 
through interview. The degree of generalisability of the proposed model is restrained by 
convenience sampling, however the large sample size used in the study may have reduced 
the sampling error and hence, may not have affected the applicability of the proposed 
model. We cannot assess the time frame for ADR occurrence after identifying patients at 
risk. Hence, further studies are required to address this issue in order to predict ADRs and 
subsequent admission in a timely fashion. Further investigation is needed to determine 
the absolute risk for people identified as being at high-risk of ADRs using this score, and 
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whether interventions in these patients by health care professionals are able to reduce this 
risk. 
  
4.7. Conclusion 
We propose a simple, efficient and practical tool to identify elderly patients living in the 
community who are at increased risk of ADR-related hospitalisation. The PADR-EC 
score was developed and externally validated reasonably in a cohort of elderly subjects 
admitted to two participating centres. It has the potential to be easily used, mainly by 
primary care physicians or perhaps other health care professionals (e.g. pharmacists and 
nurses) to identify elderly patients vulnerable to ADRs, and target interventions to prevent 
subsequent hospitalisation. Even though further refinement and testing of this tool is 
necessary before implementing the score in clinical practice, this tool could provide a 
useful starting point to predict risk for ADR-related hospitalisation in the elderly. Further 
studies are required to assess the clinical utility of this tool in different settings and 
populations.  
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CHAPTER FIVE 
 
5. Repeat Adverse Drug Reactions-Related Hospital 
Admissions in Elderly Australians: A Retrospective Study at 
the Royal Hobart Hospital 
 
5.1. Preface  
Chapter 4 described the development and validation of a simple and practical score to 
identify elderly patients who are at an increased risk of preventable ADR-related hospital 
admission. The study also concluded that the score could potentially be applied at hospital 
discharge to stratify elderly patients according to their risk of subsequent ADR-related 
hospital admission. This chapter presents the results of a study that investigated the utility 
of the ADR score in this setting. 
 
Submitted manuscript: 
Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Bereznicki LR. Repeat 
Adverse Drug Reaction-related Hospital Admissions in Elderly Australians. Drugs & 
Aging 2017; under review. 
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5.2. Abstract 
Introduction: Adverse drug reactions (ADRs) are a major cause of hospital admissions 
in older individuals, with the majority potentially preventable. Despite the apparent 
magnitude of this problem, little is known about rates of repeat admission to hospital due 
to ADRs.  
 
Objectives: To investigate the occurrence of repeat ADR-related hospital admissions in 
elderly patients within 12 months of an ADR-related admission to a medical ward and to 
investigate whether a validated ADR score could be useful in identifying patients at 
higher risk of a repeat ADR-related hospitalisation.  
 
Methods: This retrospective study followed elderly participants who were hospitalised 
with an ADR from our earlier study (the PADR-EC [Prediction of Hospitalisation due to 
Adverse Drug Reactions in Elderly Community-Dwelling Patients] study) to identify 
repeat ADR-related hospital admissions within 12-months of discharge. The PADR-EC 
score is the sum of points assigned to five significant predictors of ADR-related 
hospitalisation - antihypertensive use, renal failure, dementia, anticholinergic use and 
drug changes in the preceding three months. The causality, preventability, and severity of 
each ADR-related repeat admission within the 12-month follow up period were assessed.  
 
Results: ADR-related repeat admissions occurred after 13.4% (n=15) of 112 ADR-related 
index admissions. Patients with a repeat ADR-related admission had significantly higher 
PADR-EC scores at discharge of their index admission (median PADR-EC score 7, IQR 
7-9) than patients who were not readmitted (median PADR-EC score 7, IQR 5-7, 
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P=0.034). Most (73.3%) ADR-related repeat admissions were considered ‘preventable’. 
ADR severity was ‘moderate’ in all cases. Renal disorders (44.4%) represented the most 
common ADRs, and the most frequently implicated drug classes were diuretics (44.8%). 
All ADR-related repeat admissions were found to be ‘probable’. 
 
Conclusions: One in eight elderly patients hospitalised due to an ADR had a repeat 
admission for an ADR within 12 months of discharge. The PADR-EC score could 
potentially be used at hospital discharge to prioritise patients for interventions to prevent 
subsequent ADR-related hospital admission.  
 
Key Points 
• One in eight elderly patients hospitalised due to an adverse drug reaction (ADR) 
had a repeat admission for an ADR within 12 months of discharge. 
• A PADR-EC (Prediction of Hospitalisation due to Adverse Drug Reactions in 
Elderly Community-Dwelling Patients) score ≥6 at discharge could be used as a 
trigger for intervention to reduce the risk of subsequent ADR-related 
hospitalisation.  
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5.3. Introduction 
Adverse drug reactions (ADRs) are an important cause of hospitalisation in the elderly 
[238]. A recent study estimated that almost one in five unplanned overnight hospital 
admissions to medical wards in elderly Australian patients were related to ADRs [277] . 
It is estimated that more than half of these admissions are preventable [7]. ADRs which 
result in hospitalisation in patients with a history of ADR-related hospitalisation, or 
‘repeat ADRs’, are increasingly common and an important contributor to the burden of 
ADRs [278-280]. For example, Zhang et al. conducted a population-based longitudinal 
study (1980-2003) in Australia and found that repeat ADR-related hospitalisations had 
increased faster than first-time ADRs in the elderly since 1980 and were responsible for 
30.3% of all ADR-related admissions in 2003 [73]. 
The authors recently developed a validated ADR score (the PADR-EC [Prediction 
of Hospitalisation due to Adverse Drug Reactions in Elderly Community-Dwelling 
Patients] score) to identify community-dwelling elderly patients at risk of hospitalization 
due to preventable ADRs [214]. We concluded that the score could potentially be useful 
to stratify elderly patients at hospital discharge according to their risk of subsequent 
admission due to an ADR, and guide the provision of post-discharge medication 
management services. ADRs and subsequent ADR-related hospital admissions in the 
high-risk older population are of equally significant concern and more studies in this area 
are required to investigate methods to reduce the risk of repeat ADRs. The present study 
aimed to compare the PADR-EC score at the point of discharge in patients with and 
without repeat ADR-related admissions within 12 months of their index ADR-related 
hospital admission to identify whether a high PADR-EC score was associated with a 
higher risk of hospitalisation for repeat ADRs.   
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5.4. Methods 
We used the data collected as part of a prospective cross-sectional study on ADR-related 
hospital admissions in elderly patients (aged ≥65 years), conducted at the Royal Hobart 
Hospital (RHH), Tasmania, Australia. This published study described the derivation of 
an ADR prediction score (the PADR-EC score) using data from the RHH (March 2014 
to March 2015) and further validation of the score at a second hospital [214]. In this study, 
ADR-related admissions were identified from detailed review of medical records and 
patient interviews, followed by consensus agreement between two expert clinical 
pharmacists. The PADR-EC score assigns points to five significant predictors of ADR-
related hospitalisation: (i) antihypertensive use (3 or 5 points if 1-2 or ≥3 
antihypertensives, respectively), (ii) renal failure (estimated glomerular filtration rate 
[eGFR] <60mL/min/1.73m2) (2 points), (iii) dementia (2 points), (iv) inappropriate 
anticholinergic use (2 points), and (v) drug changes in the preceding three months (2 
points). These points are summed to produce the final score, with the risk of ADR-related 
hospitalisation more than three times higher in those with a score ≥6. 
For this analysis, we collected data from the digital medical records (DMR) of 
elderly participants in the PADR-EC study who experienced a subsequent admission due 
to an ADR. The RHH implemented a DMR in 2006 with the aim of  allowing improved 
access to all patient histories for authorised staff and improve the ability of staff to access 
all hospital clinical information databases via a single electronic link [281].The 
medication history taking and reconciliation by clinical pharmacists is standard practice 
at the RHH and this, together with the clinical notes relating to the hospital admission, 
are all available electronically via the DMR enabling comprehensive retrospective 
review.   
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Patients were included in the study if they were admitted due to an ADR within 
12 months of discharge from their initial ADR-related admission. The reasons for 
hospitalisation were multifactorial in many cases, and hence if there were other reasons 
for repeat admission as well as the ADR, the contribution of an ADR to hospital 
admission or if ADRs were one of the reasons for hospital admission were considered 
[96, 282]. We used a consensus method to identify and categorise ADR-related repeat 
hospital admissions. Patients were classified as having an ADR-related admission by the 
primary clinical pharmacist researcher if the reason for admission was consistent with the 
known ADRs of the drug and if other reasons were excluded after suitable investigations. 
All potential repeat ADR-related admissions were assessed by another senior clinical 
pharmacist, and a consensus decision was reached if there was a discrepancy between the 
two pharmacists’ assessments. The consensus decision was based on a further discussion 
and comprehensive review of the potential ADR cases again and exclusion of any 
doubtful cases. An ADR was defined as “a response to a drug that is noxious and 
unintended and occurs at doses normally used in humans for the prophylaxis, diagnosis 
or therapy of disease, or for modification of physiological function” [283]. The causality 
of the relation between drug use and ADR-related hospitalisation was assessed using the 
Naranjo algorithm (Appendix 8) [179]. ADRs were classified as definite (score from 9 to 
12), probable (score from 5 to 8), possible (score from 1 to 4), or doubtful (score from 0 
to -2), with only definite and probable ADRs being considered for this study. The 
modified Schumock and Thornton criteria were used to evaluate the preventability of the 
ADR (preventable or not preventable) [214, 221]. Severity of ADRs was assessed using 
the Hartwig et al. scale (Appendix 9) [222]. ADRs were also classified as Type A and 
Type B reactions based on the criteria of Rawlins and Thompson [223], and also whether 
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they were due to any drug-drug interactions (DDIs) as evaluated using the UpToDate 
database (Lexi-Interact™ Online) [216]. The outcome of the ADR-related admission was 
categorised as recovery (i.e., patients were clinically stable at discharge), death or 
unknown. Medications taken prior to admission were defined according to the 
Anatomical Therapeutic and Chemical classification system [219]. Clinical diagnosis and 
comorbidities were encoded according to the International Classification of Primary Care, 
2nd edition [240]. Renal failure was defined as an eGFR of less than 60 mL/min/1.73m2 
or as documented in the medical records [242, 243]. We considered acute kidney injury 
as an ADR if there was an acute reduction in renal function from baseline of 30% or more 
[284]. The study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (Appendix 1). 
 
5.4.1. Statistical Analysis 
The results were presented as either median and interquartile range (IQR) or frequencies 
and percentages. We used the Mann-Whitney U test to compare the PADR-EC scores at 
discharge of patients’ index admissions. A P value <0.05 was considered as being 
significant. Statistical analysis was performed with SPSS version 20.0 (SPSS Inc, 
Chicago, Illinois). 
 
5.5. Results 
In the prospective PADR-EC study at the RHH, 115 patients (15.0%) were judged as 
being admitted due to ADRs [214]. Of these, three patients died during their index 
admission, leaving 112 patients included in the analysis of ADR-related repeat 
admissions. Repeat ADR-related admissions occurred within 12 months of discharge in 
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13.4% (n=15) of these 112 ADR-related index admissions. Of these, eight (53.3%) 
patients had a repeat admission for ADRs within three months of their index admission, 
two (13.3%) within 3 to 6 months and five (33.3%) within 6 to 12 months. Twelve (80%) 
patients were calculated to have a PADR-EC score ≥6 at hospital discharge after their 
index admission (Table 13).  
 
Table 13. PADR-EC scores at discharge of index admissions of patients who were 
readmitted due to adverse drug reactions (n=18) 
PADR-EC score Number of patients (%) 
2 1 (5.6) 
5 2 (11.1) 
6 1 (5.6) 
7 8 (44.4) 
9 5 (27.8) 
11 1 (5.6) 
Abbreviation: PADR-EC, Prediction of Hospitalisation due to Adverse Drug Reactions in 
Elderly Community-Dwelling Patients. 
 
Patients with a repeat ADR-related admission had significantly higher PADR-EC 
scores at discharge of their index admission (median PADR-EC score 7, IQR 7-9) than 
patients who were not readmitted with ADRs (median PADR-EC score 7, IQR 5-7, 
P=0.034). A box plot of PADR-EC scores by readmission status is outlined in Appendix 
11. Eleven of the repeat admissions due to ADRs (73.3%) were considered ‘preventable’ 
based on Schumock and Thornton’s criteria. ADR severity was rated ‘moderate’ in all 
ADR-related repeat admissions. Using the Naranjo algorithm, all ADR-related repeat 
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admissions were found to be probable. For most admissions (n=14, 93.3%), the ADR 
resolved and the patient recovered; in one case (6.6%), the outcome was unknown due to 
the patient’s transfer to another hospital. In nine cases (60.0%), the patient was admitted 
with the ADR caused by the same drug/drug classes as in the index admission and in four 
cases (26.7%), the same ADRs contributed to both admissions. In five cases (33.3%), re-
prescription of discontinued medications from the index admission contributed to repeat 
admission. The nature of the ADRs in the index and repeat admissions are outlined in in 
Table 14.  
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Table 14. The nature of the adverse drug reactions in the index and repeat admissions 
 
 Index admission ADR Repeat admission ADR  
No. ADR Drugs involved Reasons of 
preventability 
ADR Drugs involved Reasons of 
preventability 
Comments  
1 Hypotension, 
dizziness, syncope 
Amlodipine, candesartan, 
furosemide, glyceryl 
trinitrate, metoprolol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Drug-drug interactions Acute kidney injury Candesartan Inappropriate 
dosing 
Antihypertensives caused both 
admissions. 
  Oxazepam Not preventable  Furosemide Not preventable 
 
 
2 Hypoglycaemia Sitagliptin, gliclazide                                                                                                                                                                                                                    Inappropriate dosing and
drug-drug interactions 
Hypothyroidism Amiodarone Inappropriate
dosing 
Patient was on amiodarone
during the index admission, 
and amiodarone was not 
discontinued during the index 
admission. 
3 Rash Furosemide History of same previous 
ADR  
Diarrhoea, acute 
kidney injury   
Ethacrynic acid, 
digoxin  
Inappropriate 
dosing 
Diuretics caused both 
admissions. 
     Losartan 
 
Not preventable  
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No. ADR Drugs involved Reasons of 
preventability 
ADR Drugs involved Reasons of 
preventability 
Comments  
4 Haemorrhage Clopidogrel  
 
Drug-drug interactions Hypoglycaemia Insulin, 
metformin  
Drug-drug 
interactions 
- 
 
 
5 Acute kidney injury Irbesartan  Not preventable Hypotension, 
syncope  
Irbesartan, 
propranolol  
Not preventable Antihypertensives caused both 
admissions. 
6 Nausea, vomiting Theophylline  Inappropriate dosing Hypotension Furosemide, 
ramipril  
Drug-drug 
interactions 
- 
7 Hyponatremia Spironolactone 
 
Inappropriate dosing Hyperkalaemia Spironolactone Not preventable Diuretics caused both 
admissions. 
  Furosemide Not preventable 
 
    
8 Acute kidney injury  Furosemide, ramipril Drug-drug interactions Acute kidney injury  Furosemide, 
ramipril  
Drug-drug 
interactions 
Diuretics and ACEIs caused 
both admissions. Repeat ADR 
occurred after re-initiation of 
diuretics and  
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No. ADR Drugs involved Reasons of 
preventability 
ADR Drugs involved Reasons of 
preventability 
Comments  
       ACEIs that were withheld in 
the index admission. 
9 Acute kidney injury  Furosemide, allopurinol  Drug-drug interactions Acute kidney injury  Spironolactone  Inappropriate 
dosing 
Diuretics caused both 
admissions. Repeat ADR 
occurred after re-initiation of 
diuretics that were withheld in 
the index admission. 
10 Acute kidney injury  Ramipril, furosemide Drug-drug interactions Acute kidney injury  Furosemide, 
ramipril  
Drug-drug 
interactions 
Diuretics and ACEIs caused 
both admissions. Repeat ADR 
occurred after re-initiation of 
diuretics and ACEIs that were 
withheld in the index 
admission. 
11 Urinary retention, 
hyponatremia  
Fluvoxamine Not preventable Severe nausea  Trimethoprim  
 
Not preventable - 
109 
 
No. ADR Drugs involved Reasons of 
preventability 
ADR Drugs involved Reasons of 
preventability 
Comments  
12 Bradycardia Metoprolol  Not preventable Acute kidney injury, 
hyperkalaemia  
Candesartan, 
spironolactone  
 
Inappropriate 
dosing and 
drug-drug 
interactions 
- 
     Furosemide Not preventable  
 
 
13 Acute kidney injury, 
hyponatremia  
Spironolactone  Inappropriate dosing Acute kidney injury  Spironolactone Inappropriate 
dosing 
Diuretics and ARBs caused 
both admissions. Repeat ADR 
occurred after re-initiation of 
diuretics and ARBs that were 
withheld in the index 
admission. 
  Furosemide, candesartan Not preventable  Candesartan, 
furosemide 
Not preventable 
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No. ADR Drugs involved Reasons of 
preventability 
ADR Drugs involved Reasons of 
preventability 
Comments  
14 Acute kidney injury, 
hyperkalaemia, 
orthostatic 
hypotension  
Spironolactone, 
perindopril, furosemide, 
prazosin 
Inappropriate drug for the 
patient’s condition and 
drug-drug interactions  
Increased lactate 
levels  
Metformin  Inappropriate 
dosing 
Patient’s eGFR was 16 mL/min 
and was on metformin 2 g/day 
during the index admission. 
Repeat ADR occurred after 
restarting of metformin, which 
was withheld in the index 
admission. 
  Amitriptyline Not preventable 
 
    
15 Bradycardia, 
hyperkalaemia  
Candesartan, 
spironolactone 
Drug-drug interactions Acute kidney injury  Candesartan, 
furosemide 
Not preventable Diuretics and ARBs caused 
both admissions. Repeat ADR 
occurred after re-initiation of 
diuretics and ARBs that were  
  Bisoprolol Not preventable 
 
   withheld in the index 
admission. 
Abbreviations: ADR, adverse drug reaction; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; eGFR, estimated 
glomerular filtration rate. 
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Twelve patients (80.0%) had a single ADR, and three (20.0%) had two ADRs. In 
four (26.7%) cases the ADRs were caused by a single drug, and in 11 (73.3%) cases, the 
ADRs were caused by a combination of drugs. DDIs were potentially involved in 33.3% 
(n=5) of the cases. Overall, 18 ADRs caused by 29 drugs contributed to all repeat 
admissions. All ADRs were classified as Type A reactions. Renal disorders (8, 44.4%) 
represented the most common manifestation of ADRs, followed by endocrine/metabolic 
disorders (5, 27.8%) (Table 15). The drug classes most frequently causing repeat 
admission due to ADRs were diuretics (13, 44.8%), renin-angiotensin system inhibitors 
(9, 31.0%) and drugs used in metabolic disorders (3, 10.3%) (Table 16). The main reasons 
for the preventable reactions in the repeat ADR-related hospital admissions were 
inappropriate drug dosing (7, 46.7%) followed by involvement of a DDI (5, 33.3%). The 
patient wise suspected drugs in the index and repeat ADR-related hospital admissions, 
and reasons for the preventable ADR in both admissions are also summarised in Table 
14. 
Table 15. Clinical presentations of repeat adverse drug reaction-related hospitalisation 
Type of ADR n (%) ADRs causing or contributing to hospital 
admission (n=18) 
Renal  8 (44.4) Acute kidney injury (8) 
 
Endocrine and metabolic 5 (27.8) Hypothyroidism (1), hypoglycaemia (1), 
hyperkalaemia (2), increased lactate levels (1) 
Cardiovascular  3 (16.7) Hypotension (2), syncope (1) 
Gastrointestinal  2 (11.1) Diarrhoea (1), nausea (1) 
Abbreviation: ADR, adverse drug reaction. 
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Table 16. Drug classes contributing to repeat adverse drug reaction-related 
hospitalisation 
Drug class  Frequency (%) Drugs involved (n=29) 
Diuretics  13 (44.8) Furosemide (8), ethacrynic acid (1), 
spironolactone (4)  
Agents acting on the renin-
angiotensin system  
9 (31.0) Candesartan (4), irbesartan (1), losartan (1), 
ramipril (3)  
Drugs used in metabolic 
disorders  
3 (10.3) Insulin (1), metformin (2) 
 
β-Blocking agents  1 (3.4) Propranolol (1)  
Cardiac glycosides  1 (3.4) Digoxin (1)  
Antiarrhythmic agents  1 (3.4) Amiodarone (1)  
Systemic antibacterial agents  1 (3.4) Trimethoprim (1) 
  
 
5.6. Discussion 
We found that approximately 13% of patients hospitalised due to an ADR had a repeat 
admission for ADR within 12 months of discharge from their initial index admission. The 
PADR-EC score was significantly higher in patients who had a repeat admission for 
ADRs, and the majority (80.0%) of patients who had a repeat ADR admission had a 
PADR-EC score ≥6 at hospital discharge after their index admission. These repeat 
admissions occurred mostly within the first three months after discharge from their initial 
index admission.   
The proportion of ADR-related repeat admissions varies in the literature [278], 
but a similar rate of 17.7% was found in another Australian study [197]. In our study, 
73% of repeat ADRs were considered preventable, and all were Type A reactions 
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resulting from known pharmacological actions of the implicated agents. In other studies, 
the preventability varied from 44.4-57.1% [278, 279], though these studies were not 
focussed on elderly patients. Renal disorders represented the most common manifestation 
of repeat ADRs, which is also consistent with the literature [279]. In more than half of 
the patients with repeat ADRs, the repeat ADR was caused by the same drug class/classes 
as in the index admission. ADRs due to the same drug combination were the suspected 
cause of repeat admission in half the cases in another study in elderly patients [280].  
We comprehensively reviewed the patients’ DMR to identify the repeat ADR 
admissions, which is different from other international studies in which repeat ADRs 
were identified using International Classification of Diseases codes [73, 197, 278, 280]. 
However, our study has some limitations. The small number of repeat ADR cases 
observed in our cohort allowed us to assess repeat ADR-related admissions only 
descriptively. Additionally, the study was performed in one hospital, and therefore we did 
not assess repeat ADR admissions to other hospitals. Since this study was a secondary ad 
hoc analysis of the main PADR-EC study, a power calculation was not done. These 
limitations might have implications for the extrapolation of the findings and reduce the 
generalisability of the results to the entire Australian population. However, the 
characteristics of our patient population, such as age, number of comorbidities, implicated 
drugs, and common repeat ADRs, were comparable to a similar Australian study in 
hospitalised elderly populations [73], supporting the generalisability of our findings. The 
data for patients who died after the index admission were also lacking. These limitations 
might result in underestimation of the number of repeat ADR cases in our study, and 
further studies exploring the burden of repeat ADRs including their independent 
predictors are required to confirm our findings. The difficulty in assessing the 
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contribution of an ADR to a repeat admission is a limitation of retrospective studies.  
However, we overcame this limitation by comprehensively reviewing the DMR, as well 
as the prospective collection of the original PADR-EC study data. Although the median 
PADR-EC scores were identical, the statistically significant difference is due to the higher 
readmission scores shown as a higher IQR compared to the non-readmission group. We 
suggest that the utility and clinical importance of the PADR-EC score should be explored 
in future studies. This method also did not allow us to determine the predictive ability of 
the score in this setting.  However, the significantly higher PADR-EC score in patients 
who had a repeat admission for ADRs suggests that a score ≥6, as estimated in the original 
PADR-EC study, could be used to screen patients who are most vulnerable to repeat 
ADR-related admissions. We suggest further studies in a large cohort of elderly patients 
to test the predictive ability of the PADR-EC score.  
Strategies to prevent repeat ADR-related hospital admissions are urgently needed 
in elderly patients. More than half of the repeat ADRs were caused by the same 
medications as at the index admission, which suggests that monitoring of high-risk 
medications (e.g., diuretics) in these patients at hospital discharge may not be adequate. 
The re-prescription of medications discontinued during the index admission was also 
responsible for some ADR-related repeat admissions. This highlights that transfer of 
information to primary care physicians or general practitioners (GPs) about drug 
discontinuation and the reasons for discontinuation is an important communication issue. 
In another descriptive study, a quarter of the drug treatments withdrawn during 
hospitalisation because of an ADR were represcribed within six months after discharge, 
however, the transfer of information to GPs and documentation by GPs were poor [285]. 
The significantly higher PADR-EC scores observed in the present study in those patients 
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who had a repeat admission for ADRs suggests that the score could potentially be used at 
hospital discharge to prioritise patients for interventions to prevent subsequent ADR-
related admissions.  To our knowledge, this approach has not been used before in the field 
of assessing repeat ADRs. Dominique et al. studied the impact of interventions on drug-
related problem-related readmission rates in older adults and found that an intervention 
was associated with 39.7% fewer readmissions related to ADRs in the elderly [286], 
which suggests that a targeted approach may be effective. The score is designed to be 
simple to use for health professionals, and could easily be incorporated into hospital-
based decision support systems to guide post-discharge medication management services 
for patients at the highest risk of misadventure.  
 
5.7. Conclusion  
One in eight elderly patients hospitalised due to an ADR had a repeat admission for ADR 
within 12 months of discharge. Improved medication management services at the point 
of discharge and in primary care are required to address preventable repeat admission due 
to preventable ADRs. The PADR-EC score could be routinely used at hospital discharge 
to screen patients who are at the highest risk of repeat ADRs to guide the use of 
interventions, such as medication management reviews, to prevent ADR-related hospital 
admissions.  
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CHAPTER SIX 
 
6. Prospective Detection versus Administrative Coding of 
Adverse Drug Reactions leading to Hospitalisations in the 
Elderly 
 
6.1. Preface  
 
Chapter 5 discussed the findings of a study, which described the utility of an ADR score 
at hospital discharge in identifying elderly patients who are at higher risk of a repeat 
ADR-related admission. The ADR score was developed using a prospective study design, 
which usually has the highest detection rate as found in studies discussed in Chapter 3 
and 4.  It is also known that different methods of ADR detection result in the reporting of 
different rates of ADRs as discussed in Chapter 1. This chapter describes the findings of 
a study which compared the prevalence and characteristics of ADR-related admissions 
identified using two different methods of detection in the same study cohort.  
 
Submitted manuscript: 
Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Curtain C, Bereznicki 
LR. Prospective Detection versus Administrative Coding of Adverse Drug Reactions 
leading to Hospitalizations in the Elderly. Pharmacoepidemiology and Drug Safety 2017; 
under review.   
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6.2. Abstract 
Purpose: To compare prospective identification of ADR-related hospital admissions in 
the elderly with administrative coding of ADRs using the International Classification of 
Diseases 10th Revision Australian Modification (ICD-10-AM) coding system. 
 
Methods: We linked the records of 768 enrolled patients from an earlier study, where 
clinical pharmacists prospectively identified ADRs, to their hospital administrative data.  
We identified patients in the prospective study whose admissions were coded as ADRs 
using ICD-10-AM codes. We then compared the prevalence and characteristics of ADRs 
identified by coding or prospective review by pharmacists in this patient sample. 
 
Results: According to ICD-10-AM coding, 2.7% of patients were admitted due to ADRs, 
while 15.0% of patients were deemed to be admitted due to ADRs based on prospective 
review by clinical pharmacists. Most (85.7%) patients coded as having an ADR-related 
admission were also identified as such in the prospective review. Haematological (23.1%) 
and metabolic reactions (23.1%) were frequent causes of ADRs identified by coding, 
whereas cardiovascular ADRs (27.8%) were more common causes of ADRs identified 
prospectively by pharmacists. Antidepressants (16.7%) and cardiac glycosides (16.7%) 
were the most commonly implicated drug groups in ADRs identified by coding, whereas 
diuretics (28.8%) and renin-angiotensin system inhibitors (17.0%) were frequently 
implicated as causes of ADRs identified prospectively by pharmacists. 
  
Conclusion: Reliance on administrative coding potentially underestimates the extent of 
the problem of ADRs as a cause of hospitalisation in the elderly, and more detailed 
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prospective review of admissions provides additional targets for strategies to prevent 
ADRs. 
 
Key Points 
• ADR detection methods in the elderly using administrative coding and 
prospective review result in markedly different rates and types of ADRs.  
• The characteristics of ADRs identified by administrative coding and prospective 
review by pharmacists differ, and this has important implications when 
considering targets for ADR prevention strategies. 
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6.3. Introduction 
Adverse drug reactions (ADRs) are a major public health problem in elderly accounting 
for 6-12% of hospital admissions [238]. Effective detection and prevention are important 
to tackle the global burden of ADRs, especially in the elderly. Administrative databases 
increasingly use the International Classification of Diseases 10th Revision (ICD-10) 
system to classify diagnostic, health services utilisation and death data [78]; in Australia, 
the Australian Modification (ICD-10-AM) is used [287]. In ICD-10-AM, adverse 
reactions to therapeutic agents are coded as Y40 to Y59 (‘drugs, medicaments and 
biological substances causing adverse effects in therapeutic use excluding accidents in 
the technique of administration of drugs’) [287]. Australian clinical coding standards 
allow ADR codes to be applied to any diagnosis and therefore retrospective ADR 
identification is possible [287].  
The use of different methods of ADR detection results in studies identifying 
varying rates and types of ADRs, and different drug classes responsible for ADRs [51].  
In one study, the frequency of ADRs causing admissions to a medical department, 
identified using ICD-10, was much lower (0.2% of admissions) than that identified by 
medical record review (5.8%) [98]. Even though there have been comparisons between 
the results of different study designs for ADR detection [78], there are few studies that 
utilise different ADR identification methods in the same cohort of patients. One such 
prospective observational study found that adverse drug events to outpatient medications 
were under-reported in emergency department administrative data compared to those 
detected at the point of care (3.9% versus 14.0% of presentations) [100]. Despite the 
burden of ADR-related admissions in the elderly, we are not aware of any studies that 
have utilised different ADR identification methods in the same cohort of elderly patients, 
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and focussed on ADRs as a cause of hospital admission. Consequently, we aimed to 
identify and characterise ADR-related hospital admissions in the elderly based on an 
administrative database utilising ICD-10-AM and compare these results with those of a 
prospective method of ADR detection. 
  
6.4. Methods 
We used data collected as part of a prospective cross-sectional study on ADR-related 
hospital admissions to medical wards in the elderly (aged ≥65 years) conducted at the 
Royal Hobart Hospital (RHH), Tasmania, Australia [214]. An ADR was defined as “a 
response to a drug that is noxious and unintended and occurs at doses normally used in 
humans for the prophylaxis, diagnosis or therapy of disease, or for modification of 
physiological function” [37]. ADR-related admissions were prospectively identified from 
detailed review of medical records and patient interviews followed by consensus 
agreement between two expert clinical pharmacists. The methodology has been published 
elsewhere [214]. The study was approved by the Tasmanian Health and Medical Human 
Research Ethics Committee (Appendix 1). 
 For this analysis, we linked the records of the 768 patients reviewed 
prospectively (March 2014 to March 2015) to their hospital administrative data using 
their medical record number (patient identifier) and identified clinical coding instances 
of ADR-related diagnoses (ICD-10-AM codes Y40 to Y59). The patients’ medical 
records were reviewed, and we excluded ADRs that occurred while patients were in 
hospital. All patients coded as having an ADR-related admission were initially 
categorised by the primary clinical pharmacist researcher. These cases were assessed 
independently and blindly by a senior clinical pharmacist. A consensus decision was 
121 
 
reached if there was a discrepancy between the two clinical pharmacists’ assessments. 
The consensus decision was based on a further discussion and comprehensive review of 
the coded ADR cases. For each method of identification, we determined the proportion 
of ADR-related admissions, commonly implicated drugs and clinical manifestations of 
ADRs. The causality and preventability of ADRs were evaluated using the Naranjo 
algorithm (Appendix 8) [179] and modified Schumock Thornton criteria [221], 
respectively. ADRs were classified as definite (score from 9 to 12), probable (score from 
5 to 8), possible (score from 1 to 4), or doubtful (score from 0 to -2), with only definite 
and probable ADRs being considered for this study  
Data were analysed descriptively using SPSS version 20.0 (SPSS Inc, Chicago, Illinois) 
and presented as number and percentages. 
   
6.5. Results 
ADR-related ICD-10-AM codes were assigned to 51 of the 768 patients. Of these, 29 
cases were excluded since the ADR diagnoses were coded based on ADRs occurring 
during hospitalisation, and one patient was excluded due to an incorrect Y code, leaving 
21 (2.7%) patients to be included in the analysis. Of the 21 patients with ADRs, 17 (81%) 
had a single ADR, three (14.3%) had two ADRs, and one (4.8%) had three ADRs. In 19 
(90.5%) cases, the ADRs were caused by a single drug, and in two (9.5%) cases, the 
ADRs were caused by a combination of drugs. Thus, there were a total of 26 ADRs caused 
by 24 drugs contributing to all ADR-related admissions identified by administrative 
coding.  
 In contrast, 115 patients (15.0%) were judged by clinical pharmacists following 
prospective review as being admitted due to ADRs. In these patients, a total of 194 ADRs 
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caused by 264 drugs were identified. Most of the ADR-related admissions identified by 
coding (n=18, 85.7%) and prospective review (n=106, 92.2%) were considered 
‘preventable’. Using the Naranjo algorithm, 81.0% (n=17) of admissions that were coded 
as ADRs were deemed ‘probable’ and 19.0% (n=4) ‘definite’, whereas there were 106 
(69.3%) probable and nine (5.8%) definite ADRs identified based on prospective review. 
A comparison of the characteristics of ADR-related admissions identified by 
administrative coding and prospective review by clinical pharmacists is presented in 
Table 17.  
 
Table 17. Characteristics of adverse drug reaction-related admissions identified using 
the administrative coding and prospective review 
Characteristic ADRs identified 
from administrative 
coding  
ADRs identified 
from prospective 
review  
Total number of ADRs identified  n=26 n=194 
Types of ADR (n, %)   
Haematological 6 (23.1) 20 (10.3) 
Endocrine and metabolic  6 (23.1) 26 (13.4) 
Neuropsychiatric 5 (19.2) 34 (17.5) 
Gastrointestinal  4 (15.4) 17 (8.8) 
Cardiovascular 3 (11.5) 54 (27.8) 
Renal and genitourinary - 34 (17.5) 
Neuromuscular and skeletal 1 (3.8) 6 (3.1) 
Dermatological/allergic - 1 (0.5) 
Others 1 (3.8) 2 (1.0) 
Total number of drugs causing ADRs  n=24 n=264 
Drug classes implicated (n, %)   
Antidepressants  4 (16.7) 14 (5.3) 
Cardiac glycosides 4 (16.7) 5 (1.9) 
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Characteristic ADRs identified 
from administrative 
coding  
ADRs identified 
from prospective 
review  
Diuretics  3 (12.5) 76 (28.8) 
Anti-Parkinson drugs  3 (12.5) 5 (1.9) 
Opioids 2 (8.3) 7 (2.7) 
Immunosuppressants  2 (8.3) 6 (2.3) 
Antithrombotic agents 2 (8.3) 17 (6.4) 
Antineoplastic agents  1 (4.2) 2 (0.8) 
Benzodiazepines  - 10 (3.8) 
β-Blocking agents  1 (4.2) 17 (6.4) 
NSAIDs - 3 (1.1) 
Antiepileptics  1 (4.2) 5 (1.9) 
RAS inhibitors - 45 (17.0) 
Calcium channel blockers  - 15 (5.7) 
Vasodilators used in cardiac diseases - 6 (2.3) 
Others  1 (4.2) 31 (11.7) 
Abbreviations: ADR, adverse drug reaction; NSAIDs, nonsteroidal anti-inflammatory drugs; 
RAS, renin-angiotensin system. 
 
The prevalence of ADRs identified by administrative coding (2.3%) was much lower than 
that identified by prospective review (15.0%). Haematological (23.1%) and metabolic 
reactions (electrolyte disturbances) (23.1%) were frequently identified using the 
administrative coding, whereas cardiovascular ADRs (27.8%) were commonly identified 
by prospective review. Antidepressants (16.7%) and cardiac glycosides (16.7%) were the 
most commonly implicated drug groups in ADRs identified by administrative coding, 
whereas diuretics (28.8%) and renin-angiotensin system (RAS) inhibitors (17%) were 
frequently implicated in ADRs identified by prospective review.  
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  Most (18, 85.7 %) of the 21 patients coded as having ADR-related admissions were 
also identified in the prospective review. Among these, 17 (81.0 %) patients were coded 
with the same ADRs caused by the same drug classes as in the prospective study. 
However, one (4.8%) patient was coded with a different ADR, and in three (14.3%) 
patients, the coded ADRs were not identified in the prospective study. Thus, the 
admission of a total of 118 patients was identified by either administrative coding or 
prospective review as being due to an ADR. The overlap in the identification of ADR-
related admissions identified by administrative coding and prospective review is outlined 
in Figure 4.  
 
Figure 4. Comparison of hospital admissions due to adverse drug reactions (n=118) 
identified by administrative coding alone (A), administrative coding and prospective 
review (B) and prospective review alone (C) 
 
6.6. Discussion  
Almost 3% of elderly patients admitted to medical wards of an Australian hospital were 
coded as having an ADR-related admission. Other international studies using 
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administrative coding have reported similar ADR rates (2.7–3.9%) although these studies 
were not focussed on the elderly [85, 100]. Our estimate based on administrative coding 
was much lower than the figure of 15.0% identified by prospective review. The 
discrepancy between the two methods of ADR identification is an expected finding. This 
discrepancy could be due to clinical pharmacists being more skilled in the identification 
of ADRs and more comfortable with their reporting than their medical colleagues. There 
is strong evidence that pharmacists report a higher rate of adverse drug events compared 
to non-pharmacists [226]. A systematic review of prospective observational studies 
reported a similarly high rate (10.7%) of ADR-related admissions in the elderly [53]. 
Additionally, medical staff (usually junior doctors) may be hesitant to assign an ADR-
related diagnosis in the absence of clear evidence of drug-induced disease [288], and 
hence fewer ADRs may have been identified using the administrative data. 
 Differences were seen in the type of ADRs and drug classes responsible for the 
identified ADRs. ADRs detected by administrative coding were more likely to involve 
additional treatment, or abnormal laboratory tests and/or elevated drug levels, rather than 
drug cessation or dose adjustment. Also, patients whose admissions were related to a more 
obvious consequence of an ADR, such as a fall or functional impairment, might have 
been prioritised for documentation as an ADR in the administrative database. On the other 
hand, prospective review allowed us to comprehensively assess the different drug classes, 
including concomitant drugs possibly contributing to an ADR, and detect more ADRs. 
Prospective review identified more cardiovascular ADRs, largely hypotension/orthostatic 
hypotension/syncope, than the database study; perhaps because doctors might be more 
likely to attribute ADR signs to an underlying disease, and pharmacists to a drug.  
126 
 
 Both ADR-reporting methods have limitations.  In studies that rely on the coding 
of ADRs, ADRs may be under-reported due to under-recognition and under-recording of 
ADR diagnoses by medical staff and limitations of the coding system [289]. Even though 
prospective review was expected to comprehensively identify ADRs, there is inevitably 
some subjectivity in this process as seen in the present study, in which the administrative 
coding identified three ADR cases that were not identified using the prospective review. 
Another inherent limitation to the use of administrative databases is wrong or incomplete 
information [85]; while labour and cost may be prohibitive to prospective ADR 
identification [100].  
 In conclusion, our study suggests that reliance on coded ADRs identifies only a 
small proportion of ADR-related events and perhaps only certain types of events 
contributing to hospital admission. ADR identification using coding alone may under-
estimate the ADR incidence or bias the findings in relation to drugs causing ADR-related 
admissions. Administrative coding is entrenched and easy to access, while prospective 
review is intensive and time-consuming, but yields more information which can be used 
to identify additional targets for interventions to prevent ADR-related admissions.     
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CHAPTER SEVEN 
 
 
7. General Discussion and Conclusion 
 
 
7.1. Preface  
The overall aim of this thesis was to develop and validate a method of identifying elderly 
patients who are at risk of an adverse drug reaction (ADR)-related hospital admission. To 
achieve this aim, a narrative literature review and a prospective study including four 
subset analyses were undertaken. The rationale, objectives, methods, findings, and 
limitations of each study analysis have been presented in detail in previous chapters 
(Chapter 3, 4, 5 and 6). The final section of this thesis will summarise the overall findings 
of the thesis and discuss the practical implications and future research directions. 
 
7.2. General discussion 
ADRs represent a major burden on health care [3, 86], which necessitate a major shift in 
the nature and delivery of ADR prevention strategies that would reduce the burden of 
ADRs, particularly in older patients. This work has developed and validated a simple and 
practical tool, the ‘PADR-EC’ (Prediction of Hospitalisation due to Adverse Drug 
Reactions in Elderly Community-Dwelling Patients) score to identify community-
dwelling elderly patients at risk of hospitalisation due to preventable ADRs. To the best 
of our knowledge, this is the first tool developed for such a purpose in the field of ADRs. 
The tool was developed from two prospective studies conducted in two different 
Tasmanian hospitals, which utilised an intensive ADR detection method. These studies 
further enhanced the understanding of ADR-related hospital admissions and the potential 
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risk factors among the older population. Our data showed that almost one in five 
unplanned medical ward admissions in elderly Australians were ADR-related, and one in 
eight patients had a repeat ADR-related admission within 12 months of discharge. 
Clearly, the problem of ADRs leading to admissions or repeated admissions is persisting 
in elderly Australians despite the available strategies for ADR prevention, so additional 
strategies are needed. It could also be that the available strategies for ADR prevention are 
being implemented in a sub-optimal manner.  Against this backdrop, the newly developed 
PADR-EC score is highly relevant to prevent ADR-related hospital admissions. The 
sensitivity of the score was found to be 72% which indicates that the score is a good 
predictor of ADR-related admissions though the specificity was found to be low (Chapter 
4).  The score could be used at the time of hospital discharge to identify patients requiring 
intensive intervention to prevent ADR-related repeat admissions since our repeat 
admission study (Chapter 5) found that the PADR-EC score among those who were 
readmitted due to ADRs within 12 months of hospital discharge was higher than those 
who were not. Hence, the development and validation of the PADR-EC score is a crucial 
step towards the reduction of ADRs in the older population.  
Our prospective analysis of ADRs as a cause of admission to hospital in the 
elderly found that almost 90% of ADR-related admissions were preventable. These 
findings suggest that the available systems of preventing medication misadventure are not 
adequate for elderly Australians, corroborating the findings of previous community-based 
studies [5, 88, 290]. Cardiovascular drugs, especially antihypertensives, were commonly 
implicated in ADR-related admissions and repeat admissions in the elderly, due to 
hypotension, orthostatic hypotension, syncope, dizziness and acute kidney injury. A 
combination of two or more drugs sharing a similar ADR profile was involved in the 
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majority of ADR cases (e.g., hypotension) in our study which warrants urgent attention 
by prescribers. Additionally, three among the four deaths that were observed in our study 
due to the severe ADRs were due to cardiovascular medications. Cardiovascular agents 
(anticoagulants) were found to be one of the most common drug classes associated with 
ADR-related mortality in a study reported in United States [68]. In another large 
prospective study, amongst the overall fatality (0.15%) of ADR-related admissions, 
cardiovascular medications (antihypertensives and anticoagulants) were responsible for 
most of the deaths. [58]. The 2016 National Heart Foundation guidelines in Australia 
suggest a patient-centred approach in the management of hypertension, balancing the 
benefits of blood pressure lowering medications versus patients’ experiences of adverse 
drug effects [291]. The guidelines suggest starting with low-to-moderate doses of 
antihypertensive medications and gradually increasing to minimise ADRs such as 
hypotension. Additionally, listening carefully to patients and verifying temporal 
relationships between drug treatment changes and clinical effects can strengthen 
recognition of ADRs and improve management through timely intervention [286, 291]. 
This is particularly important when patients are taking a combination of antihypertensive 
medications. 
When administering multiple medications, the ADRs associated with either drug 
could be enhanced [292] or sometimes, the adverse effects of some drug combinations 
may also be synergistic [66]. In this scenario, drug-drug interactions (DDIs) also play a 
potential role in inducing ADRs [173], such as severe hypotension. In our study, almost 
43% of ADR-related admissions involved potentially relevant DDIs. The DDIs between 
antihypertensive medications have been well established. For example, the prescribing 
information for angiotensin converting enzyme inhibitors (ACEIs) or diuretics states that 
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co-administration may result in excessive blood pressure reduction [293, 294]. The 
recommendations include temporarily stopping or reducing diuretic dosing for three days 
before starting or increasing the dose of an ACEI. Orthostatic hypotension and 
antihypertensive drugs are associated with falls among older people [295, 296]. 
Minimisation of medications including the withdrawal (deprescribing) of causative 
medications is one of the intervention strategies to prevent falls in the elderly [297].  
Deprescribing in the elderly has demonstrated a significant reduction in mortality [235]. 
Overall, we suggest that increased ADR-related hospital admissions from cardiovascular 
medications, especially antihypertensive drugs, warrant urgent attention to additional 
strategies of prevention.  
Elderly patients with a history of an ADR-related hospitalisation were more 
vulnerable to repeat ADR-related hospital admission. In our study, more than half of the 
repeat ADRs were caused by the same medications as at the index admission. Our data 
suggest that interventions are needed to reduce repeat ADR-related hospital admissions 
in elderly patients. High-risk medications (e.g., diuretics) that contribute to a patients’ 
admission must be reviewed carefully at hospital discharge with frequent post-discharge 
monitoring. In a randomised open-label trial, although underpowered, discharge-planning 
intervention combining chronic medication review, education, and enhanced transition-
of-care communication was associated with 39.7% fewer readmissions related to ADRs 
[286]. Pharmacist medication review, patient counselling, and telephone follow-up were 
associated with a lower rate of preventable adverse drug events 30 days after hospital 
discharge in another randomised trial [138]. 
The transition from hospital to home is a potentially vulnerable period for ADRs 
[298]. Promoting effective transitions of care at hospital discharge including 
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improvements in communication between inpatient and primary care physicians, 
effective medication reconciliation at discharge, adequate patient education about their 
medication use and recent drug changes, closer medical follow-up, engagement with 
social support systems, and greater clarity in physician–patient communication [299] 
might help to prevent ADRs in the post-discharge period. There is also need for more 
comprehensive medication review and reconciliation at hospital discharge and ongoing 
monitoring in primary care to prevent ADR-related admissions in the elderly. The present 
system of annual home visits (Home Medicines Review) by pharmacists may not be 
adequate in reducing ADRs in these complex elderly patients. The greater number of 
ADR-related hospital admissions found in our study suggests that these patients require 
more intensive and frequent monitoring to prevent ADR recurrence. We suggest there is 
a need to change existing medication management service models. Identifying elderly 
patients at risk of ADR-related admissions is the initial step followed by necessary 
intervention (e.g., alteration or substitution of high-risk medications) and frequent 
monitoring of these patients. This role could be handled by a team of general practitioner 
(GP), pharmacist, consultant pharmacist or practice nurse. We suggest coordination of 
these activities by pharmacists who can work collaboratively with GPs in primary care 
settings. We also suggest having pharmacists in general practices with access to all the 
available data to drive the medication safety agenda in primary care to prevent ADR-
related admissions in the community-dwelling older population.  
Despite the concerns about ADRs, there is insufficient information regarding the 
risk factors for ADR-related hospital admissions in community-dwelling patients, mainly 
due to the limited number of studies that have been performed in community settings [52, 
238]. Additionally, there are a lack of prospective Australian studies in community 
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settings that have focused on this issue. A previous prospective ADR study in elderly 
Australians mainly investigated the frequency, severity, and preventability of ADR-
related admissions rather than identifying the potential risk factors for admissions [88]. 
Most of the other prospective studies were conducted among the general population [300, 
301]. A few retrospective studies were conducted in Australian community settings using 
administrative databases (e.g., administrative claims data from the Australian Department 
of Veterans' Affairs) [302-306], but findings from these studies were limited due to the 
high chance of missing potential adverse reactions using the retrospective approach. This 
was highlighted in our coding study (Chapter 6), in which the frequency of ADRs causing 
admissions to a medical ward identified using an administrative database was much lower 
than that identified by the prospective review (Chapter 4). Prospective studies with 
intensive monitoring of ADRs provide us with a greater range of events, and potentially 
a better understanding of the risk factors involved. We, therefore, believe that our work 
addressed a significant gap in the literature. Our study identified various risk factors 
predicting ADR-related admissions in the elderly. The number of antihypertensive 
medications was found to be the strongest predictor of an ADR, followed by using 
inappropriate anticholinergics, renal failure, dementia and drug changes within the 
preceding three months. These risk factors were assigned a score, and the ADR risk score 
was computed based on the sum of scores of individual risk factors. We identified that 
patients with a PADR-EC score of ≥6 have a high chance of ADR-related admission. The 
predictive ability of the PADR-EC score was found to be 0.70 [95% confidence interval 
(CI) 0.65–0.75] suggesting the ability of the PADR-EC score to predict ADR-related 
admissions is high. The score was validated with a predictive ability of 0.67 (95% CI 
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0.56–0.78) in another hospital (the Launceston General Hospital) suggesting that the 
findings are generalisable.  
 
7.3. Practice implications 
The PADR-EC score has a wide range of potential applications in clinical and 
pharmaceutical care services in different healthcare settings. The score could be used in 
primary care settings and at the point of hospital discharge so that primary care-based 
medication management services could be targeted to the patients at highest risk. It could 
be implemented as a routine tool during the process of medication review, particularly at 
the point of discharge of elderly patients. Available studies on medication reviews had 
different foci, and the findings from a recent systematic review showed that only one-
quarter of studies evaluated the impact of medication review on ADR-related outcomes 
[127]. Currently, there is a lack of clear evidence on the effectiveness of medication 
reviews on outcomes related to ADRs. This might be due to an improper targeting of 
medication reviews, possibly based on the current guidelines that identify high-risk 
patients. Furthermore, there are often other factors such as patient complexity and the 
variety of recommendations made to address a range of heterogeneous outcomes (e.g., 
the number of drugs or potentially inappropriate medicines, drug overuse, the number of 
GP visits, medication adherence, medication management, etc.). It might be that 
medication reviews are effective, but we are perhaps not investigating the right outcomes 
to measure the impact of medication review services. We suggest that, if we want to 
measure the effectiveness of medication reviews on important outcomes like ADR-related 
hospitalisation, we need to target these service at the risk factors identified in our study. 
In addition, the medication review studies might have looked at ADRs detected 
retrospectively (e.g., coded ADRs) which identify fewer events. We suggest that there is 
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a need for changing the eligibility criteria for medication reviews; medication reviews 
might be better targeted using the PADR-EC risk score, in addition to other criteria 
deemed to be important in preventing ADR-related hospital admissions based on the local 
context and clinical judgement. During a clinical medication review, the risk factors 
identified in our study could be easily retrieved from the patients’ clinical notes or through 
a direct patient interview.  
The PADR-EC tool could also be applied during the medication reconciliation 
process especially in transitions of care. Previous studies of medication reconciliation 
programs at hospital transitions identified outcomes mostly related to medication 
discrepancies, but not the risk of ADRs [131]. In transitions of care, there are high chances 
of medication discrepancies and DRPs [307]. Hence identifying and targeting high-risk 
patients for ADRs using the score in this setting is also feasible. In adult patients, 
medication reconciliation reduced adverse drug event-related hospital revisits (relative 
risk reduction of 67%) [136]. Applying the PADR-EC score during the medication 
reconciliation process would enhance the reduction of ADR-related hospital revisits by 
identifying high-risk patients for follow-up interventions. ADR risk stratification during 
medication review or medication reconciliation and communication of this risk, together 
with recommendations that target the specific risk factors identified, to prescribing 
physicians or GPs at discharge are likely to reduce the risk of ADR-related 
hospitalisation. Integrating the score into prescribing software, such as computerised 
physician order entry and clinical decision support systems, could alert the prescribing 
physicians to patients’ risk of ADRs and subsequent admissions. Thus, we believe that 
the PADR-EC score is a practical tool that could be readily incorporated into clinical 
processes to assist clinical teams in hospitals and allow GPs to provide better-informed 
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post-discharge medication management to their patients in collaboration with other 
primary healthcare providers.  
 
7.4. Future directions 
While this thesis has demonstrated the potential of an ADR prediction score, there are 
opportunities for extending the scope of this work. Future research should endeavour to 
do the following; 
• Validate the applicability of the PADR-EC score in different populations from 
various settings.  
• Investigate the effectiveness of PADR-EC score guided medication review on 
ADR-related hospitalisation in appropriately designed prospective studies with 
tailored interventions to address the risk factors of ADR-related admissions in the 
elderly.  
• Conduct further prospective studies on ADR-related admissions in other regions 
of Australia to further enhance the understanding of ADR burden in the elderly.    
• Conduct future studies focussing on the contributive role of immunological or 
idiosyncratic reactions ADRs causing hospital admissions in the complex older 
population. 
• Conduct further larger studies on repeat admissions due to ADRs in the older 
population and investigate the utility of the PADR-EC score.  
 
7.5. Conclusion 
Collectively, the work in this thesis has addressed several important gaps in knowledge 
in relation to ADRs leading to hospital admissions in the older population. Overall, the 
thesis highlighted the importance of a tool for prevention of ADR-related hospital 
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admission in the elderly, and successfully developed and validated such a tool to identify 
patients at risk of these ADRs. The tool can readily target elderly patients that can benefit 
from interventions aimed to alleviate ADR-related consequences such as hospital 
admissions. This work also has highlighted that a more detailed prospective review of 
admissions gave a clearer understanding of the number of ADRs for directing appropriate 
medication management services towards addressing the problem. Overall, this thesis has 
significantly added to the literature on hospitalisation due to ADRs, and the findings have 
the potential to make a major contribution to clinical practice and policy.  
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1. B. Prospective study at Launceston General Hospital 
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1. C. Retrospective study (repeat ADR-related admissions study) at Royal Hobart Hospital 
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Appendix 2. Patient consent form and participant information sheets 
 
2. A. Patient consent form (Prospective studies at Royal Hobart and Launceston General 
Hospitals) 
 
CONSENT FORM 
 
Title of Project: “Prediction of Adverse Drug Reactions (ADRs) Causing Older People to 
be admitted to Hospital” 
 
 
1. I acknowledge that the nature, purpose and contemplated effects of the project so far as it 
affects me, have been fully explained to my satisfaction by the research worker and my consent 
is given voluntarily.  
2. The details of the project methods have also been explained to me, including the anticipated 
length of time it will take and an indication of any discomfort, which may be expected.  I understand 
that my involvement means that the research officer has my permission to collect information from 
my medical records, and that I will be asked to participate in an interview with the research officer. 
3. I understand that these are the following risks or possible discomfort: 
• Possible discomfort due to the underlying medical condition. 
• Possible discomfort due to not understanding clearly the scientific 
reasons for the questions being asked. 
• Discomfort trying to remember the events before admission or 
medication history asked about by the research officer. 
 
168 
 
I am aware that if I become distressed during the interview, I may either end the interview or ask 
the researcher to move the discussion in another direction. If necessary, counselling will be 
arranged for me or at no expense to me. 
4. Although I understand that the purpose of this research project is to improve the quality of 
medical care, it has also been explained that my involvement may not be of any benefit to me. 
5. I have been given the opportunity to have a member of my family or friend present while the 
project was explained to me. 
6. I am informed that no information regarding any medical history will be divulged and the results 
of any analyses involving me will not be published so as to reveal my identity. 
7. I understand that my involvement in the project will not affect my relationship with my medical 
advisers in their management of my health.  I also understand that I am free to withdraw from the 
project at any stage and any of my data that have been collected.  My withdrawal will not affect 
my legal rights, my medical care or my relationship with the hospital or my doctors. 
8. I understand that I will be given a signed copy of this patient information sheet and consent 
form.  I am not giving up my legal rights by signing this consent form. 
9. I understand that the study will be conducted in accordance with the latest versions of the 
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws. 
 
Name of participant”________________________________________________  
             Signature of participant ___________________ Date___________________  
 
10. I have explained this project and the implications of participation in it to this volunteer and I 
believe that the consent is informed and that he/she understands the implications of 
participation. 
 
           Name of investigator:  ___________________   
         Signature of investigator:______________________ Date: _______________ 
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2. B. Participant information sheet (Prospective study at Royal Hobart Hospital)  
 
 
“Prediction of Adverse Drug Reactions (ADRs) Causing Older People to be Admitted to 
Hospital” --Participant Information Sheet 
You are invited to participate in a research study, conducted by the University of Tasmania, 
School of Medicine. You were selected as a possible participant in this research because you are 
65 years of age or older, and were admitted to a medical ward of the Royal Hobart Hospital (RHH) 
between March 2014 and March 2015. 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being done and what it will involve. Please take the time to read 
the following information carefully and discuss it with others if you wish. 
 
1. What is the background of this study? 
Complications related to medicines are an increasingly important health concern. Older patients 
have a higher chance for developing more than one disease. Also, as we age, there are changes 
in the body systems which may imitate a disease condition. Because of these reasons, older 
people are more likely to be prescribed medication by their doctors and to take multiple medicines. 
This puts them at a higher risk of suffering adverse drug reactions (ADRs). Between 1 in 20 and 
1 in 3 older people living in the community will experience an ADR.  
 
2. What is an adverse drug reaction (ADR)? 
Adverse reactions to drugs are common. Most are predictable and are known as side effects. 
Common examples include diarrhoea caused by antibiotics and drowsiness caused by some anti-
allergy medicines. 
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3. What is the purpose of this study? 
This study aims to investigate ADRs that cause older people to be admitted to hospital, including 
what causes them, how severe they are and whether they can possibly be prevented. The overall 
aim is to develop a ‘score’ for predicting which older people are likely to need to be admitted to 
hospital because of an ADR. The hope is that this score will be used to help identify people living 
in the community who have a high chance of ADRs, so that they can receive additional care and 
attention from healthcare professionals to reduce their chance of ending up in hospital. 
This project will form a part of Nibu Parameswaran Nair’s PhD thesis. 
 
4. What does this study involve? 
If you agree to participate in this study, you can indicate that you want to be involved in using the 
attached Participant Consent Form. The study will be conducted over 12 months from March 2014 
to March 2015. 
This study consists of two methods. Firstly, you will be interviewed with a short questionnaire 
regarding any recent changes to your drug therapy, how you take your medicines, alcohol use, 
smoking status, and previous ADRs. The interview will last not more than 30 minutes.  Secondly, 
your medical records at the RHH will be reviewed to determine whether you experienced an ADR 
and what factors contributed to any ADR that may have occurred. 
 
5. What are the risks associated with these procedures? 
You are unlikely to experience any discomfort during this procedure. If you experience some 
discomfort during the interview process, it may be due to the following reasons 
a) Possible discomfort due to the underlying medical condition. 
b) Possible discomfort due to not understanding clearly the scientific reasons for the questions 
being asked. 
c) Discomfort trying to remember the events before admission or medication history asked about 
by the research officer. 
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If you find that you are becoming distressed during the interview, you are free to either end the 
interview or ask the researcher to move the discussion in another direction. If necessary, we will 
arrange for you to see a counsellor at no expense to you. 
 
6. What are the benefits of this study? 
Your participation may contribute to a better understanding of ADRs occurring in older people. 
This may lead to future improvements in ADR prediction for people like you, with the aim of 
reducing the risks of ADRs for these people. This study also assists health practitioners to identify 
people who are at increased risk of ADRs and promote safer use of medicines, with a subsequent 
reduction in the associated costs of admissions due to ADRs. 
 
7. What happens if I don’t want to take part in the study? 
Participation is entirely voluntary. It is completely up to you whether or not you participate. If you 
decide not to participate, it will not affect your future care. 
 
8. How will my confidentiality be protected? 
Of the people treating you, only the research pharmacist will know whether or not you are 
participating in this study. All information will be treated in a confidential manner and all data, 
including your personal information, will be coded against a unique identifying number so your 
personal information will be protected. Your name and any other personal information will not be 
used in reports or publications resulting from this study. All of the information collected as part of 
this research will be kept in secure storage in the School of Medicine and will be destroyed after 
a period of 10 years in line with University regulations. 
 
9. Will I benefit from the study? 
This study aims to further medical knowledge and may prevent older people experiencing ADRs 
in the future; however it will may directly benefit you. 
 
10. What should I do if I want to discuss this study further before I decide? 
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When you have read this information, if you have any queries regarding this study or your 
participation in this study, please do not hesitate to contact one of the study investigators listed 
below:  
Nibu Parameswaran Nair (PhD candidate) 
Telephone: 0469417704; Email: nnair@utas.edu.au 
Associate Professor Luke Bereznicki (Deputy Head, School of Medicine) 
Telephone: 0438232864; Email: Luke.Bereznicki@utas.edu.au 
Dr Leanne Chalmers (Lecturer, Pharmacy, School of Medicine) 
Telephone: 0417919369; Email: Leanne.Chalmers@utas.edu.au 
Dr Ronald Castelino (Lecturer, Pharmacy, School of Medicine) 
Telephone: 0406360715; Email: Ronald.Castelino@utas.edu.au 
Professor Gregory Peterson (Professor, Pharmacy, School of Medicine) 
Telephone: 62261080; Email: G.Peterson@utas.edu.au 
Michael Connolly (Senior Clinical Pharmacist) 
Telephone:   03 6222 8485; Email: Michael.Connolly@dhhs.tas.gov.au 
 
11. Who should I contact if I have concerns about the conduct of this study? 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have any concerns of an ethical nature, or complaints about the manner in 
which the study is conducted, you may contact the Executive Officer of the Human Research 
Ethics Committee (Tasmania) Network on (03) 6226 7479 or human.ethics@utas.edu.au. The 
Executive Officer is the person nominated to receive complaints from research participants.   
Please quote the ethics reference number H0013773 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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2. C. Participant information sheet (Prospective study at Launceston General Hospital) 
 
 
“Prediction of Adverse Drug Reactions (ADRs) Causing Older People to be Admitted to 
Hospital” ---- Participant Information Sheet 
You are invited to participate in a research study, conducted by the University of Tasmania’s 
School of Medicine. You were selected as a possible participant in this research because you are 
65 years of age or older, and were admitted to a medical ward of the Launceston General Hospital 
(LGH) between August 2015 and February2016. 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being done and what it will involve. Please take the time to read 
the following information carefully and discuss it with others if you wish. 
 
1. What is the background of this study? 
Complications related to medicines are an increasingly important health concern. Older patients 
have a higher chance for developing more than one disease. Also, as we age, there are changes 
in the body systems that may imitate a disease condition. Because of these reasons, older people 
are more likely to be prescribed medication by their doctors and to take multiple medicines. This 
puts them at an increased risk of suffering adverse drug reactions (ADRs). Between 1 in 20 and 
1 in 3 older people living in the community will experience an ADR.  
 
2. What is an adverse drug reaction (ADR)? 
Adverse reactions to drugs are common. Most are predictable and are known as side effects. 
Common examples include diarrhoea caused by antibiotics and drowsiness caused by some anti-
allergy medicines. 
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3. What is the purpose of this study? 
This study aims to investigate ADRs that cause older people to be admitted to hospital, including 
what causes them, how severe they are and whether they can possibly be prevented. The overall 
aim is to develop a ‘score’ for predicting which older people are likely to need to be admitted to 
hospital because of an ADR. The hope is that this score will be used to help identify people living 
in the community who have a high chance of ADRs, so that they can receive additional care and 
attention from healthcare professionals to reduce their chance of ending up in hospital. 
This project will form a part of Nibu Parameswaran Nair’s PhD thesis. 
 
4. What does this study involve? 
If you agree to participate in this study, you can indicate that you want to be involved in using the 
attached Participant Consent Form. The study will be conducted over 6 months from August 15th 
2015 to February 15th 2006. This study consists of two methods. Firstly, you will be interviewed 
with a short questionnaire regarding any recent changes to your drug therapy, how you take your 
medicines, alcohol use, smoking status, and previous ADRs. The interview will last not more than 
20 minutes. Secondly, your medical records at the LGH will be reviewed to determine whether 
you experienced an ADR and what factors contributed to any ADR that may have occurred. 
 
5. What are the risks associated with these procedures? 
You are unlikely to experience any discomfort during this procedure. If you experience some 
discomfort during the interview process, it may be due to the following reasons 
a) Possible discomfort due to the underlying medical condition. 
b) Possible discomfort due to not understanding clearly the scientific reasons for the questions 
being asked. 
c) Discomfort trying to remember the events before admission or medication history asked about 
by the research officer. 
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If you find that you are becoming distressed during the interview, you are free to either end the 
interview or ask the researcher to move the discussion in another direction. If necessary, we will 
arrange for you to see a counsellor at no expense to you. 
 
6. What are the benefits of this study? 
Your participation may contribute to a better understanding of ADRs occurring in older people. 
This may lead to future improvements in ADR prediction for people like you, with the aim of 
reducing the risks of ADRs for these people. This study also assists health practitioners to identify 
people who are at increased risk of ADRs and promote safer use of medicines, with a subsequent 
reduction in the associated costs of admissions due to ADRs. 
 
7. What happens if I don’t want to take part in the study? 
Participation is entirely voluntary. It is completely up to you whether or not you participate. If you 
decide not to participate, it will not affect your future care. 
 
8. How will my confidentiality be protected? 
Of the people treating you, only the research pharmacist will know whether or not you are 
participating in this study. Your name will be removed from any data collected, and replaced with 
an identification number. Also, your name and any other personal information will not be used in 
reports or publications resulting from this study. All of the information collected as part of this 
research will be kept in secure storage in the School of Medicine and will be destroyed after a 
period of 10 years in line with University regulations. 
 
9. Will I benefit from the study? 
This study aims to further medical knowledge and may prevent older people experiencing ADRs 
in the future; however it may not directly benefit you. 
 
10. What should I do if I want to discuss this study further before I decide? 
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When you have read this information, if you have any queries regarding this study or your 
participation in this study, please do not hesitate to contact one of the study investigators listed 
below:  
Nibu Parameswaran Nair (PhD candidate) 
Telephone: 0469417704; Email: nnair@utas.edu.au 
Associate Professor Luke Bereznicki (Deputy Head, School of Medicine) 
Telephone: 0438232864; Email: Luke.Bereznicki@utas.edu.au 
Dr Leanne Chalmers (Lecturer, Pharmacy, School of Medicine) 
Telephone: 0417919369; Email: Leanne.Chalmers@utas.edu.au 
Dr Bonnie Bereznicki (Lecturer, Pharmacy, School of Medicine) 
Telephone: 6226 2191; Email: Bonnie. Bereznicki@utas.edu.au 
Dr Ronald Castelino (Lecturer, Pharmacy, School of Medicine) 
Telephone: 0406360715; Email: Ronald.Castelino@utas.edu.au 
Professor Gregory Peterson (Professor, Pharmacy, School of Medicine) 
Telephone: 62261080; Email: G.Peterson@utas.edu.au 
Michael Connolly (Senior Clinical Pharmacist) 
Telephone:   03 6222 8485; Email: Michael.Connolly@dhhs.tas.gov.au 
 
11. Who should I contact if I have concerns about the conduct of this study? 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have any concerns of an ethical nature, or complaints about the manner in 
which the study is conducted, you may contact the Executive Officer of the Human Research 
Ethics Committee (Tasmania) Network on (03) 6226 6254 or email human.ethics@utas.edu.au. 
The Executive Officer is the person nominated to receive complaints from research participants.   
Please quote the ethics reference number H0015152 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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Appendix 3. Data collection form  
 
Predicting Adverse Drug Reaction-related Hospitalisation in Elderly Patients 
 
Date of 
admission:          
Date of discharge: Post Code: Weight (kg): 
Height (cm): Sex:  
 
 Male    Female 
Date of Birth: Number of admissions in preceding 
month: 
Living Status:                 
 Alone    With family/friends    Nursing home 
Number of admissions in preceding 
three months 
Comorbid conditions: 
 AIDS                                                                 Any tumour                                       
 Cerebrovascular disease                                Hemiplegia or paraplegia                      
 Chronic respiratory disease                              Leukaemia                                         
 Congestive heart failure                                Lymphoma                              
 Connective tissue disease                            Myocardial infarction                             
 Dementia                                                        Diabetes mellitus with end organ damage 
 Peripheral vascular disease                            Diabetes mellitus without end organ damage                                        
 Peptic ulcer disease                                       Mild liver disease                      
 Moderate or severe liver disease                         Moderate or severe renal disease  
 Metastatic solid tumour                                          Others (Specify 
Previous ADR:       
 
 Yes       No 
 
 
Admission diagnosis: 
 
Charlson Comorbidity 
Index:  
Barthel 
(ADL) 
Score:  
 
 
Patient outcome:  Discharged home    Transferred to another hospital or nursing home    Death 
 
Se Cr: eGFR: Serum drug level if any: Albumin: AST: 
 
ALT: 
 
GGT: 
 
ALP: 
 
 
Bilirubin: 
 
Hb: 
 
 
INR: Possible ADR-related 
admission: 
 
 Yes       No 
Cognitive impairment: 
 
 Yes       No 
Fibrinogen: 
 
 
 
 
PT (secs): 
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 Medications taken prior to hospital admission 
 
 
Drug Name(s) 
including OTC and 
herbal medicines 
 
 
Brand name if 
any 
Dose   Frequency Route Notes 
 
 
 
 
 
 
 
     
      
 
 
 
 
 
ADR Nature /Description: 
 
 
 
 
 
ADR outcome: 
 
 Fatal                            Not yet recovered                      Recovered                           Unknown    
 
 
 
Drug outcome:  
 
 Drug stopped      Drug withheld       Drug continued      Drug substituted         Dose reduced 
 
 
ADR classification: 
   
 Toxicity                           Side effect                    Drug Interaction       Immunological 
 
Causality  Preventability Severity Implicated Medications 
 Definite (>9)    
 Probable (5-8)   
 Possible (1-4) 
 Doubtful (≤0)    
 
 
 Preventable 
 Not preventable 
 
 Severe 
 Moderate          
1.  
 
2.  
 
3.  
 
4.  
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Appendix 4. Questionnaire to study participants (Prospective studies at Royal Hobart 
and Launceston General Hospitals) 
No Questionnaire  Answer 
 
1. a) Do you drink alcohol? 
If answer “YES”,  
b) What type of alcohol do you like to drink (e.g., beer, wine, 
spirits)? 
c) In a week, how many times would you drink and how much 
would you drink each time? 
 
 Yes       No 
2. Do you smoke?  Yes       No 
3. Were you recently hospitalised for any reason? If so, when?  Yes      No 
 
4. Do you remember any recent changes in drug therapy before your 
admission at Royal Hobart Hospital?  
 
If answer “YES”, please recollect the names of the medicines 
changed. 
 
 Yes      No 
 
5. Are you allergic to any medicines – e.g., Penicillin or Aspirin? 
 
If “YES”, list the allergy and the reaction. 
 
 Yes      No 
 
6. Within the last three months, have you experienced any ‘bad 
reactions’ to any medicines? 
 Yes      No 
 
7. Have you taken any OTC medications apart from your regular 
medications? 
 
If “YES”, please recollect the names/s of those. 
 
 Yes      No 
 
8. Do you take any complimentary medicines/herbal medicines? 
  
If “YES”, please recollect the names/s of those. 
 
 Yes      No 
 
9. Do you have a regular community pharmacy?  
 
How many pharmacies do you attend for your prescription 
medications? 
 
 Yes      No 
 
10. Do you usually use dosage administration aids (for example, a 
dosette box, or Websterpak, where the pharmacy packs your 
medicines into days and weeks for you)? 
 
 Yes      No 
11. a) Do you use different brands of the same medication, sometimes 
called generic prescription medications?  
 
 Yes      No 
12. Have you recently had a Home Medicines Review (pharmacist 
interviewing you about your medications in your 
home)/MedsCheck/Diabetes MedsCheck? 
  
 Yes      No 
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Appendix 5. Drug exposure in the study population, n=1008 (Prospective studies at Royal 
Hobart and Launceston General Hospitals) 
Characteristic  Value 
ACEIs or ARBs 55.0 
Diuretics 49.5 
Antiplatelets 47.8 
β-Blockers 35.7 
Calcium channel blockers 26.7 
α-Blocking agents 35.0 
Opioids 31.1 
Drugs of narrow therapeutic index* 24.4 
Psycholeptics** 24.0 
Drugs used in diabetes 23.2 
Benzodiazepines 20.4 
Anticoagulants 20.4 
Antibacterials 15.0 
Cardiac glycosides 10.9 
Antipsychotics 4.6 
NSAIDs 4.2 
Specific high-risk drugs, %  
Warfarin 12.0 
Rivaroxaban 4.7 
Amiodarone 2.8 
Apixaban 2.2 
Dabigatran 1.7 
Theophylline 0.2 
** Antipsychotics, anxiolytics, hypnotics and sedatives. 
* Digoxin, amiodarone, theophylline, phenytoin, carbamazepine and sodium valproate. 
Abbreviations: ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor 
blockers; NSAIDs, nonsteroidal anti-inflammatory drugs. 
181 
 
Appendix 6. Drug classes and drugs causing or contributing to hospital admission due to adverse drug reactions 
Drug class  Frequency (%) Drugs involved (n=452) 
Cardiovascular drugs  269 (59.5)  
Diuretics (108)  Furosemide (61), spironolactone (18), hydrochlorothiazide (14), indapamide (13), 
amiloride (2) 
Agents acting on the renin-angiotensin system (74)  Perindopril (19), candesartan (15), irbesartan (13), ramipril (13), telmisartan (6), 
valsartan (1), quinapril (1), enalapril (3), fosinopril (1), olmesartan (1), trandolapril (1) 
β-Blocking agents (32)  Metoprolol (15), atenolol (5), carvedilol (5), bisoprolol (5), sotalol (2)  
Calcium channel blockers (22)  Amlodipine (11), felodipine (4), diltiazem (3), verapamil (2), lercanidipine (2) 
Vasodilators used in cardiac diseases (9)  Isosorbide mononitrate (8), glyceryl trinitrate (1) 
Cardiac glycosides (7)  Digoxin (7) 
Antiarrhythmic drugs (4)  Amiodarone (4) 
α-Adrenoreceptor antagonists (6)  Prazosin (6) 
Lipid modifying agents (5)  Atorvastatin (3), simvastatin (1), rosuvastatin (1) 
Other cardiac preparations (2)  Ivabradine (1), macitentan (1) 
Drugs acting on the nervous system 100 (22.1)  
Antidepressants (31)  Amitriptyline (14), venlafaxine (3), desvenlafaxine (2), duloxetine (3), citalopram (3), 
escitalopram (1), paroxetine (1), mirtazapine (2), fluvoxamine (1), sertraline (1)  
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Drug class  Frequency (%) Drugs involved (n=452) 
Opioids (22)  Buprenorphine (8), oxycodone (7), morphine (3), tramadol (2), codeine (1), 
tapentadol (1)  
Benzodiazepines (19)  Diazepam (6), temazepam (4), nitrazepam (3), oxazepam (3), alprazolam (3) 
Antiepileptics (12)  Pregabalin (10), valproate sodium (1), gabapentin (1) 
Anti-Parkinson drugs (9)  Levodopa combinations (7), pramipexole (2) 
Antipsychotics (7)  Quetiapine (3), prochlorperazine (2), risperidone (1), olanzapine (1) 
Antithrombotic agents  31 (6.9) Acetylsalicylic acid (11), warfarin (7), rivaroxaban (6), clopidogrel (4), enoxaparin (2), 
apixaban (1) 
Immunosuppressants  12 (2.7) Methotrexate (6), mycophenolate mofetil (1), etanercept (1), tocilizumab (1), 
thalidomide (1), azathioprine (1), leflunomide (1) 
Antineoplastic agents  3 (0.7) Chlorambucil (1), melphalan (1), hydroxycarbamide (1) 
NSAIDs  4 (0.9) Naproxen (1), ibuprofen (1), diclofenac (1), meloxicam (1) 
Drugs for obstructive airway diseases  1 (0.2) Theophylline (1) 
Drugs used for urinary frequency and incontinence  2 (0.4) Oxybutynin (2) 
Thyroid preparations  2 (0.4) Thyroxine (2) 
Drugs for constipation  2 (0.4) Sodium picosulfate combinations (2) 
Antimalarials  2 (0.4) Hydroxychloroquine (1), quinine (1) 
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Drug class  Frequency (%) Drugs involved (n=452) 
Drugs used in diabetes  4 (0.9) Insulin (2), sitagliptin (1), gliclazide (1)  
Systemic antibacterials   5 (1.1) Sulfamethoxazole and trimethoprim (2), flucloxacillin (1), ciprofloxacin (1), 
doxycycline (1) 
Systemic corticosteroids 6 (1.3) Prednisolone (4), dexamethasone (1), prednisone (1) 
Others  9 (2.0) Naloxone (3), cyproterone (1), magnesium aspartate (1), denosumab (1), zoledronic 
acid (1), risedronate (1), allopurinol (1) 
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs. 
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Appendix 7. Clinical presentations of adverse drug reactions 
Type of ADR n (%) ADRs causing or contributing to hospital admission (n=328) 
Cardiovascular  96 (29.3) Hypotension/orthostatic hypotension/syncope (78), bradycardia (12), peripheral oedema (2), tachycardia (2), fluid 
retention (1), ventricular extrasystoles (1) 
Neuropsychiatric 72 (20.0) Dizziness (44), confusion (14), delirium (3), hallucinations (2), falling (2), drowsiness (1), ataxia (1), mental 
disturbances (1), nervousness (1), delusions (1), disorientation (1), peripheral neuropathy (1)   
Renal and genitourinary 50 (15.2) Acute kidney injury (49), urinary retention (1) 
Haematological 35 (10.7) Haemorrhage (22), anaemia (9), thrombocytopenia (1), leukopenia (1), bruise (1), myelosuppression (1) 
Endocrine and metabolic 30 (9.1) Hyperkalaemia (11), hyponatremia (11), hypoglycaemia (4), hypokalaemia (2), hypocalcaemia (1), hypothyroidism (1) 
Gastrointestinal  24 (7.3) Nausea (8), vomiting (5), anorexia (3), constipation (3), diarrhoea (3), abdominal pain (1), esophagitis (1) 
Neuromuscular and skeletal 12 (3.7) Myalgia (4), weakness (2), arthralgia (1), dyskinesia (1), tremor (1), limb pain (1), myopathy (1) 
decreased bone density (1) 
Hepatic 1 (0.3) Increased liver enzymes (1) 
Dermatological/allergic 2 (0.6) Rash (1), erythema (1) 
Other 6 (1.8) Infection (5), flu-like symptoms (1) 
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Appendix 8. The Naranjo adverse drug reaction probability scale  
To assess the adverse drug reaction, please answer the following questionnaire and give the 
pertinent score. 
 Yes No Do not know Score 
Are there previous conclusive reports on this reaction? +1 0 0  
Did the adverse event appear after the suspected drug was 
administered? 
+2 -1 0  
Did the adverse  reaction improve when  the  drug  was 
discontinued or a specific antagonist  was  administered? 
+1 0 0  
Did the adverse reaction reappear when the drug was 
readministered? 
+2 -1 
 
0  
Are there alternative causes (other than the drug) that could 
on their own have caused the reaction? 
-1 +2 0  
Did the reaction reappear when a placebo was given? -1 +1 0  
Was the drug detected in the blood (or other fluids) in 
concentrations known to be toxic? 
+1 0 0  
Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
+1 0 0  
Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
+1 0 0  
Was the adverse event confirmed by any objective 
evidence? 
+1 0 
 
0  
 
The ADR was assigned to a probability category from the total score as follows: definite >9, 
probable 5 to 8, possible 1 to 4, doubtful ≤0.  
a) A "definite" reaction was one that (1) followed a reasonable temporal sequence after a 
drug or in which a toxic drug level had been established in body fluids or tissues, (2) 
186 
 
followed a recognised response to the suspected drug, and (3) was confirmed by 
improvement on withdrawing the drug and reappeared on re-exposure. 
b) A "probable" reaction (1) followed a reasonable temporal sequence after a drug, (2) 
followed a recognised response to the suspected drug, (3) was confirmed by withdrawal 
but not by exposure to the drug, and (4) could not be reasonably explained by the 
known characteristics of the patient's clinical state. 
c) A "possible" reaction (1) followed a temporal sequence after a drug, (2) possibly 
followed a recognised pattern to the suspected drug, and (3) could be explained by 
characteristics of the patient's disease. 
d) A reaction was defined as “doubtful" if it was likely related to factors other than a drug. 
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Appendix 9. Hartwig's adverse drug reaction severity assessment scale 
 
Level 1 An ADR occurred but required no change in treatment with the suspected drug. 
Level 2 The ADR required that the suspected drug be held, discontinued, or otherwise 
changed. No antidote or other treatment is required. No increase in length of 
stay. 
Level 3 The ADR required that the suspected drug be held, discontinued, or otherwise 
changed, AND/OR an antidote or other treatment was required. No increase in 
length of stay. 
Level 4 (a) Any level 3 ADR that increases length of stay by at least one day, OR 
(b) The ADR was the reason for admission. 
Level 5 Any level 4 ADR that requires intensive medical care. 
Level 6 The adverse reaction caused permanent harm to the patient. 
Level 7 The adverse reaction either directly or indirectly led to the death of the patient. 
 
Mild = Levels 1 and 2 
Moderate = Levels 3 and 4 
Severe = Levels 5, 6 and 7 
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Appendix 10. Receiver operator characteristic curve for the derivation (Royal Hobart 
Hospital) dataset (A) and the validation (Launceston General Hospital) dataset (B) 
 
 
 
 
The area under the curve are 0.70 (95% CI 0.65–0.75) and 0.67 (95% CI 0.56–0.78) for the 
derivation and validation datasets respectively.  
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Appendix 11. A box plot of PADR-EC scores by readmission status 
 
 
